Page last updated: 2024-08-25

sofosbuvir and Hepatitis C

sofosbuvir has been researched along with Hepatitis C in 656 studies

Research

Studies (656)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's436 (66.46)24.3611
2020's220 (33.54)2.80

Authors

AuthorsStudies
Beigelman, L; Deval, J; Dyatkina, N; Fung, A; Hu, Y; Huang, Y; Jekle, A; Jin, Z; Kang, H; Prhavc, M; Serebryany, V; Shaw, K; Smith, DB; Stoycheva, A; Tam, Y; Tan, H; Wan, J; Wang, G; Williams, C; Wu, X; Zhang, Q1
Abe, H; Andrei, G; Balzarini, J; Haraguchi, K; Hotta, K; Kaneda, R; Kato, N; Kitagawa, Y; Miyaike, T; Mori, K; Shimada, H; Shuto, S; Snoeck, R; Tanaka, H; Ueda, Y1
Chang, J; Ho, W; Li, E; Li, H; Li, S; Liu, B; Lv, Z; Peng, Y; Wang, Q; Wang, Y; Yu, W1
Dadej, A; Jelińska, A; Muszalska, I; Sobczak, A; Tomczak, S; Zając, M1
Biancone, L; Buggisch, P; Camargo, M; Chuang, WL; Dvory-Sobol, H; Gaggar, A; Hu, TH; Hyland, R; Kirby, BJ; Liu, CH; Lu, S; Mangia, A; Moreno, C; Osinusi, A; Peng, CY; Sise, ME; Su, WW1
Chen, R; Li, D; Yuan, X; Zhang, M1
Blanquicett, CJ; Cartwright, EJ; Jaglal, M; Johnson, TM; Mirk, A; Raavi, T1
El-Shenawy, R; Helmy, NM; Shawky, H1
Arteaga, L; Brinkley, S; Brooner, RK; Falade-Nwulia, O; Haselhuhn, T; Herne, K; Katz, S; Latkin, C; Mehta, SH; Moon, J; Sulkowski, MS; Sutcliffe, CG; Ward, KM1
Hou, MC; Huang, YH; Lan, KH; Lee, WP; Wang, YW1
Abbass, A; Abdeen, N; Afify, S; Alboraie, M; El Kassas, M; ELshazly, HM; Eltabbakh, M; Emadeldeen, M; Ezzat, S; Farghaly, R; Ghalwash, A; Hamdy, H; Omar, H; Omran, D; Salaheldin, M; Sweedy, A; Tahoon, M1
Bado, P; Djigma, FW; Kabré, MK; Kiendrebeogo, IT; Obiri-Yeboah, D; Ouattara, AK; Simpore, J; Sombie, HK; Sorgho, AP; Tao, I; Yelemkoure, ET; Yonli, AT; Zeba, MTA; Zohoncon, TM; Zongo, AW; Zouré, AA1
Alavian, SM; Anvar, A; Azizi-Saraji, A; Behnava, B; Namvar, A; Salimi, S; Sharafi, H1
AbdAllah, M; Abdel Maksoud, MH; Abdelaziz, H; Ali, L; Cordie, A; Doss, W; El Garhy, N; El Serafy, M; Esmat, G; Khalil, M; Mohamed, R; Omar, H1
Abd-Elsalam, S; AbdElrahman, M; Bader El Din, NG; Barakat, AZ; El Awady, MK; Elbatae, H; Farouk, S; Ibrahim, MK; Omran, D; Tawfik, S1
Gan, T; Guo, M; Han, L; Leumi, S; Lu, J; Ngari, J; Tong, Y; Wang, L; Wang, Z; Xiang, X; Xie, Q; Zhong, J1
Camus, G; Chang, TT; Chen, CY; Chen, JJ; Chen, PJ; Chien, RN; Chu, CJ; Chuang, WL; Gaggar, A; Hsu, YC; Hu, TH; Jiang, D; Liu, CJ; Lo, GH; Massetto, B; Peng, CY; Sheen, IS; Suri, V; Tseng, KC; Wang, HY; Yang, J; Zhang, F1
Chayama, K; Hayes, CN; Imamura, M; Tanaka, J1
Anthony, D; Avihingsanon, A; Bennet, JA; Benson, CA; Brates, I; Cheinquer, N; Kityo, C; Kliemann, DA; Linas, B; Naggie, S; Nunes, EP; Robbins, G; Santana-Bagur, J; Scello, C; Smeaton, L; Solomon, SS; Son, A; Sowah, LA; Sulkowski, M; Supparatpinyo, K; Tebas, P; Van Schalkwyk, M; Wagner-Cardoso, S; Wimbish, C; Wyles, D1
Li, J; Liu, J; Ma, HX; Wang, CY; Wen, J1
Bailey, H; Collins, IJ; Malik, F; Malyuta, R; Thorne, C; Volokha, A1
AbdEl-Maksoud, HA; Alsaab, SM; El-Hamid, OA; El-Sorady, EM; Elharrif, MG1
Bansal, S; Giacomet, V; Hsueh, CH; Indolfi, G; Iorio, R; Kelly, D; Kersey, K; Mangia, A; Mania, A; Nebbia, G; Parhy, B; Pawlowska, M; Sang Yue, M; Shao, J; Szenborn, L1
Anderson, PL; Blum, J; Brooks, KM; Bushman, LR; Castillo-Mancilla, JR; Huntley, R; Jimmerson, LC; Kiser, JJ; Mawhinney, S; Morrow, M; Roon, L; Rowan, SE; Salah, L; Tehrani, A; Wyles, D1
El-Mehasseb, IM; El-Shafai, NM; Ibrahim, MM; Masoud, MS; Mersal, GAM; Ramadan, MS1
Kao, JH; Liu, CH; Liu, CJ1
Adinolfi, LE; De Lucia Sposito, P; Fusco, R; Gaglione, P; Izzi, A; Lumino, P; Maggi, P; Marrone, A; Messina, V; Nevola, R; Rega, R; Rinaldi, L; Sasso, FC; Simeone, F1
Abd-Aal, MS; Abdel-Hafez, AS; Abdel-Hamid, TM; Abdel-Rahman, RZ; Abdelsalam, MFA; Elaatar, MB; Elgohary, MA; Elkady, AO; Elnagar, MT; Elnagdy, TR; Elsaied, MA; Emam, ME; Fatoh, AR; Hamada, MM; Hasan, EM; Helmy, S; Ibrahim, AA; Lotfy, HH; Mubark, MA; Nawar, OM; Sakr, MA; Seadawy, MG; Selem, MA; Shehata, MM; Zaki, AI1
Waked, I1
Chen, JJ; Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC; Lee, PL; Tung, HD1
Bae, SH; Chang, UI; Choi, JY; Han, JW; Jang, JW; Kim, CW; Kim, HY; Kim, SH; Kwon, JH; Lee, HL; Lee, J; Lee, SK; Lee, SW; Nam, H; Nam, SW; Song, DS; Song, MJ; Sung, PS; Yang, H; Yang, JM; Yoo, SH; Yoon, SK1
Dong, M; Evon, DM; Lok, AS; Michael, L; Nelson, DR; Peter, J; Reeve, BB; Stewart, PW1
Bova, SE; Freedman, SR; Pluckrose, DM; Szczepanik, A1
Alavian, SM; Hajarizadeh, B; Hl Borba, H; Sabermahani, A; Sharafi, H; Tasavon Gholamhoseini, M1
Ebell, M; Elshafie, S; Trivedi-Kapoor, R1
Rabarioely, SS; Rabenjanahary, TH; Rakotozafindrabe, ALR; Ramanampamonjy, RM; Randriamifidy, NH; Rasolonjatovo, AS; Razafimahefa, SH; Razafindrazoto, CI1
Esteves, J; Forehand, J; Gradus, JL; Gui, J; Hoyt, JE; Huybrechts, K; Jiang, T; Ray, K; Rozema, L; Schnurr, PP; Shiner, B; Watts, BV1
Abdine, HH; Aboras, SI; El-Yazbi, AF; Korany, MA; Ragab, MAA1
Hui, VK; Kao, JH; Kumar, R; Liu, CH; Tan, J; Tan, SS; Thurairajah, PH; Wong, GH; Wong, YJ1
Gowda, C; Honegger, JR1
Kao, JH; Liu, CH1
Dai, H; Fang, C; Guo, Y; Hu, S; Lan, G; Liu, Q; Nie, M; Peng, F; Peng, L; Tan, L; Xie, X; Zhang, H; Zhong, M1
Chen, S; Dzakah, EE; Gong, P; Liu, S; Rashid, F; Sun, Q; Tang, S; Wang, H; Wang, J; Wu, J; Yang, X1
Buti, M; Castellanos Fernández, MI; Chan, WK; Duseja, A; El-Kassas, M; Esmat, G; Gordon, SC; Hamid, S; Henry, L; Isakov, V; Lam, B; Méndez-Sánchez, N; Nader, F; Ong, JP; Papatheodoridis, G; Racila, A; Romero-Gómez, M; Stepanova, M; Yilmaz, Y; Younossi, I; Younossi, ZM; Yu, ML; Ziayee, M1
Bishai, N; Fiki, ME; Garem, NE; Ibrahim, M; Nabawy, WE1
Aoki, K; Force, L; Ishizaki, A; Konishi, H; Liu, LJ; Mita, E; Mizutani, H; Nakamoto, D; Ng, LJ; Shing, D1
Angelidakis, G; Granwehr, BP; Hosry, J; Jiang, Y; Mustafayev, K; Torres, HA; Yepez Guevara, E; Yibirin, M1
Fernandes, F; Pereira, G; Perez, R; Piedade, J; Victor, L; Villela-Nogueira, CA1
Anushree, N; Seetharaman, K; Venkatesh, V1
Abd El-Hameed, M; Dawood, RM; El Ray, AA; Mahmoud Diab, T; Mashaal, AR; Seyam, M; Shemis, MA1
Ajdarkosh, H; Amirkalali, B; Faraji, AH; Karbalaie Niya, MH; Khoonsari, M; Maadi, M; Motamed, N; Nikkhah, M; Safarnezhad Tameshkel, F; Sobrakhshankhah, E; Sohrabi, M; Vafaeimanesh, J; Zamani, F1
Fu, X; Guo, M; He, YQ; Li, CY; Qiao, M; Ren, XD1
Biering, SB; Chien, M; Dugast-Darzacq, C; Garzia, A; Graham, TGW; Jockusch, S; Ju, J; Meyer, C; Näär, AM; Nguyenla, X; Patel, DJ; Russo, JJ; Schaletzky, J; Stanley, S; Stroumza, J; Tao, C; Tuschl, T; Van Dis, E; Wang, X; Wehri, E; Xie, W; Yamashiro, LH; Zhu, C1
Cordie, A; Esmat, G; Kamel, AM; Sabry, N1
Agyemang, L; Anderson, J; Arnsten, J; Blalock, KL; Borsuk, C; Falade-Nwulia, O; Feinberg, J; Heo, M; Jacobsohn, V; Johnson, N; Karasz, A; Kim, AY; Litwin, AH; Luetkemeyer, AF; Lum, PJ; Mckee, MD; Mehta, SH; Meissner, P; Murray-Krezan, C; Norton, BL; Page, K; Pericot-Valverde, I; Roche, J; Stein, ES; Taylor, LE; Thomas, A; Tsui, JI; Wagner, K; Ward, JW; Wilkinson, S1
Li, J; Wang, L; Xie, W; Zhou, Y; Zhu, X1
Abdel Alem, S; Abdelbary, MS; Cordie, A; El Garhy, N; El Khateeb, E; Elsharkawy, A; Esmat, G; Fouad, R; Khalil, M1
Acosta-López, S; Borgia, SM; Buti, M; Di Marco, V; Fenech, M; Fraser, C; Garcia-Retortillo, M; Guerra-Veloz, MF; Hernández, C; Martins, A; Mertens, M; Milella, M; Milligan, S; Morano Amado, LE; Ntalla, I; O'Loan, J; Ramji, A; Ramroth, H; Rodriguez-Tajes, S; Teti, E; Vanstraelen, K; Wedemeyer, H1
Fujita, K; Manabe, T; Masaki, T; Morishita, A; Nakahara, M; Ogawa, C; Ohura, K; Tadokoro, T; Tani, J1
Gamil, AN; Hassuna, NA; Khairy, R; Mahmoud, MS; Mohamed, WK1
Katz, R; Mod, AT1
Diculescu, MM; Gheorghe, L; Iacob, SM; Iliescu, L; Istratescu, D; Manuc, M; Manuc, T; Popescu, CP; Preda, C; Stanciu, C; Stroie, TG; Tieranu, CG; Trifan, A1
Ansari, MA; Barnes, E; Chau, NVV; Cooke, GS; Dang Trong, T; Day, JN; Flower, B; Hoglund, RM; Hung, LM; Kestelyn, E; Kingsley, C; Le Ngoc, C; Le Thi, T; Mccabe, L; Nguyen Bao, T; Nguyen Thi Ngoc, P; Pett, SL; Phuong, LT; Quang, VM; Rahman, M; Smith, D; Tarning, J; Thwaites, GE; Turner, H; van Doorn, R; Van Nuil, JI; Vo Thi, T; Vu Thi Kim, H; Walker, AS1
Chen, CY; Hung, HY; Lai, HH; Lin, HC1
Hung, A; Seetasith, A; Wong, WB; Zullig, LL1
Bhattacharya, D; Brates, I; Kreter, B; Linas, B; Robbins, GK; Smeaton, L; Solomon, S; Sowah, LA; Sulkowski, M; Wagner-Cardoso, S1
Aktas, H; Burger, D; de Knegt, R1
Balagopal, A; Bowden, K; Leep-Lazar, J; Quinn, J; Ribeiro, RM; Sachithanandham, J; Sulkowski, MS; Ward, K1
Enomoto, M; Fujii, H; Hagihara, A; Higashiyama, S; Kageyama, K; Kawabe, J; Kawada, N; Kawamura, E; Kotani, K; Kozuka, R; Motoyama, H; Odagiri, N; Tamori, A; Uchida-Kobayashi, S; Yamamoto, A; Yoshida, A; Yukawa-Muto, Y1
Byrns, J; Kiser, JJ; Maziarz, E; Naggie, S; Narayanasamy, S; Steinbrink, JM; Wolfe, CR1
Bourgeois, S; Foster, GR; Gerken, G; Hernandez, C; Jacobson, IM; Mathurin, P; Osinusi, A; Ryder, SD; Scherbakovsky, S; Tedesco, D; Thuluvath, P; Vanstraelen, K1
Chang, ML; Chen, CJ; Chen, YC; Chien, RN; Hsu, CW; Huang, YH; Lin, CY; Shen, YH1
Hechter, V; Kayuni, N; Saayman, E; Sonderup, MW1
Ahn, SH; Cho, SB; Chung, WJ; Jang, ES; Jeong, SH; Kim, IH; Kim, KA; Kim, S; Kim, YS; Lee, BS; Lee, S; Lee, YJ; Park, HJ1
Hampejskova, L; Hasnain, A; Shah, S1
Azzeri, A; Dahlui, M; Jaafar, H; McDonald, SA; Mohamed, R; Shabaruddin, FH1
Bukh, J; Fahnøe, U; Fernandez-Antunez, C; Gottwein, JM; Mikkelsen, LS; Ramirez, S; Wang, K1
Charlton, C; Hlavay, BA; Klein, MB; Ogando, N; Power, C; Stapleton, JT; Zhuo, R1
Congly, SE; El-Kassas, M; El-Raey, F; Emadeldeen, M; Esmat, G; Gomaa, AA; Hassany, M; Lee, SS; Liu, H1
Mahgoub, A; Schulz, P; Wiginton, A1
Awasthi, A; Deep, A; Goel, A; Katiyar, H; Kumar, A; Kumar, V; Rungta, S; Tiwari, P1
El-Marakby, MG; Sabri, NA; Solayman, MH1
Buonomo, AR; Cattaneo, L; De Filippis, F; Ercolini, D; Gentile, I; Gison, F; Maraolo, AE; Pinchera, B; Schiano Moriello, N; Scotto, R; Viceconte, G; Villari, R; Zappulo, E1
Bhagat, N; Charak, S; De, A; Duseja, A; Goel, K; Premkumar, M; Rathi, S; Sharma, A; Singh, V; Taneja, S; Verma, N1
Domingo, H; Moser, A; Patel, S1
Abdel-Aziz, MM; Hafez, HA; Kamel, MA; Khafaga, RHM; Mahmoud, SA; Shaker, SA1
Hsin, YH; Huang, CW; Ko, CY; Tsai, QZ; Tsai, YC; Yu, ML1
Kottilil, S; Lee, MH; O'Brien, TR; Wilson, E1
Bukh, J; Fahnøe, U; Filskov, J; Jenssen, H; Pedersen, MS; Schønning, K; Sølund, C; Weis, N1
Briones, C; de Ávila, AI; Domingo, E; Durán-Pastor, A; Gallego, I; García-Crespo, C; Gómez, J; Gregori, J; Martínez-González, B; Perales, C; Quer, J; Somovilla, P; Soria, ME1
Al-Qahtani, SD; Alalawy, AI; Alatawi, K; El-Mehasseb, IM; El-Shafai, NM; Farrag, MA; Nada, AI1
Shin, HP1
Ahn, SH; Byun, KS; Cho, JY; Heo, J; Jang, BK; Jang, JW; Jeong, SH; Jung, YJ; Kim, HJ; Kim, IH; Kim, JH; Kim, YJ; Kwon, JH; Kwon, KM; Lee, BS; Lee, SW; Lee, YJ; Lim, YS; Paik, SW; Park, NH; Suri, V; Tak, WY; Wu, P; Yang, SH; Yoon, KT1
Elmowafy, AY; Elrakaiby, MT; Mohamed Abdelnajid, D; Rostaing, L1
Coppola, N; Devan, P; Mohan, BP; Neo, JE; Preda, CM; Tam, YCS; Tiong, KLA; Wijarnpreecha, K; Wong, YJ1
Akhtar, MF; Anwar, F; Khan, A; Shah, SA; Yasmeen, S1
Kampmann, C; Weiland, O; Wejstål, R; Westin, J; Ydreborg, M1
Martinello, M; Matthews, GV; Naggie, S; Rockstroh, JK1
Ahmad, B; Ahmad, J; Ahmad, L; Bashir, K; Chen, TW; Hameed, H; Haq, I; Haq, M; Hussain, K; M Aljowaie, R; Malik, G; Maryam, A; Mohsen Abougazia, E; Ullah, A1
Anuradha, K; Ismal, K; Lakshmi, J; Sahay, M1
Alonzo-García, C; Contreras, AG; Fernández-Ramírez, A; García-Juárez, I; Romero-Hernández, F; Ruiz, I; Servín-Rojas, M1
Duong, V; Guo, M; Han, L; Liu, C; Lu, J; Nouhin, J; Tong, Y; Xiang, X; Xie, Q; Zhong, J1
Alhmoud, JF; Hafez, HA; Kamel, MA; Khafaga, RHM; Mahmoud, SA; Shaker, SA1
Collins, M; Conway, B; Dylla, DE; Khan, T; Marcinak, J; Martinez, A; Saget, B1
Luetkemeyer, AF; McDonell, C; McKinney, J; Morris, MD; Price, JC; Thawley, R1
Alsina, A; Borg, B; Chang, C; Charlton, M; Flamm, S; Hernandez, C; Hézode, C; Landis, C; Lawitz, E; Mercier, RC; Ravendhran, N; Reddy, KR; Samuel, D; Scherbakovsky, S; Shiffman, M1
Assem, NM; Atoom, AM; Hafez, HA; Kamel, MA; Khafaga, RHM; Mahmoud, SA; Shaker, SA1
Daryani, N; Imam, U; Mumtaz, F; Parkash, A1
Abdelmahmoud, MB; AlAlwan, AM; AlGhamdi, HS; AlHabobi, AA; Aljumah, AA; AlOun, AA; AlQahtani, RS; AlThiab, KM; AlTraif, IH; Ghomraoui, FA1
Awad, J; Balsara, K; Brinkley, DM; Brown Sacks, S; Danter, M; Darragh, C; Fowler, R; Lindenfeld, J; Menachem, J; O'Dell, H; Ooi, H; Perri, R; Punnoose, L; Ruzevich-Scholl, S; Schlendorf, K; Shah, A; Smith, S; Wigger, M; Zalawadiya, SK1
Bahuguna, P; Chugh, Y; Dhiman, RK; Premkumar, M; Prinja, S; Singh Grover, G1
Grasso, AG; Loiacono, S; Maestro, A; Maximova, N; Sonzogni, A; Zanon, D1
Anis, AH; Azim, T; Chowdhury, EI; Faruque, MO; Janjua, NZ; Kabir, A; Khan, SI; Rahman, M; Reza, M; Sarker, MS; Shafiq, TKI1
Afzal, MS; Ahmed, H; Ali, M; Haqqi, A; Khalid, M; Khurram, M; Munir, R; Shah, ZH; Zaid, M1
Abutidze, A; Adamia, E; Afdhal, N; Arora, S; Averhoff, F; Butsashvili, M; Chkhartishvili, N; Gamkrelidze, A; Gvinjilia, L; Kerashvili, V; Kuchuloria, T; Lagvilava, M; Metreveli, D; Nasrullah, M; Sergeenko, D; Shadaker, S; Sharvadze, L; Skaggs, B; Thornton, K; Tsertsvadze, T; Zeuzem, S1
Cescon, M; De Pace, V; Galli, S; Maggi, F; Morelli, MC; Pistello, M; Ravaioli, M; Re, MC; Vero, V1
Brown, CH; Fang, LJ; Goldberg, R; Graydon, M; Himelhoch, S; Kreyenbuhl, J; Slade, E; Travaglini, LE1
Mandimika, C; Ogbuagu, O1
Blackard, JT; Horn, PS; Karns, R; Kong, L; Kottilil, S; Rouster, SD; Shata, MT; Sherman, KE1
Alonso López, S; Guerra Romero, AR; Pérez Figueras, M1
Barclay, ST; Boyle, A; Datta, S; Heydtmann, M; Marra, F; Peters, E; Priest, M; Ritchie, T1
Alavi, M; Danta, M; Dore, GJ; Hajarizadeh, B; He, S; Lockart, I1
Hikita, H; Takehara, T1
Al-Ahmed, SH; Aldrazi, FA; Alfouzan, WA; Alsuliman, SA; Bazzi, AM; Haque, S; Rabaan, AA1
Farcomeni, A; Gioia, S; Nardelli, S; Ridola, L; Riggio, O; Rosati, D1
Cui, LY; Liu, LD; Nan, YM; Zhao, W1
Lazarus, JV; Lens, S1
Giannini, EG; Indolfi, G1
Aghemo, A; Aimo, G; Baiguera, C; Bella, D; Bernasconi, DP; Bhoori, S; Boldizzoni, R; Bonfanti, P; Capretti, A; Carderi, I; Carriero, C; Centenaro, R; Ciaccio, A; Colella, E; Cologni, G; Colombo, A; Colombo, S; D'Ambrosio, R; d'Arminio Monforte, A; De Bona, A; Degasperi, E; Del Poggio, P; Di Marco, M; Dionigi, E; Fagiuoli, S; Fava, M; Gatti, F; Giglio, O; Giorgini, A; Graffeo, M; Grossi, PA; Hasson, H; Lampertico, P; Landonio, S; Lapadula, G; Lazzaroni, S; Liani, C; Lombardi, A; Menzaghi, B; Migliorino, GM; Molteni, C; Noventa, F; Pagnucco, L; Pan, A; Pasulo, L; Perini, P; Pigozzi, MG; Polo, S; Puoti, M; Rizzardini, G; Rossotti, R; Rumi, MG; Schiavini, M; Soria, A; Spinelli, O; Spinetti, A; Terreni, N; Uberti-Foppa, C; Valenti, L; Valsecchi, MG; Viganò, M; Viganò, P; Vinci, M1
Afshar, B; Agah, S; Amiriani, T; Fattahi Abdizadeh, M; Fattahi, MR; Hormati, A; Khoshnia, M; Latifnia, M; Majd Jabbari, S; Maleki, I; Malekzadeh, R; Malekzadeh, Z; Mansour-Ghanaei, F; Merat, D; Merat, S; Minakari, M; Moini, M; Mokhtare, M; Poustchi, H; Roozbeh, F; Sharifi, AH; Shayesteh, AA; Shayesteh, E; Sofian, M; Sohrabi, M; Somi, MH1
Applin, S; Asmuth, DM; Cox, S; Das, M; Goldstein, D; Guyer, B; Haubrich, RH; Hinestrosa, F; Huhn, GD; Jain, MK; Jiang, S; Nguyen-Cleary, T; Piontkowsky, D; Ramgopal, M; Rossaro, L; Ryu, JH; Slim, J1
Dholaria, B; Juskevicius, R; Moreno Vanegas, YA1
Cazorla, JM; Garcia, T; Mazuecos, A; Merino, MJ; Moreno-Ramirez, M; Naranjo, J; Vigara, LA; Villanego, F1
Heinz, A; Johnson, NL; Lasser, KE; Lee, KS; Quintiliani, L; Truong, V; Xuan, Z1
Althoff, KN; Elion, RA; Eron, JJ; Gillman, J; Huhn, GD; Jayaweera, DT; Mills, A; Mounzer, K; Moyle, G; Patel, SV; Radtchenko, J; Santiago, S; Sax, PE1
Brennfleck, FW; Brunner, SM; Evert, K; Junger, H; Knoppke, B; Melter, M; Schlitt, HJ; Weigand, K1
Abdel Moneim, A; Mabrouk, D; Mahmoud, B; Suleiman, HA; Zaky, MY1
Nabavi, N; Pourahmad, J; Yousefsani, BS1
Banga, J; Nagarakanti, S; Nizami, S; Portilla, M; Slim, J; Swaminathan, S1
Haseltine, WA1
Guyader, D; Jézéquel, C; Lalanne, S; Lemaitre, F; Mercerolle, M; Pronier, C; Tron, C; Verdier, MC1
Angelico, M; Aragri, M; Carioti, L; Ceccherini-Silberstein, F; Di Maio, VC; Lenci, I; Milana, M; Perno, CF; Svicher, V1
El-Sayed, HM; Elmasry, MS; Hassan, WS; Shalaby, A; Zidan, DW1
Castro-Iglesias, Á; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, Á; Rotea-Salvo, S; Sanclaudio-Luhia, AI; Suárez-López, F; Vázquez-Rodríguez, P1
Chang, TS; Chen, CH; Chen, MY; Chen, WM; Chiu, WN; Hu, JH; Hu, TH; Hung, CH; Lu, CK; Lu, SN; Tung, SY; Wei, KL1
Balkan, S; Brucker, C; Chhit, D; Dousset, JP; Hang, V; Iwamoto, M; Jolivet, P; Kien, A; Le Paih, M; Ly, S; Marquardt, T; O'Keefe, D; Sann, K; Zhang, M1
Khalil, H; Kim, NG; Kullar, R; Saab, S1
Barnes, E; Chau, NVV; Cooke, GS; McCabe, L; Pett, SL; Walker, AS; White, IR1
Bronowicki, JP; Carrat, F; Chazouillères, O; Chevaliez, S; de Lédinghen, V; Dorival, C; Fontaine, H; Larrey, D; Lusivika-Nzinga, C; Marcellin, P; Metivier, S; Pawlotsky, JM; Pol, S; Samuel, D; Tran, A; Zoulim, F1
Agarwal, K; Bestwick, J; Drysdale, K; Elsharkawy, AM; Forton, D; Foster, GR; Gelson, W; Mahomed, F; Mutimer, D; Ntuli, Y; Townley, C1
Borgia, SM; Brown, RS; Carrat, F; Doucette, K; Fagiuoli, S; Khalili, M; Lampertico, P; Losappio, R; Mangia, A; Mertens, M; Milligan, S; Ntalla, I; Ouzan, D; Papatheodoridis, G; Pérez-Hernandez, F; Ramji, A; Ramroth, H; Shafran, SD; Turnes, J; Vanstraelen, K; Wedemeyer, H; Wick, N1
Barbera, F; Conaldi, PG; Curcio, G; Gallo, A; Pietrosi, G; Russelli, G; Tuzzolino, F; Vizzini, G; Volpes, R1
Barclay, ST; de Bruin, M; Dillon, JF; Donnan, PT; Fraser, A; Hapca, A; Inglis, SK; Radley, A1
Bruchfeld, A1
Bonacini, M; Brainard, DM; De-Oertel, S; Flamm, SL; Gane, EJ; Gordon, SC; Huang, J; Hyland, RH; Kirby, BJ; Landis, CS; Lawitz, E; Maliakkal, BJ; Ortiz-Lasanta, G; Osinusi, AO; Robson, R; Zhang, J1
Da, BL; Dieterich, D; Kushner, T; Lourdusamy, V; Saberi, B1
Aschenbrenner, DS4
Applegate, TL; Barash, D; Churkin, A; Cotler, SJ; Dahari, H; Dasgupta, S; Etzion, O; Gorstein, E; Martinello, M; Matthews, GV; Uprichard, SL; Walsh, K; Yardeni, D1
Averhoff, F; Butsashvili, M; Dvali, S; Gamkrelidze, A; Gvinjilia, L; Kamkamidze, G; Metreveli, D; Morgan, J; Nasrullah, M; Rukhadze, T; Shadaker, S1
Aikata, H; Chayama, K; Fukuhara, T; Hayes, CN; Imamura, M; Mori, N; Ohya, K; Takaki, S; Tsuji, K; Yamaguchi, S1
Devi, S1
Blackard, JT; Celentano, DD; Jamieson, DJ; King, CC; Klein, RS; Kong, L; Lin, D; Mayer, KH; Ngwaga, T; Schoborg, C; Sobel, JD; Tavis, JE; Taylor, LE1
Chander, PN; Chugh, S; Singh, J; Solanki, S; Wolf, DC1
Gauci, J; Gerada, J; Micallef, S1
Byrd, K; D'Agata, EMC; Kalligeros, M; Martin, P; Mylonakis, E; Shehadeh, F; Shemin, D1
Burger, DM; Colbers, A; Drenth, JPH; Freriksen, JJM; Greupink, R; Meijerhof, M; Russel, FGM; van Drongelen, J1
Ahlenstiel, G; Bowden, S; Dore, GJ; Douglas, M; Doyle, J; Farrell, G; Fisher, L; George, J; Haque, M; Hazeldine, S; Hellard, M; Levy, M; MacQuillan, G; McGarity, B; New, K; O'Beirne, J; O'Keefe, J; Papaluca, T; Prewett, E; Roberts, SK; Sawhney, R; Sievert, W; Sinclair, M; Sood, S; Stoove, M; Strasser, SI; Stuart, KA; Thomas, J; Thompson, AJ; Tse, E; Valaydon, Z; Valiozis, I; Wade, AJ; Weltman, M; Wigg, A; Wilson, M; Woodward, A1
Janjua, NZ; Klein, MB; Wong, S; Young, J1
Kakizaki, S; Kizawa, K; Kosone, T; Marubashi, K; Sato, K; Shimizu, M; Takagi, H; Takakusagi, S; Uraoka, T; Yokoyama, Y1
Baicus, C; Chifulescu, AE; Diculescu, M; Gheorghe, LS; Iacob, S; Iliescu, L; Istratescu, D; Manuc, M; Meianu, C; Pop, CS; Preda, C; Stanciu, C; Tieranu, C; Trifan, A; Tugui, L; Voiosu, T1
Bayer, J; Burton, J; Dodge, J; Ghobrial, M; Klein, C; Mohan, S; Niemann, CU; Rubin, RA; Terrault, NA; Trotter, J; Verna, E; Victor, D1
Barralon, M; Bijl, M; Cavenaugh, C; Chasela, CS; Chew, KW; Drame, N; Freiman, MJ; Gandhi, MM; Kyi, KP; Lwin, AA; Marange, F; Min Thaung, Y; Minior, T; Mohamed, S; Naing, AY; Rosen, S; Sanne, I; Sein, YY; Thura, S; Thwin, HT; van der Horst, C; Wose Kinge, C; Xulu, T1
Bogen, DL; Bunge, KE; Chappell, CA; Gaggar, A; Hillier, SL; Kirby, BJ; Krans, EE; Macio, IS; Meyn, LA; Scarsi, KK; Suri, V1
Chien, M; Jockusch, S; Ju, J; Kalachikov, S; Kumar, S; Li, X; Morozova, I; Russo, JJ; Tao, C1
Masuda, T; Miyasaka, A; Okamoto, H; Suzuki, A; Takikawa, Y; Yoshida, Y1
Bhakuni, P; Chakrabarti, S; Gupta, M; Jaiswal, SR; Soni, M; Thatai, A1
Aho, I; Amele, S; Bhagani, S; Chkhartisvili, N; Clarke, A; Domingo, P; Falconer, K; Fonquernie, L; Jabłonowska, E; Leen, C; Lundgren, J; Maltez, F; Matulionyte, R; Mocroft, A; Peters, L; Rockstroh, J; Rodger, A; Sarcletti, M; Stephan, C; Szlavik, J; Wandeler, G; Zaccarelli, M; Østergaard, L1
Dee, YKS; Linn, YH; Lwin, KM1
Aggarwal, R; Bhadauria, DS; Goel, A; Gupta, A; Kaul, A; Rai, P; Rungta, S; Tiwari, P; Verma, A1
Abd El-Maksoud, MDE; Ahmed, AE; Ahmed, OM; El-Garem, H; Gamal, A; Sakr, AA1
Bittar, C; Chen, S; Fernandes Campos, GR; Harris, M; Martinelli, ALC; Pereira, LRL; Rahal, P; Souza, FF; Vilela Rodrigues, JP; Ward, J1
Mendizabal, M; Piñero, F; Ridruejo, E; Silva, M1
Chen, YM; Mei, YY; Wu, YK; Xu, WX; Zhang, XH1
Ahmed-Belkacem, A; Chevaliez, S; Demontant, V; Donati, F; Fourati, S; François, M; N'Debi, M; Pawlotsky, JM; Poiteau, L; Rodriguez, C; Ruiz, I; Scoazec, G; Soulier, A1
Abdelbaser, ES; Elsadek, HM; Emara, MH; Farag, AA; Soliman, HH1
Chen, S; Song, W; Yi, Z; Yuan, Z; Zhang, Y1
Farooq, MO; Malik, K; Mengal, FUA; Salim, A1
Choi, IS; Kim, KM; Shim, SG1
Bhangui, P; Choudhary, NS; Rastogi, A; Saigal, S; Saraf, N; Soin, AS; Thiagrajan, S1
Ahn, SH; Amarsanaa, J; Baatarkhuu, O; Badamsuren, D; Batbayar, P; Choijamts, N; Enkhtuya, D; Gantuul, C; Gegeebadrakh, B; Han, KH; Kim, DY; Lee, JS; Naranzul, N; Otgonbayar, R; Otgonbold, J; Saruul, BU; Tuvshinbayar, N; Ulzmaa, G1
Ali, M; Ali, S; Haque, S; Lougher, E; Nawaz, MS; Paudyal, V; Rasheed, F; Ur-Rehman, T1
Amara, D; Blumberg, E; Dove, L; Durand, CM; Emond, J; Fishbein, T; Florman, S; Grab, J; Haydel, B; Huprikar, S; Husson, J; Kottilil, S; Luetkemeyer, AF; Masur, H; Olthoff, K; Peters, MG; Rogers, R; Smith, C; Stock, PG; Sulkowski, MS; Terrault, N1
Chang, JM; Chen, SC; Chiu, YW; Chuang, WL; Dai, CY; Hsieh, MY; Hsu, CT; Hsu, PY; Huang, CF; Huang, CI; Huang, JC; Huang, JF; Hung, TS; Hwang, SJ; Lee, JJ; Liang, PC; Lin, WY; Lin, YH; Liu, TW; Niu, SW; Wei, YJ; Yeh, ML; Yu, ML1
Chang, JM; Chen, SC; Chiu, YW; Chuang, WL; Dai, CY; Hsieh, MH; Hsieh, MY; Hsu, CT; Hsu, PY; Huang, CF; Huang, CI; Huang, JC; Huang, JF; Hwang, SJ; Jang, TY; Lee, JJ; Liang, PC; Lin, YH; Lin, ZY; Niu, SW; Wei, YJ; Yeh, ML; Yu, ML1
Chifulescu, AE; Diculescu, M; Gheorghe, LS; Iliescu, L; Istratescu, D; Manuc, M; Pop, CS; Preda, CM; Tieranu, C; Voiosu, T1
Morillo-Verdugo, R; Sicras-Mainar, A1
Ampuero, J; García-García, Y; García-Monzón, C; González-Rodríguez, Á; Majano, P; Marañón, P; Molina-Jiménez, F; Múñoz-Hernández, R; Rey, E; Romero-Gómez, M1
Aregay, A; Björkström, NK; Cornberg, M; Deterding, K; Du, Y; Hardtke, S; Hardtke-Wolenski, M; Hengst, J; Khera, T; Manns, MP; Port, K; Steinmann, E; Strunz, B; Todt, D; Wedemeyer, H1
Maajani, K; Majd Jabbari, S; Merat, S; Poustchi, H; Sepanlou, SG1
Abdullatif, H; Alem, SA; El-Karaksy, H; El-Raziky, MS; Eldeen, HG; Mogahed, EA; Nagy, A; Yasin, NA1
Mühlbacher, AC; Sadler, A1
Callegaro, FS; de Camargo Vieira, MC; Gonçalves, WRB; Guerra, RA; Lazaretti-Castro, M; Maeda, SS1
Darwish, NHE; Elbasiony, M; Mousa, SA; Shiha, G; Soliman, R1
Doi, A; Hikita, H; Kodama, T; Sakamori, R; Shigekawa, M; Shinkai, K; Tahata, Y; Takehara, T; Tatsumi, T; Yamada, R; Yamada, T1
Harrison, M; Ho, H; Janjua, NZ; Law, MR; McGrail, KM1
Bair, MJ; Chang, CC; Chen, CH; Chen, CT; Chen, CY; Chen, GY; Cheng, PN; Chong, LW; Chuang, WL; Dai, CY; Hsieh, TY; Hsiung, CK; Hu, JT; Huang, CF; Huang, CS; Huang, JF; Huang, YH; Hung, CH; Kao, CN; Kao, JH; Kuo, HT; Lee, MH; Lee, PL; Lee, TH; Lin, CL; Lin, CW; Lin, CY; Lin, HC; Liu, CH; Liu, CJ; Lo, CC; Mo, LR; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tsai, WL; Tseng, KC; Wang, CC; Wang, SJ; Wu, WC; Yang, CC; Yang, SS; Yeh, ML; Yu, ML1
Bilal, M; Farooq, N; Hussain, N; Maqsood, M; Rajoka, MSR1
Aghemo, A; Solitano, V1
Balkan, S; Bunreth, V; Craig, J; Dousset, JP; Jolivet, P; Le Paih, M; Marquardt, T; O'Keefe, D; Samley, K; Zhang, M1
Ehl, S; Maccari, ME; Speckmann, C; Thalhammer, J; Wegehaupt, O1
Ahmed, A; Davis, MM; Dekker, CL; Du, H; Fram, BJ; Furman, D; Glenn, JS; Grant, PM; Khatri, P; Lopez Angel, CJ; Maecker, HT; Nguyen, T; Perez, K; Pham, EA; Rosenberg-Hasson, Y; Vallania, F1
Derayea, SM; Hamad, AE; Mohammed, BS1
Martin, P; McQuaid, T; Sise, ME1
Draper, B; Hellard, M; Pedrana, A1
Burden, AM; Burkard, T; Hayes, KN; Tadrous, M; Weiler, S1
Rabenjanahary, TH; Rakotozafindrabe, ALR; Ramanampamonjy, RM; Randriamifidy, NH; Rasolonjatovo, AS; Razafimahefa, SH; Razafindrazoto, CI1
Akhan, S; Aktuğ Demir, N; Arslan Özel, S; Asan, A; Aygen, B; Barut, Ş; Batırel, A; Bilgin, H; Çağatay, A; Çelen, MK; Çelik, İ; Çetinkaya, RA; Demirtürk, N; Doğan, N; Ersöz, G; Gürbüz, Y; Hakyemez, İN; İnan, D; Kamalak Güzel, D; Karakeçili, F; Kınıklı, S; Konya, P; Korkmaz, P; Kuruüzüm, Z; Mıstık, R; Örmen, B; Öztürk, S; Saltoğlu, N; Şener, A; Şimşek, F; Şimşek, S; Suer, K; Tarakçı, H; Tülek, N; Tuna, N; Tuncer Ertem, G; Türker, N; Türkoğlu, E; Ural, O; Yıldız, O; Yıldız, U1
Chang, KC; Chang, TS; Chen, WM; Chiu, WN; Ding, YJ; Hsieh, YY; Hung, CH; Lu, CK; Lu, SN; Shen, CH; Tung, SY; Wei, KL; Yen, CW1
Inoue, J; Iwata, T; Kakazu, E; Masamune, A; Ninomiya, M; Sano, A; Sato, K; Tsuruoka, M1
Amano, N; Genda, T; Ikeda, Y; Kabemura, D; Kita, Y; Murata, A; Sato, S; Shimada, Y; Tsuzura, H; Yatagai, N1
Ansari, MA; Aranday-Cortes, E; Barnes, E; Benselin, J; Bibby, DF; Bradshaw, D; Brown, A; da Silva Filipe, A; Healy, B; Hudson, E; Irving, WL; Manso, CF; Mbisa, JL; McLauchlan, J; Singer, JB; Smith, DA; Thomson, EC; Troke, P1
Bergquist, K; Fried, MW; Kort, JJ; Larsen, L; Magee, A; Michael, LC; Nelson, DR; Patel, CB; Peter, JA; Schnell, GL; Schuster, L; Sidhu, GS; Tamashiro, R; Tripathi, RL; Wang, GP; Whitlock, JA1
Applegate, TL; Bhagani, S; Bruneau, J; Dore, GJ; Feld, JJ; Gane, E; Grebely, J; Hellard, M; Ingiliz, P; Kim, A; Marks, P; Martinello, M; Matthews, GV; Nelson, M; Petoumenos, K; Rauch, A; Rockstroh, J; Shaw, D; Thurnheer, C; Van der Valk, M1
Bai, L; Chen, L; Du, L; He, M; Kang, S; Li, C; Ma, F; Tang, H1
D'Antiga, L; Di Giorgio, A; Indolfi, G; Nicastro, E; Norsa, L1
Chang, KC; Chang, TS; Chen, WM; Hsieh, YY; Huang, YT; Hung, CH; Lu, CK; Lu, SN; Shen, CH; Tung, SY; Wei, KL; Yen, CW1
Abbassi, MM; Ebeid, FS; El-Baraky, IA; El-Sayed, MH; Hassany, M; Sabry, NA1
Bhati, C; Carroll, N; Cotterell, A; Gupta, G; Ijioma, S; Kamal, L; Kang, L; Khan, A; Kimball, P; King, A; Kumar, D; Levy, M; Mitchell, K; Moinuddin, I; Patterson, J; Sharma, A; Shinbashi, M; Sterling, R; Yakubu, I; Zhang, Y1
Fraser, H; Havens, JR; Hoven, A; Lofwall, M; Schaninger, T; Staton, M; Vickerman, P; Walsh, SL; Young, AM1
Chang, CC; Chang, CH; Chang, CY; Chen, CY; Chen, JJ; Chen, PY; Fang, YJ; Hsieh, TY; Huang, CS; Huang, KJ; Huang, YJ; Hwang, JJ; Kao, JH; Kao, WY; Lai, HC; Lee, FJ; Lee, PL; Liu, CH; Liu, CJ; Lo, CC; Peng, CY; Shih, YL; Su, PY; Su, WW; Tsai, MC; Tseng, CW; Tseng, KC; Wu, JH; Yang, SS1
Bloom, DE; Khoury, A; Srinivasan, V1
Pang, L; Tang, H; Tang, Y; Xu, D; Xu, P; Yang, X; Zhang, G1
Lonze, BE; Parent, B; Richter, BI1
Brainard, DM; Chung, R; Fierer, DS; Hollabaugh, K; Hughes, M; Kim, A; Kiser, JJ; Macbrayne, C; Marks, KM; McHutchison, JG; Naggie, S; Peters, MG; Roa, J; Symonds, B1
Akhil, MS; Arumugam, K; Ganesh Prasad, NK; Kirushnan, B; Martin, M; Ravichandran, R1
Chowdhury, R; Tsen, A1
Aggarwal, R; Bhadauria, DS; Goel, A; Gupta, A; Kaul, A; Prasad, N; Rai, P; Sharma, RK1
Adeyemi, O; Brainard, DM; Bräu, N; Daar, ES; Doehle, B; Huang, KC; Kim, AY; Kottilil, S; Luetkemeyer, A; McHutchison, JG; McNally, J; Mogalian, E; Naggie, S; Osinusi, A; Ruane, P; Sulkowski, M; Workowski, K; Wyles, D1
Chevaliez, S; Fourati, S; François, M; Hézode, C; Mallat, A; Pawlotsky, JM; Roudot-Thoraval, F; Ruiz, I; Scoazec, G; Soulier, A; Varaut, A1
Deming, P; Martin, MT1
Angarano, G; Bruno, G; Milella, M; Saracino, A1
Hirayama, A; Matsuoka, S; Moriyama, M; Nakamura, H; Nirei, K; Yamana, Y; Yoda, S1
Bhagani, S; Boesecke, C; Brainard, DM; Dvory-Sobol, H; Hyland, RH; Ingiliz, P; Lutz, T; Nelson, M; Rockstroh, JK; Yun, C; Zheng, W1
Abd-Elsalam, S; Ahmed, OA; Hassan A Fouad, M; Hawash, N; Kaisar, HH; Rizk, F; Samir, H; Shabana, SST1
Bonfanti, P; Celesia, BM; De Socio, GV; Di Biagio, A; Maggi, P; Martinelli, C; Nicolini, LA; Quirino, T; Ricci, E; Squillace, N; Taramasso, L1
Balkan, II; Mete, B; Ozaras, R; Tabak, F; Yemisen, M1
Haba, S; Kobayashi, Y; Matsuda, S; Miyagishima, T; Morikawa, K; Nakano, S; Oda, H; Sakamoto, N; Sarashina, K; Sogabe, S; Takahashi, K; Takahashi, T; Terashita, K; Yamamura, T; Yoshikawa, A1
Hunt, S; Kottilil, S; Stepanova, M; Sulkowski, M; Wyles, D; Younossi, ZM1
Gonzalez-Estrada, A; Sankhyan, P1
Aung, ST; Bwa, AH; Hlaing, NKT; Kyaw, AMM; Mitrani, RA; Phyo, WW; Reddy, KR; Serper, M; Win, KM1
Arencibia, AC; Baliellas, C; Blasco, A; Cabezas, J; Calleja, JL; Carrión, JA; Castellote, J; Castells, L; Castro, MA; Crespo, J; Cuervas-Mons, V; de Artaza, T; Diago, M; Fernández, I; Forné, M; Forns, X; Gallego, A; García-Samaniego, J; Gea-Rodríguez, F; Giráldez, Á; Gómez, A; Hontangas, V; López-Núñez, C; Mariño, Z; Montero, JL; Moreno, JM; Morillas, R; Narváez, I; Pascasio-Acevedo, JM; Pascual, S; Prieto, M; Romero-Gómez, M; Sánchez-Antolín, G; Sánchez-Ruano, JJ; Torras, X; Turnes, J; Vergara, M1
Angiola, A; Caruso, A; Casari, S; Castelli, F; Festa, E; Gargiulo, F; Lanza, P; Nasta, P; Odolini, S; Rodella, A; Urbinati, L; Vavassori, A; Viganò, M; Zaltron, S1
Heil, EL; Hoke, KS; Mattingly Ii, TJ1
Alfieri, R; Andreoni, M; Angelico, M; Antonucci, FP; Babudieri, S; Bernardini, S; Biliotti, E; Bolis, M; Calvaruso, V; Casalino, P; Ceccherini-Silberstein, F; Cento, V; Cerrone, M; Craxì, A; D'Arminio Monforte, A; Danieli, E; Di Biagio, A; Di Carlo, D; Di Maio, VC; Di Paolo, D; Gianserra, L; Guedj, J; Lenci, I; Magni, CF; Melis, M; Menzaghi, B; Micheli, V; Nguyen, THT; Nicolini, LA; Parruti, G; Pasquazzi, C; Perno, CF; Polilli, E; Puoti, M; Quirino, T; Rizzardini, G; Romagnoli, D; Sarmati, L; Siciliano, M; Taliani, G; Teti, E1
Augustyniak, K; Badurek, A; Baka-Ćwierz, B; Berak, H; Białkowska, J; Flisiak, R; Garlicki, A; Gietka, A; Janczewska, E; Kozielewicz, D; Mazur, W; Mozer-Lisewska, I; Musialik, J; Nowak, K; Olszok, I; Piekarska, A; Pleśniak, R; Sikorska, K; Simon, K; Stolarz, W; Tomasiewicz, K; Wawrzynowicz-Syczewska, M; Zarębska-Michaluk, D; Łucejko, M1
Amblard, F; Amiralaei, S; Cho, JH; Coats, SJ; Ehteshami, M; Li, H; Lu, X; McBrayer, TR; Ozturk, T; Schinazi, RF; Shelton, JR; Stanton, R; Zhang, H; Zhou, L1
Bansal, MB; Bourlière, M; Brainard, DM; Buggisch, P; Cooper, CL; Curry, MP; de Lédinghen, V; Dvory-Sobol, H; Flamm, SL; Gordon, SC; Huang, KC; Hyland, RH; Kowdley, KV; Landis, CS; Manns, MP; McHutchison, JG; Pianko, S; Ramji, A; Ravendhran, N; Reddy, KR; Schiff, ER; Stamm, LM; Strasser, SI; Subramanian, GM; Svarovskaia, E; Tong, M; Tran, TT; Verna, EC; Vierling, JM; Younes, ZH; Zeuzem, S; Zhang, J1
Bielen, R; Bourgeois, S; Brixko, C; Cool, M; Cools, W; D'heygere, F; De Galocsy, C; Decaestecker, J; Janssens, F; Moreno, C; Mulkay, JP; Nevens, F; Robaeys, G; Van Overbeke, L; Van Steenkiste, C; Van Vlierberghe, H; Vanwolleghem, T; Verlinden, W1
Sise, ME1
Sokol, R1
Mauss, S; Tacke, F1
Goda, Y; Hakamatsuka, T; Hosoe, J; Kamakura, H; Maruyama, T; Masada, S; Tokumoto, H; Tsujimoto, T; Uchiyama, N1
Arias, A; Barreiro, P; Benítez-Gutiérrez, L; Carrasco, I; de Mendoza, C; Peña, JM; Soriano, V1
Bhayani, V; Desai, P; Kabrawala, M; Mehta, R; Nandwani, S; Parekh, V; Patel, S1
Barra, M; Caldeira, D; Costa, J; Duarte, MM; Ferreira, JJ; Gonçalves, N; Pinto, FJ; Rodrigues, FB; Sterrantino, C1
Andriulli, A; Barone, M; Brancaccio, G; Conti, F; Di Leo, A; Francavilla, R; Gatti, P; Iannone, A; Ippolito, AM; Lauletta, G; Masetti, C; Messina, V; Milella, M; Morisco, F; Napoli, N; Pesce, F; Santantonio, T; Shahini, E; Smedile, A; Termite, AP; Tundo, P1
Abaalkhail, F; Ajlan, A; Al Sebayel, M; Al-Hamoudi, W; Al-Jedai, A; Alabbad, S; Broering, D; Elbeshbeshy, H; Elsiesy, H; Saab, S; Shawkat, M; Ullah, W; Yousif, S1
Altice, FL; Barnard, T; Filippovych, S; Mazhnaya, A; Meteliuk, A; Zelenev, A1
Cheema, HA; Hashmi, MA1
Abunimeh, M; Agarwal, K; Charafeddine, M; Cohen, DE; Cohen, E; Foster, GR; Fu, B; Gane, E; Pilot-Matias, T; Pothacamury, RK; Shafran, SD; Shaw, D1
Baz, M; Harris, DD; Shafii, AE1
Antonini, TM; Botta-Fridlund, D; Canva, V; Coilly, A; De Ledinghen, V; Diallo, A; Duclos-Vallée, JC; Dumortier, J; Durand, F; Fougerou-Leurent, C; Houssel-Debry, P; Kamar, N; Leroy, V; Pageaux, GP; Perré, P; Radenne, S; Rohel, A; Rossignol, E; Samuel, D; Taburet, AM; Veislinger, A1
Abd-Elsalam, S; Ahmad, YK; Badawi, R; Elfert, A; Sharaf-Eldin, M; Soliman, S1
Reddy, KR; Weinberg, EM1
Birnkrant, D; Chan-Tack, K; Naeger, LK; Qi, K; Struble, K1
Fulco, PP; Lavoie, SR; Sterling, RK1
Ikeda, A; Ikeda, K; Inagaki, N; Kokuryu, H; Marusawa, H; Seno, H; Takahashi, K; Takai, A; Ueda, Y1
Brancaccio, G; Cantone, M; Ceccherini-Silberstein, F; Fabeni, L; Frigeri, F; Gaeta, GB; Genderini, F; Perno, CF; Pinto, A; Rizzo, V; Sorbo, MC1
Frey, A; Gerken, G; Herzer, K; Piras-Straub, K; Timm, J; Walker, A1
Chahine, EB; Childs-Kean, LM; Kelley, D1
Agudelo, EZ; Campos-Varela, I; Roberts, JP; Sarkar, M; Terrault, NA1
Eurich, D; Globke, B; Pratschke, J; Schott, E; Teegen, EM1
Kalal, C; Mohanka, R; Patel, P; Shah, S; Shukla, A; Vora, M1
Brainard, DM; Camus, G; Chang, TT; Chen, CY; Chen, JJ; Chen, PJ; Chien, RN; Chu, CJ; Chuang, WL; Hsu, YC; Hu, TH; Jiang, D; Knox, SJ; Liu, CJ; Lo, GH; Massetto, B; McHutchison, JG; Osinusi, A; Peng, CY; Sheen, IS; Tseng, KC; Wang, HY; Yang, JC; Yun, C1
Assoumou, SA; Horsburgh, CR; Huang, W; Linas, BP; Young, K1
Crutcher, EL; Greene, EM; Lenz, DU1
Ahmed, B; Ghaffar, A; Jalal, F; Kamran, SK; Kiran, S; Munir, B; Oranab, S; Shehzadi, S; Zahoor, MK1
Angelico, M; Biolato, M; Calvaruso, V; Carrai, P; Craxì, A; D'offizi, G; Fagiuoli, S; Guaraldi, G; Lenci, I; Lionetti, R; Loiacono, L; Mancusi, RL; Mazzarelli, C; Milana, M; Montalbano, M; Piccolo, P; Valente, G; Visco-Comandini, U1
Carlton-Smith, C; Chung, RT; Holmes, JA; Kim, AY; Lauer, GM; Lidofsky, A; Naggie, S1
Agarwal, K; Carey, I; Lampejo, T1
Chen, TY; Dong, J; Gao, H; He, YL; Hu, CH; Liu, JF; Ren, DF; Yan, TT; Yang, SJ; Yang, Y; Zhao, YR; Zhu, L1
Blackard, JT; Hammerstad, SS; Homann, D; Kong, L; Lombardi, A; Tomer, Y1
Agrati, C; Ammassari, A; Antinori, A; Fabbri, G; Libertone, R; Notari, S; Tempestilli, M1
Elhenawee, M; Hashem, H; Ibrahim, AE; Saleh, H1
El-Amin, H; El-Khayat, H; Fouad, Y; Kamal, EM; Maher, M; Mohamed, HI; Risk, A1
Elfert, AA1
Asensi-Diez, R; Del Rio-Valencia, JC; Madera-Pajin, R; Muñoz-Castillo, I; Yunquera-Romero, L1
Scott, LJ1
Khattak, MA; Kothapalli, A1
Ansari, MA; Barnes, E; Bonsall, D; Bowden, R; Brown, A; Ip, CLC; Magri, A; Nguyen, D; Piazza, P; Simmonds, P; Smith, D; Trebes, A1
Doi, A; Furuta, K; Hikita, H; Imai, Y; Kai, Y; Kodama, T; Mita, E; Ohkawa, K; Sakamori, R; Tahata, Y; Takehara, T; Tatsumi, T; Yakushijin, T; Yamada, R1
Ali, M; Aziz, H; Raza, A; Shinwari, ZK; Zia, A; Zia, M1
Desai, K; Desai, N; Kabrawala, M; Mehta, R; Nandwani, S; Parekh, V; Shah, J1
Afdhal, N; Babusis, D; Curry, MP; Kirby, B; Mathias, A; McHutchison, JG; Murakami, E; Park, Y; Ray, AS; Wang, T1
Fan, R; Hou, J; Liang, X; Sun, J1
Ferenci, P1
Fung, P; Lingiah, VA; Punnoose, M; Pyrsopoulos, N; Trilianos, P1
Bair, N; Bowring, MG; Brown, DM; Chattergoon, MA; Desai, NM; Durand, CM; Massaccesi, G; Naqvi, FF; Ostrander, D; Reyad, A; Segev, DL; Sugarman, J; Sulkowski, M; Wesson, R1
Bergmann, OM; Björnsson, ES; Fridriksdottir, RH; Gottfredsson, M; Gudnason, T; Hansdottir, I; Heimisdottir, M; Hellard, M; Johannsson, B; Löve, A; Löve, TJ; Olafsson, S; Runarsdottir, V; Sigurdardottir, B; Tyrfingsson, T1
Brainard, DM; Curtis, C; Lasseter, K; Lawitz, E; Ling, KHJ; Marbury, T; Mathias, A; Mogalian, E; Moorehead, L; Murray, B; Osinusi, A; Perry, R1
Goldstein, DB; Kleinstein, SE; Naggie, S; Shea, PR; Stamm, LM; Sulkowski, M1
Dashti-Khavidaki, S; Khalili, H; Nasiri-Toosi, M1
Ansari, MA; Barnes, E; Bowden, R; Hudson, E; Klenerman, P; Marchi, E; Mclean, A; Pedergnana, V; Ramamurthy, N; Spencer, CCA1
Baumgarten, A; Boesecke, C; Busch, HW; Christensen, S; Daeumer, M; Hueppe, D; Ingiliz, P; Luebke, N; Lutz, T; Mauss, S; Rockstroh, JK; Sarrazin, C; Schewe, K; Schulze Zur Wiesch, J; Simon, KG; Timm, J; Vermehren, J; von Felden, J1
More, B1
Aljudaibi, B; Bilodeau, M; Congly, SE; Faisal, N; Ghali, MP; Hirch, G; Hussaini, T; Lilly, LB; Ma, MM; Yoshida, EM1
Benson, AA; Lederman, N; Safadi, R; Wolf, D1
Hu, J; Li, C1
Adragão, T; Birne, R; Bruges, M; Carvalho, L; Chagas, C; Jorge, C; Lebre, L; Machado, D; Matias, P; Nascimento, C; Querido, S; Weigert, A1
Bandeira de Mello Brandao, A; Costabeber, AM; Cracco Cantisani, GP; Kiss, G; Leipnitz, I; Marroni, CA; Martini, J; Medeiros Fleck, A; Meine, MH; Mucenic, M; Sacco, FKF; Soares Schlindwein, E; Zanotelli, ML1
Basile, M; Cicchetti, A; Drago, C; Favaretti, C; Kheiraoui, F; Rolli, FR; Ruggeri, M1
Reinke, T1
Abbas, B; Asem, N; Elsharkawy, A; Esmat, G; Gomaa, A; Hassany, M; Maged, A; Mehrez, M; Mostafa, Z; Soliman, M1
Anderson, PL; Brainard, DM; Bushman, LR; Castillo-Mancilla, JR; Chung, RT; Fierer, DS; Hughes, MD; Kim, AY; Kiser, JJ; MacBrayne, CE; Marks, KM; Naggie, S; Peters, MG; Seifert, SM1
Cázares-Cortázar, A; Gaytán-Martínez, J; Gómez-Torres, ME; Martínez-Rodríguez, ML; Mata-Marín, JA; Ocaña-Mondragón, A; Ribas-Aparicio, RM; Uribe-Noguez, LA1
Boldt, M; Hassan, MA; Huepfel, W; Lake, JR; Shaukat, AP; Tierney, AR; Wang, Q1
Aggarwal, R; Chen, Q; Chhatwal, J; Goel, A1
Abo-Zeid, MN; Atia, NN; El-Gizawy, SM; El-Shaboury, SR1
Summers, BB1
Berg, CP; Berg, T; Blessin, U; Engelmann, C; Grottenthaler, JM; Harrer, E; Hinterleitner, C; Lauer, UM; Malek, NP; Pathil, A; Sarrazin, C; Scholten, S; Schott, E; Seybold, U; Spengler, U; Steurer, M; Stremmel, W; von Hahn, T; Wedemeyer, H; Welker, MW; Werner, CR1
Sadler, MD1
Christensen, S; Sarrazin, C; Schulze Zur Wiesch, J; Vermehren, J; von Felden, J1
Chen, L; Li, B; Ma, L; Qing, J; Zhai, PB; Zhang, LQ1
Andrade, RJ; Brainard, DM; Buti, M; Calleja, JL; Camus, G; Carrión, JA; Casado, M; Esteban, R; Forns, X; Lens, S; McNabb, B; Morano Amado, LE; Morillas, RM; Pascasio Acevedo, JM; Pineda, JA; Riveiro-Barciela, M; Rivero, A; Rodríguez, M; Stamm, LM; Subramanian, GM; Turnes, J; Zhang, G1
Abd Alla, MDA; Al-Azhari, SS; Dawood, RM; El Awady, MK; Elhawary, MA; Galal, AGM1
Aghemo, A; Brancaccio, G; D'Offizi, G; Gaeta, GB; Giorgini, A; Hasson, H; Menzaghi, B; Palma, M; Termini, R1
Enomoto, N; Maekawa, S1
Chu, TC; Fasanmi, EO; MacDonald, BR; Moore, JD; Ojha, RP; Stewart, RA1
Abd Elaziz, D; Aiuti, A; Appleby, J; Barzaghi, F; Bernardo, ME; Boeri, E; Calbi, V; Calzatini, F; Canarutto, D; Casiraghi, M; Cestone, E; Cicalese, MP; Ciceri, F; Consiglieri, G; Darin, S; Dionisio, F; Ferrua, F; Finazzi, R; Gabaldo, M; Lucano, C; Marktel, S; Mieli-Vergani, G; Migliavacca, M; Recupero, S; Tucci, F1
Boeker, KHW; Buggisch, P; Günther, R; Hüppe, D; Maasoumy, B; Manns, MP; Mauss, S; Müller, T; Sarrazin, C; Vermehren, J; Wedemeyer, H; Zimmermann, T1
Hamano, T; Inoue, M; Someda, H; Tachibana, N; Tsuzaki, K1
Hill, L; Kerr, J; Mansour, M1
Gandhi, M; Jhaveri, A; Merchant, R; Nagral, A; Nagral, N; Parikh, NS; Sawant, S1
Chu, TC; MacDonald, BR; Marcus, JL; Ojha, RP1
Herrera, JL; Marshall, MC1
Abdel-Lateef, MA; Ali, R; Derayea, SM; Omar, MA1
Aqel, B; Keaveny, AP; Leise, M; Pungpapong, S; Vargas, HE; Watt, KD; Zhang, N1
Chua, JV; Claeys, K; Heil, EL; Hynicka, LM; Vega, AD1
Jacobson, IM1
Brainard, DM; Chayama, K; De-Oertel, S; Dvory-Sobol, H; Ikeda, F; Kanda, T; Kurosaki, M; Matsuda, T; Mita, E; Nishiguchi, S; Sakamoto, M; Sakamoto, N; Stamm, LM; Takehara, T; Takikawa, Y; Tamori, A; Tanaka, Y; Tatsumi, T; Ueno, Y; Yatsuhashi, H; Zhang, G1
Kottilil, S; Mathur, P; Wilson, E1
Domalakes, E; He, L; Lee, GT; Mason, CW; Parrott, J; Pfeifer, E; Zhou, H1
Aghemo, A; Craviotto, V; Lamonaca, L; Lleo, A1
Arai, M; Chiba, T; Kanda, T; Kato, N; Maruyama, H; Miho, K; Mochizuki, H; Nakamura, M; Ogasawara, S; Omata, M; Ooka, Y; Shuntaro, O; Suzuki, E; Yasui, S; Yokosuka, O1
Buonanno, P; Camera, S; Caporaso, N; Capuano, I; Donnarumma, L; Ferreri, L; Morisco, F; Sabbatini, M1
Aziz, A; Durazo, F; Hanna, RM; Latt, N; Mikhail, MM; Mitry, A; Saab, S; Sahota, A; Yanny, B1
Dupuy, CA; Glotz, D; Parlati, L; Pol, S; Sirmai, L1
Almeida, J; Arrelaro, R; Cintra, M; Corrêa, B; Cunha-Silva, M; Lopes, T; Lorena, S; Mazo, D; Rabello, M; Sevá-Pereira, T; Torino, AB; Vaz, N1
Costa, C; D'Ascoli, GL; De Rosa, S; Focà, A; Indolfi, C; Liberto, MC; Mazzitelli, M; Pisani, V; Raffetti, E; Sabatino, J; Strazzulla, A; Torti, C1
Biggs, BA; Kanhutu, K; Sasadeusz, J; Schulz, TR; Watkinson, S1
Ali, Q; Imran, M; Iqbal, K; Jamal, A; Kalam, I; Ullah, S; Waqar, AB1
Morrison, C1
Brainard, DM; McHutchison, JG; Stamm, LM1
Enomoto, M; Hai, H; Kawada, N; Kumada, H; Okada, M; Tamori, A; Uchida-Kobayashi, S1
Abdurakhmanov, D; Bakulin, I; Brainard, DM; Burnevich, E; Chulanov, V; Gankina, N; Hyland, RH; Isakov, V; Ivashkin, V; Kozhevnikova, G; Lagging, M; Lu, S; McNally, J; Morozov, V; Nurmukhametova, E; Romanova, S; Svarovskaia, ES; Weiland, O; Zhdanov, K; Zhuravel, S1
Zeuzem, S1
Muljono, DH1
Alcazer, V; Charre, C; Cotte, L; Miailhes, P; Ramière, C1
Bakr, MA; El Maghrabi, HM; Elmowafy, AY; Elwasif, SM; Zahab, MA1
Kimura, K1
Laique, SN; Vargas, HE1
Clément, V; Raimond, V1
Castro-Iglesias, A; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, A; Pernas-Souto, B; Pertega-Díaz, S; Rodríguez-Osorio, I1
Bastos, FI; da Fonseca, EM; Shadlen, K1
Aziz, T; Hanif, FM; Lail, G; Luck, NH; Mandhwani, R1
Dellay, B; Hess, GP; Israni, AK; Ray Kim, W; Sexter, A; Wang, JH1
Akahane, T; Furukawa, M; Kaji, K; Kawaratani, H; Kitade, M; Kitagawa, K; Mitoro, A; Moriya, K; Namisaki, T; Okura, Y; Saikawa, S; Sato, S; Sawada, Y; Seki, K; Shimozato, N; Takaya, H; Yamao, J; Yoshiji, H1
Brown, A; Dufour, JF; Gordon, SC; Mauss, S; Mensa, FJ; Pilot-Matias, T; Poordad, F; Rodrigues, L; Stoehr, A; Weiland, O; Weilert, F; Wyles, D; Yao, B; Zhang, Z1
Brainard, DM; Gao, Z; Huang, R; Jiang, D; Li, W; Massetto, B; Mo, H; Rao, H; Stamm, LM; Wei, L; Xie, Q1
Chen, J; Fang, Z; Li, M; Li, Y; Lin, Q1
Bixby, AL; Fitzgerald, L; Leek, R; Mellinger, J; Sharma, P; Tischer, S1
Campise, M; D'Ambrosio, R; Franchina, M; Lampertico, P; Messa, P; Parlati, L; Pasulo, L; Pol, S; Vinci, M; Zaltron, S1
Baden, LR; Camp, PC; Chen, K; Coppolino, A; Fanikos, J; Givertz, MM; Goldberg, HJ; Haddad, EA; Harrington, DP; Johnson, ME; Kusztos, AE; Mallidi, HR; Mehra, MR; Singh, SK; Woolley, AE1
Douglas, MW; Eden, JS; George, J; Tay, ES1
Chen, M; Hu, P; Liu, K; Pan, Z; Peng, M; Qiu, K; Ren, H; Shen, Y; Xue, W1
Aghemo, A; Parigi, TL; Torres, MCP1
Angulo-Diaz, V; Lim, JK; Mandimika, C; Maughan, A; Ogbuagu, O; Sadigh, K; Villanueva, M1
Barreca, GS; Casalinuovo, F; Costa, C; Giancotti, A; Greco, G; Liberto, MC; Marascio, N; Matera, G; Mazzitelli, M; Pavia, G; Pisani, V; Serapide, F; Torti, C; Trecarichi, EM1
Brandão-Mello, CE; Costa, VD; de Souza Rodrigues, LLLX; do Amaral Mello, FC; Dos Santos Silva, PGC; Lampe, E; Nunes, EP1
Buggisch, P; Klinker, H; Lonjon-Domanec, I; Mauss, S; Müller, T; Nalpas, C; Pathil-Warth, A; Sarrazin, C; Schlag, M; Simon, KG; Wegner, S; Zimmermann, T1
Agostinacchio, E; Carraturo, I; Cela, M; Chimenti, A; Copetti, M; Cuccorese, G; De Gioia, S; Giannelli, A; Lauletta, G; Losappio, R; Mangia, A; Mazzola, M; Mennea, G; Metrangolo, A; Minerva, N; Napoli, N; Palmieri, V; Piazzolla, V; Piccigallo, E; Potenza, D; Sabbà, C; Santoro, R; Tagarielli, V; Visaggi, E1
Bianchi, L; Campione, E; Dattola, A; Di Paolo, D; Di Prete, M; Ferlosio, A; Orlandi, A1
Behar, E; Coffin, PO; Fox, R; Hern, J; Kinnard, EN; Matheson, T; Page, K; Santos, GM; Silvis, J; Vittinghoff, E; Walker, J1
Deng, H; Fan, X; Han, Q; Li, N; Liu, Z; Wang, X; Wang, Y; Zhang, K; Zhang, X1
Brainard, DM; Chung, RT; Fierer, DS; Hughes, MD; Kim, AY; Kiser, JJ; Luetkemeyer, A; Marks, KM; McHutchison, JG; Naggie, S; Peters, MG; Roa, J; Rwema, S; Vu, V1
Asensi-Diez, R; Del Rio-Valencia, JC; Muñoz-Castillo, I; Tamayo-Bermejo, R1
Abdullatif, HM; El Rasheed Abd El Zaher, BA; El Raziky, MS; El-Karaksy, HM; Ghobrial, CM; Mogahed, EA; Ramzi, R1
Aizaki, H; Hatanaka, T; Hmwe, SS; Hoshino, T; Kakizaki, S; Naganuma, A; Sato, K; Tateyama, Y; Uraoka, T; Wakita, T; Yoshinari, F1
Kanda, T; Kaneko, T; Komoriya, T; Kuroda, K; Matsumoto, N; Matsuoka, S; Moriyama, M; Nakajima, N; Nirei, K; Ogawa, M; Shibata, T; Takayama, T; Tamura, A; Yamamoto, T; Yamazaki, M1
Chu, CJ; Hou, MC; Huang, YH; Wu, SH1
Alados-Arboledas, JC; Aldámiz-Echevarría, T; Casado, M; Chueca, N; García, F; García-Bujalance, S; García-Deltoro, M; Lara-Pérez, MM; Martínez-Sapiña, AM; Merino, D; Pascasio, JM; Pérez, AB; Pineda, JA; Poyato, A; Rivero-Juárez, A; Rosales-Zábal, JM; Salmerón, J; Téllez, F; Vera-Méndez, FJ; Vivancos-Gallego, MJ1
Alavi, M; Dore, GJ; Grebely, J; Hajarizadeh, B; Kaveh-Ei, S; Malekzadeh, R; Merat, S; Poustchi, H; Rahimi-Movaghar, A; Shadloo, B1
Eisenberger, U; Friebus-Kardash, J; Gäckler, A; Herzer, K; Kribben, A; Treckmann, J; Wedemeyer, H; Witzke, O1
Wahid, B1
Chen, J; Li, J; Lu, H; Wang, J; Xiao, H; Yang, F1
Arachchi, N; Bowden, S; Cameron, K; Doyle, J; Gow, P; Hellard, M; Iser, D; O'Keefe, J; Papaluca, T; Pianko, S; Sievert, W; Sinclair, M; Stoove, M; Thompson, A1
Bruckert, E; Caron, J; Dubart-Kupperschmitt, A; Fourrier, A; Gómez-Lechón, MJ; Heslan, JM; Luce, E; Nguyen, TH; Pène, V; Rosenberg, AR; Saheb, S; Tolosa, L; Villaret, M; Weber, A1
Barrail-Tran, A; Botta-Fridlund, D; Cagnot, C; Canva, V; Coilly, A; Conti, F; D'Alteroche, L; Danjou, H; De Ledinghen, V; Duclos-Vallée, JC; Durand, F; Duvoux, C; Fougerou-Leurent, C; Gelé, T; Goldwirt, L; Houssel-Debry, P; Kamar, N; Laforest, C; Lavenu, A; Leroy, V; Moreno, C; Pageaux, GP; Radenne, S; Samuel, D; Taburet, AM1
Ataíde, EC; Boin, IFSF; Santos, AG; Stucchi, RSB; Zanaga, LP1
Mole, B1
Dalzell, MD1
Tse, MT1
Borgia, F; Borgia, G; Buonomo, AR; Castaldo, G; Gentile, I1
Barrett, L; Bon, D; Chavez, J; Dewar, R; Fauci, AS; Fishbein, D; Gu, W; Herrmann, E; Heytens, L; Highbarger, H; Kleiner, D; Kohli, A; Kotb, C; Kottilil, S; Kwan, R; Lee, YJ; Masur, H; McHutchison, J; Meissner, EG; Nelson, A; Osinusi, A; Polis, MA; Proschan, M; Shivakumar, B; Silk, R; Sneller, M; Subramanian, M; Symonds, WT; Talwani, R; Teferi, G; Wood, BJ; Wroblewski, S; Zhang, X1
Berrey, MM; Cornpropst, MT; Denning, J; Gao, B; Lawitz, EJ; Mathias, A; Mo, H; Rodriguez-Torres, M; Symonds, WT1
Flisiak, R; Jaroszewicz, J; Parfieniuk-Kowerda, A1
Berg, T; Forns, X; Mariño, Z; van Bömmel, F1
Ding, X; Gane, EJ; Hyland, RH; McHutchison, JG; Pang, PS; Stedman, CA; Subramanian, GM; Svarovskaia, E; Symonds, WT1
Asselah, T1
Cohen, J2
Corouge, M; Pol, S; Vallet-Pichard, A1
Boccaccio, V; Bruno, S1
Dieterich, DT; Martel-Laferrière, V2
Asselah, T; Marcellin, P1
Asselah, T; Halfon, P; Marcellin, P; Schinazi, R1
Ford, N; Fortunak, J; Hill, A; Khoo, S; Simmons, B1
Sheridan, C1
Denning, J; Guedj, J; Lawitz, E; Pang, PS; Perelson, AS; Rodriguez-Torres, M; Symonds, W1
Fralick, M1
Chung, RT; deLemos, AS1
Andronescu, CI; Andronescu, D; Diaconu, S; Purcarea, RM; Tiuca, N1
Gane, E; Hunt, SL; Jacobson, IM; Lawitz, E; Nader, F; Nelson, D; Stepanova, M; Younossi, ZM1
Watts, G1
Callaway, E1
Feld, JJ1
Chan, J1
Adler, H; Lambert, JS1
Rice, CM; Saeed, M1
Senior, M1
Slomski, A1
Borgia, G; Buonomo, AR; Gentile, I; Zappulo, E1
Henry, L; Lam, B; Younossi, Z1
Burki, T1
Chung, RT; Feeney, ER1
Rolland, S; Vachon, ML1
Cooke, G; Hill, A1
Carroll, J2
Aghemo, A; Colombo, M; Donato, MF; Maggioni, M; Malinverno, F; Monico, S; Reggiani, P1
Brainard, D; Chodavarapu, K; Crespo Garcia, J; De Knegt, R; Doehle, B; Drenth, JP; Gontcharova, V; Hedskog, C; McHutchison, JG; Miller, MD; Mo, H; Stamm, LM; Svarovskaia, E1
Borentain, P; Botta-Fridlund, D; Colson, P; Dhiver, C; Garcia, S; Gerolami, R; Gregoire, E; Hardwigsen, J1
Donaldson, EF; Harrington, PR; Naeger, LK; O'Rear, JJ1
Bureau, C; Danjoux, M; Delabaudière, C; Dörr, G; Izopet, J; Kamar, N; Lavayssière, L; Muscari, F; Peron, JM; Rostaing, L; Sallusto, F1
Beavers, JW; Klibanov, OM; Summers, BB1
Price, JC; Terrault, NA1
Abd-Rabou, AA; Belousova, V; Mousa, SA1
Wapner, J1
Kuehn, BM1
Cook, C; Phelan, M1
Afdhal, N; Arterburn, S; Befeler, A; Brown, R; Chung, RT; Curry, MP; Denning, J; Everson, G; Fenkel, JM; Forns, X; Gane, E; Gordon, F; Kuo, A; McHutchison, JG; McNair, L; Moonka, D; O'Leary, J; Saab, S; Schiano, T; Schiff, E; Subramanian, GM; Svarovskaia, E; Symonds, WT; Terrault, NA1
Foster, GR1
Chan, E; Gandhi, M; Lim, SG1
Arterburn, S; Brainard, D; Brown, RS; Charlton, M; Curry, MP; Denning, J; Dvory-Sobol, H; Fontana, RJ; Forns, X; Gane, E; Gilroy, R; Kirby, B; Kwo, PY; Manns, MP; McHutchison, JG; Muir, AJ; Samuel, D; Symonds, WT; Teperman, L; Terrault, NA1
Goozner, M1
Beaumont, JL; Beckerich, F; Cordonnier, C; Gautier, E; Hézode, C; Maury, S; Robin, C1
Agudelo, EZ; Campos-Varela, I; Carlson, L; Straley, S; Terrault, NA1
Alqahtani, SA; Dhingra, A; Kapoor, S1
Firpi, RJ; Hilgenfeldt, E1
Charlton, MR; Gallegos-Orozco, JF1
Aghemo, A; Donato, MF1
Adhoute, X; Ansaldi, C; Bourlière, M; Castellani, P; Oules, V1
Baiguera, C; Panzeri, C; Puoti, M; Rossotti, R1
Hablas, A; Hutton, DW; Kim, DD; Raouf, AA; Salama, M; Seifeldin, IA; Soliman, AS1
Schwartz, M1
Serfaty, L1
Childs-Kean, LM; Hand, EO1
Bennett, M; Bernstein, D; Cooper, JN; Freilich, BF; Ghalib, R; Gitlin, N; Harlan, W; Hawkins, T; Hennicken, D; Hughes, EA; Kowdley, KV; Lalezari, JP; Lawitz, E; McPhee, F; Nelson, DR; Oguchi, G; Ortiz-Lasanta, G; Pockros, PJ; Rabinovitz, M; Rana, K; Ravendhran, N; Sheikh, AM; Thuluvath, PJ; Varunok, P; Younes, ZH1
Carey, L1
Denk, G; Eberle, J; Guba, M; Kaspar, M; Kolligs, F; Pichler, M; Seybold, U; Spannagl, M; Stemberger, M1
Aqel, B; Chervenak, AE; Henry, TM; Keaveny, AP; Leise, M; Murphy, JL; Pungpapong, S; Ryland, K; Vargas, HE; Watt, KD; Werner, KT1
Bartlett, C; Griffin, S; Harris, M; Ross-Thriepland, D; Shaw, J; Stewart, H1
Hayward, P1
Manns, MP; Wedemeyer, H; Zeuzem, S1
Avalos, D; Bhamidimarri, KR; Carrion, AF; Gutierrez, JA; Martin, P; O'Brien, C; Peyton, A1
Brault, P; Klotz, C; Mallet, V; Pol, S; Sultanik, P1
Chu, EY; McCausland, D; Simpson, CL1
Besur, SV; deLemos, AS; Noell, BC1
Bagcchi, S1
Dasgupta, A; Nyberg, A; Nyberg, L; Pauly, M; Piasecki, B; Ready, J; Redd, J; Saxena, V; Terrault, NA; Winston, B1
Fazel, Y; Golabi, P; Lam, B; Younossi, Z1
Botta, D; Coilly, A; D'Alteroche, L; Diallo, A; Duclos-Vallee, JC; Dumortier, J; Durand, F; Fougerou-Leurent, C; Houssel-Debry, P; Kamar, N; Lebray, P; Leroy, V; Pageaux, GP; Petrov-Sanchez, V; Radenne, S; Sebagh, M; Silvain, C1
Ryoo, JY; Yang, HJ; Yoo, BK1
Bonacci, M; Campistol, JM; Esforzado, N; Forns, X; Londoño, MC; Sotoca, JM1
Baldelli, S; Cattaneo, D; Gervasoni, C; Milazzo, L; Peri, AM; Rizzardini, G1
Ahmed, A; Daugherty, TJ; Higgins, JP; Perumpail, RB; Pham, EA; Wong, RJ1
Adam, P; Bhamidimarri, KR; Christopher, O; Cynthia, L; Czul, F; David, R; Eugene, S; Frank, C; Hernandez, M; Jeffers, L; Kalyan Ram, B; Lennox, J; Levy, C; Maria, H; Martin, P; O'Brien, C; Paul, M; Peyton, A; Roth, D; Schiff, E1
Aqel, BA; Chervenak, AE; Keaveny, AP; Leise, M; McLemore, R; Murphy, JL; Pungpapong, S; Ryland, K; Vargas, HE; Watt, KD; Werner, KT1
Kmietowicz, Z1
Backus, LI; Belperio, PS; Loomis, TP; Mole, LA; Shahoumian, TA2
Dusheiko, G; Kalafateli, M; Manousou, P1
Gori, A; Grossi, PA; Marigliano, A; Menzo, S; Tavio, M; Vivarelli, M1
McCarthy, M1
Berg, T; Manns, MP; Zeuzem, S1
Giard, JM; Terrault, NA1
Forns, X; Gambato, M; Lens, S; Mariño, Z1
Brainard, D; Dieterich, D; Esteban, R; Gane, E; Jacobson, IM; Lawitz, E; McHutchison, JG; McNally, J; Nelson, DR; Sulkowski, MS; Symonds, WT; Zeuzem, S1
Bhamidimarri, KR; Carrion, A; Gutierrez, JA; Peyton, AL1
Klibanov, OM; Lomberk, M1
Barnard, GF; Barry, C; Bozorgzadeh, A; Mehta, S; Punzalan, CS; Rodrigues, J; Zacharias, I1
Chung, RT; Corey, KE; Friedman, LS; Hundemer, GL; Sise, ME; Ufere, N; Wisocky, J1
Kalsekar, A; Kelley, C; Kim, S; Mu, F; Noviello, S; Signorovitch, J; Song, J; Swallow, E; Yuan, Y1
Beckebaum, S; Bester, C; Heinzow, H; Hüsing, A; Kabar, I; Schmidt, HH; Seifert, LL; Stahl, M; Vorona, E1
Anderson, PL; Bushman, LR; Chen, X; Hodara, A; Jimmerson, LC; Kiser, JJ; Rower, JE; Zheng, JH1
Debes, JD; Ricci, P1
Brainard, DM; Chung, RT; Doehle, B; Gustafson, J; Kim, AY; Lauer, GM; Liu, L; McHutchison, JG; Mo, H; Pang, PS; Simon, TG; Stamm, LM1
Cheung, EJ; English, JC; Jedrych, JJ1
Costilla, V; Gutierrez, JA; Mathur, N1
Wyles, DL1
Gibson, W; Klibanov, OM; Mullins, C1
Jordan, S; Lang, M; Lohse, AW; Nashan, B; Pischke, S; Polywka, S; Proske, VM; Sterneck, M1
Mohammad, RA; Regal, RE; Smith, MA1
Brown, RS; Darling, JM; Di Bisceglie, AM; Feld, JJ; Frazier, LM; Fried, MW; Jacobson, IM; Kuo, A; Lim, JK; Morelli, G; Nelson, DR; Reddy, KR; Stewart, TG; Sulkowski, MS; Vargas, HE1
Brainard, DM; Chan, HL; Han, LL; Knox, SJ; Lai, CL; Mo, H; Wong, VW; Yang, JC; Yuen, MF1
Brown, RS; Burton, JR; Di Bisceglie, AM; Durand, C; Frenette, CT; Fried, MW; Kuo, A; Kwo, P; Morelli, GJ; Nelson, DR; O'Leary, JG; Reddy, KR; Stewart, TG; Stravitz, RT; Terrault, NA1
Ryder, SD; Thiagarajan, P1
Alric, L; Cacoub, P; Costopoulos, M; Fontaine, H; Guillaud, C; Hezode, C; Izzedine, H; Le Garff-Tavernier, M; Mallet, M; Musset, L; Plaisier, A; Pol, S; Poynard, T; Saadoun, D; Si Ahmed, SN; Thibault, V1
Alric, L; Barange, K; Cointault, O; Del Bello, A; Esposito, L; Izopet, J; Kamar, N; Lavayssière, L; Marion, O; Métivier, S; Ribes, D; Rostaing, L1
Abbott, S; Akoth, E; Chavez, J; Emmanuel, B; Gross, C; Jolley, TA; Kattakuzhy, S; Kohli, A; Kottilil, S; Masur, H; McLaughlin, M; Meissner, EG; Mo, H; Nelson, A; Osinusi, A; Polis, MA; Price, A; Proschan, M; Seamon, C; Sidharthan, S; Silk, R; Sims, Z; Tang, L; Teferi, G; Wilson, E1
Adhoute, X; Ansaldi, C; Benali, S; Bourlière, M; Castellani, P; Halfon, P; Oules, V; Portal, I1
Brainard, DM; Doehle, B; Dvory-Sobol, H; Gane, E; Hedskog, C; Jacobson, IM; Lawitz, E; Martin, R; McHutchison, JG; Miller, MD; Mo, H; Nelson, DR; Svarovskaia, ES1
Alao, O; Anastos, K; Brennan-Ing, M; Ernst, J; Karpiak, SE; Kuniholm, MH; Leach, T; Lunievicz, J; Nash, D; Olivo, N; Vazquez, Y1
Dominguez-Dominguez, L; Jarrin-Estupiñan, ME; Kessler-Saiz, P; Marchan-Lopez, A1
Luo, R; Nong, J; Qing, J; Shao, Y; Sun, Y; Tang, R; Wang, Y; Wu, M; Yin, Z; Yu, X1
Abecassis, MM; Brooks, H; Grant, JL; Hawkins, C; Koppe, SW; Palella, FJ; Stosor, V1
Dallas, MH; Santiago, T; Thomas, P1
Chen, TM; Huang, PT; Li, YC1
Gonzalez, HC; Nair, S; Satapathy, SK1
Li, CX; Li, W; Xu, GH; Yu, ZJ; Zeng, QL; Zhang, DW1
Borgia, G; Buonomo, AR; Gentile, I; Pinchera, B; Scotto, R; Zappulo, E1
Berkowitz, L; Bichoupan, K; Branch, AD; Cha, A; Del Bello, D; Dieterich, DT; Doyle, E; Fierer, DS; Gardenier, D; Harty, A; Levine, C; Ng, M; Odin, J; Patel, N; Perumalswami, PV; Schiano, TD; Sorbera, M1
Aljudaibi, B; Bilodeau, M; Congly, SE; Cooper, C; Faisal, N; Ghali, MP; Hirsch, G; Hussaini, T; Leonard, J; Lilly, LB; Ma, MM; Peltekian, K; Renner, EL; Yoshida, EM1
Agarwal, K; Feld, J; Henry, L; Hezode, C; Hunt, S; Jacobson, I; Nader, F; Stepanova, M; Younossi, ZM; Zeuzem, S1
Diefenbach, CS; Hymes, KB; Lin, RJ; Moskovits, T1
Agarwal, R; Ahmad, J; Bach, N; Bansal, M; Bichoupan, K; Branch, A; Chang, C; Dieterich, D; Friedman, S; Gardenier, D; Grewal, P; Harty, A; Im, G; Khaitova, V; Kim-Schluger, L; Ku, L; Leong, J; Liu, L; Motamed, D; Ng, M; Odin, J; Patel, N; Perumalswami, P; Schiano, T; Yalamanchili, R1
Ciesek, S; Costa, R; Klempnauer, J; Lohse, AW; Lüthgehetmann, M; Manns, MP; Mix, H; Nashan, B; Otto, B; Pischke, S; Polywka, S; Proske, V; Sterneck, M; von Hahn, T; Wedemeyer, H1
Park, SH1
Jung, YK1
Chandrasekar, PH; Surapaneni, M; Wahba, MR1
Alkhouri, N; Apfel, T; Hanouneh, IA; Hanouneh, M; Jackson, WE; John, BV; Zein, NN; Zervos, X1
Ackerman, P; Bhore, R; Luetkemeyer, AF; McDonald, C; Noviello, S; Ramgopal, M1
Bremer, B; Cloherty, G; Cornberg, M; Deterding, K; Höner Zu Siederdissen, C; Lehmann, P; Maasoumy, B; Manns, MP; Pawlotsky, JM; Perner, D; Reinhardt, B; Sarrazin, C; Vermehren, J; Wedemeyer, H; Welker, MW; Zeuzem, S1
Alshatti, F; Hull, MW; Moosavi, S; Yoshida, EM1
Chodavarapu, K; McNally, J; Moreno, C; Schreiber, J; Svarovskaia, E1
Tseng, A; Wong, DK1
Amblard, F; Amiralaei, S; Cho, JH; Coats, SJ; Domaoal, RA; Ehteshami, M; Khalil, A; Lee, SS; Lin, B; Lu, X; Ozturk, T; Schinazi, RF; Shelton, JR; Stanton, RA; Suesserman, JE; Tao, S; Whitaker, T; Zhang, H; Zhou, L1
Brainard, DM; Gane, EJ; Hyland, RH; McHutchison, JG; Schwabe, C; Stamm, LM; Stedman, CA; Svarovskaia, E; Yang, Y1
Beyer, P; de Joncheere, K; Hill, S; Iyengar, S; Tay-Teo, K; Vogler, S; Wiktor, S1
Abergel, A; Anty, R; Besch, C; Botta-Fridlund, D; Canva, V; Coilly, A; Conti, F; D'Alteroche, L; Danjou, H; de Ledinghen, V; Debette-Gratien, M; Di Martino, V; Duclos-Vallée, JC; Dumortier, J; Duvoux, C; Fougerou-Leurent, C; Francoz, C; Habersetzer, F; Houssel-Debry, P; Kamar, N; Lebray, P; Leroy, V; Moreno, C; Pageaux, GP; Perre, P; Radenne, S; Rohel, A; Roque-Afonso, AM; Rossignol, E; Samuel, D; Silvain, C1
Silverman, E1
Berry, K; Beste, LA; Chang, MF; Green, PK; Ioannou, GN; Lowy, E; Su, F; Tsui, JI1
Chen, GF; Chen, J; Cheng, J; Dou, XG; Du, N; Duan, ZP; Fan, JG; Fu, QC; Han, Y; Hou, JL; Ji, D; Jia, JD; Jia, ZS; Lau, G; Li, B; Li, F; Liu, JL; Lu, LG; Niu, XX; Ren, H; Shang, J; Shao, Q; Wang, C; Wang, GQ; Wang, JP; Wang, XJ; Wang, YD; Wei, L; Wong, A; Wu, V; Xie, Q; Yang, XX; Zhang, WH; Zhang, YX; Zhuang, H1
Afdhal, NH; Brainard, DM; Chuang, SM; Ding, X; Doehle, BP; Dvory-Sobol, H; Gane, EJ; Kowdley, KV; Lawitz, E; Ma, J; McHutchison, JG; Miller, MD; Mo, H; Pang, PS; Sarrazin, C; Svarovskaia, ES1
Ampuero, J; Reddy, KR; Romero-Gomez, M1
Brügger, U; Girardin, F; Goossens, N; Negro, F; Perrier, A; Riguzzi, M; Vernaz, N1
Alric, L; Aumaître, H; Bani-Sadr, F; Billaud, E; Bouchaud, O; Boué, F; Chas, J; Dabis, F; Dominguez, S; Esterle, L; Gervais, A; Gilbert, C; Goujard, C; Lacombe, K; Lascoux-Combe, C; Miailhes, P; Morlat, P; Neau, D; Piroth, L; Poizot-Martin, I; Rosenthal, E; Salmon, D; Simon, A; Sogni, P; Valantin, MA; Vittecoq, D; Wittkop, L; Zucman, D1
Bryce, CL; Chidi, AP; Donohue, JM; Fine, MJ; Landsittel, DP; Myaskovsky, L; Rogal, SS; Smith, KJ; Switzer, GE; Tsung, A1
Amoroso, A; Arese, D; Cocchis, D; Dell Olio, D; Magistroni, P; Martini, S; Mirabella, S; Moschini, P; Ottobrelli, A; Rizza, G; Rizzetto, M; Romagnoli, R; Sacco, M; Salizzoni, M; Saracco, GM; Stradella, D; Strona, S; Tandoi, F1
Abergel, A; Besch, C; Botta-Fridlund, D; Canva, V; Coilly, A; Conti, F; d'Alteroche, L; de Ledinghen, V; di Martino, V; Diallo, A; Duclos-Vallée, JC; Dumortier, J; Duvoux, C; Fougerou-Leurent, C; Francoz, C; Houssel-Debry, P; Kamar, N; Lebray, P; Leroy, V; Moreno, C; Pageaux, GP; Radenne, S; Rohel, A; Rossignol, E; Samuel, D; Tran, A1
Durlik, M; Hreńczuk, M; Kosieradzki, M; Małkowski, P; Pacholczyk, M; Sowińska, R; Tronina, O1
An, D; Brainard, D; Gane, EJ; Hyland, RH; McHutchison, JG; Svarovskaia, ES1
Andreis, S; Basso, M; Cattelan, AM; Cavinato, S; Dal Bello, F; Loregian, A; Messa, L; Nannetti, G; Palù, G; Parisi, SG; Scaggiante, R1
Agüero, F; Ambrosioni, J; Costa, J; Forner, A; Laguno, M; Lligoña, A; Londoño, MC; Manzardo, C; Miró, JM; Moreno, A; Rimola, A; Ruiz, P1
Bobardt, M; Chatterji, U; Gallay, PA; Schaffer, L; Wood, M1
Bunnell, KL; Gallagher, MA; Glowacki, RC; Huhn, G; Osei, AM; Vibhakar, S1
Maasoumy, B; Sarrazin, C; Vermehren, J; Wedemeyer, H1
D'Ambrosio, R; De Nicola, S; Degasperi, E; Rumi, M1
Ahn, J; Badano, G; Chalkidou, K; Cubillos, L; Hauegen, RC; Henshall, C; Kieslich, K; Krubiner, CB; Littlejohns, P; Lu, L; Pearson, SD; Rid, A; Whitty, JA; Wilson, J1
Gornall, J; Hoey, A; Ozieranski, P1
Brainard, DM; Chuang, WL; Gane, E; Gao, B; Han, KH; Kao, JH; Sulkowski, MS; Yang, JC1
Ahmed, A; Chang, CY; Daugherty, T; Doshi, D; Garcia, G; Gupta, S; Kumari, R; Lutchman, G; Nguyen, MH; Nguyen, NH1
Iacob, G; McCann, J; Uzoigwe, CE1
Abushouk, AI; Ahmed, H; Attia, A; Elgebaly, A; Hammad, AM; Negida, A1
Chahine, EB; Hemstreet, BA; Sucher, AJ1
Cardoso, H; Gaspar, R; Macedo, G; Silva, M1
Fortune, BE; Lim, JK; McCarty, TR; Njei, B1
Beckman, AL; Bilinski, A; Boyko, R; Bruce, RD; Camp, GM; Gonsalves, GS; Lim, JK; Wall, AT; Wang, EA1
Cattaneo, A; Maciocco, G1
Guo, Y; Li, T; Qu, Y; Sun, C; Wang, L; Yang, B; Ye, Q1
Stafford, N1
Berry, K; Green, PK; Ioannou, GN; Su, F1
Mendes, LC; Miotto, N; Stucchi, RS; Vigani, AG; Zanaga, LP1
Ardeshna, K; Maciocia, N; O'Brien, A1
Xia, N; Zhao, Q1
Cuenca-Lopez, F; Rivero, A; Rivero-Juárez, A1
Moiseev, S; Mukhin, N; Novikov, P1
Ashimkhanova, A; Kaliaskarova, K; Yesmembetov, K1
Berry, K; Green, PK; Ioannou, GN; Su, F; Tsui, JI; Williams, EC1
King, L; Roy, V1
Mazzucato, M1
Canbay, A; Gerken, G; Herzer, K; Paul, A; Timm, J; Treckmann, J; Willuweit, K1
Botta-Fridlund, D; Hachicha, M1
Bhattarai, S; Fallon, JP; Galang, H; Habeeb, R; Johnson, TM; Shukla, PP; Sison, R; Slim, J1
Berardi, S; Bhoori, S; Caraceni, P; Donato, MF; Iemmolo, RM; Invernizzi, F; Lenci, I; Martini, S; Mazzarelli, C; Montalbano, M; Morelli, C; Pieri, G; Romagnoli, R1
Heppt, F; Sticherling, M1
Abravanel, F; Bramley, P; Campbell, JD; Dalton, HR; Donnelly, MC; Fraser, AR; Hayes, PC; Imlach, SN; Johannessen, I; Kamar, N; Petrik, J; Ramalingam, S; Simpson, KJ1
Buti, M; Esteban, R; Llaneras, J; Riveiro-Barciela, M1
King, L; Ozieranski, P1
Klaus, G; Szucs, TD; Weiss, M1
Liu, H; Yan, Y; Zhang, T1
Acevedo, P; Bernal Blanco, G; Gentil Govantez, MA; Gonzalez Roncero, FM; Gonzalez-Corvillo, C; Perez Valdivia, MA; Sousa, JM; Suarez Benjumea, A; Suñer Poblet, M1
Alonso, A; Franco, A; Gentil, MA; González-Corvillo, C; Hernández-Marrero, D; Jiménez-Martín, C; Lauzurica, LR; Perelló, M; Sánchez-Fructuoso, A; Zarraga, S1
Huysentruyt, K; Leclercq, G; Scheers, I; Smets, F; Sokal, EM; Stephenne, X; Varma, S1
Hernandez, D; McPhee, F; Zhou, N1
Cornberg, M; Deterding, K; Gerken, G; Hardtke, S; Klinker, H; Koch, A; Manns, MP; Papkalla, A; Pathil, A; Schott, E; Schulze Zur Wiesch, J; Spengler, U; Spinner, CD; Umgelter, A; von der Leyen, H; von Witzendorff, D; Weber, K; Wedemeyer, H; Welzel, TM; Wiegand, J; Zeuzem, S; Zöllner, C1
Martin, SI; Pope-Harman, A; Pouch, S; Theodoropoulos, N; Whitson, BA1
Cameron, A; Fenkel, JM; Frank, AM; Shah, AP; Singh, P1
Allerton, M; Lai, JB; Pauly, MP; Ready, J; Seo, S; Witt, DJ; Witt, MA1
Huang, J; Liao, H; Tan, P; Yan, X; Zhu, Z1
Brandão-Mello, CE; Lampe, E; Peres-da-Silva, A1
Chen, YS; Kao, JH; Liu, CH; Wang, SS1
Yu, ML1
Boucher, E; Chapman, W; Cheslock, P; Chung, RT; Curry, MP; Mantry, P; Molrine, DC; Schiano, TD; Smith, HL; Wang, Y1
Booth, M1
Brieva, T; Rivero, A; Rivero-Juarez, A1
Barbati, ZR; Dieterich, DT; El Sayed, A; Fierer, DS; Foster, AL; Morey, T; Turner, SS1
Jansen, JW; Linneman, TW; Powderly, GM1
Backus, LI; Belperio, PS; Bhattacharya, D; Goetz, MB; Loomis, TP; Mole, LA; Shahoumian, TA1
Lim, SG1
Barauskas, O; Doehle, B; Dvory-Sobol, H; Feng, J; Han, B; Miller, MD; Mo, H; Perry, J; Rajyaguru, S; Svarovskaia, ES; Xu, S1
Ammassari, A; Antinori, A; Fabbri, G; Grisetti, S; Mastrorosa, I; Mazzotta, V; Pinnetti, C; Vergori, A; Zaccarelli, M1
Aziz, T; Hanif, FM; Laeeq, SM; Luck, NH; Mandhwani, RK; Mehdi, SH1
Bhasin, D; Pollinger, H; Rubin, RA; Shrestha, R; Stein, L; Tracy, B1
Alric, L; Bellier, B; Cacoub, P; Comarmond, C; Costopoulos, M; Desbois, AC; Fontaine, H; Garrido, M; Klatzmann, D; Le Garff-Tavernier, M; Maciejewski, A; Musset, L; Pol, S; Poynard, T; Rosenzwajg, M; Saadoun, D; Si Ahmed, SN1
Bergin, C; Cannon, M; Courtney, G; Crosbie, O; De Gascun, CF; Fanning, LJ; Feeney, E; Gray, E; Houlihan, DD; Kelleher, B; Lambert, JS; Lee, J; Mallon, P; McConkey, S; McCormick, A; McKiernan, S; McNally, C; Murray, F; Norris, S; O'Leary, A; Sheehan, G; Stewart, S; Walsh, C1
Casari, S; Castelli, F; Festa, E; Izzo, I; Lanza, P; Odolini, S; Vavassori, A; Zaltron, S1
Alric, L; Bouyer, AS; Cacoub, P; Comarmond, C; de Saint Martin, L; Ferfar, Y; Hezode, C; Musset, L; Pol, S; Poynard, T; Resche Rigon, M; Saadoun, D; Si Ahmed, SN1
Lawitz, EJ; Membreno, FE1
Rachakonda, S; Reddy, PG; Ross, BS; Sofia, MJ; Zhang, HR1
Bao, D; Chang, W; Chun, BK; Du, J; Espiritu, CL; Furman, PA; Jiang, Y; Keilman, M; Ross, BS; Sofia, MJ; Steuer, HM; Zhang, HR1
Chee, GM; Poordad, F1
Pockros, PJ1
Desoky, OS; Elfiky, AA; Elshemey, WM; Gawad, WA1

Reviews

93 review(s) available for sofosbuvir and Hepatitis C

ArticleYear
Hepatitis C - New drugs and treatment prospects.
    European journal of medicinal chemistry, 2019, Mar-01, Volume: 165

    Topics: Animals; Antiviral Agents; DNA-Directed RNA Polymerases; Enzyme Inhibitors; Hepatitis C; Humans; Molecular Structure; Molecular Targeted Therapy; Protease Inhibitors

2019
Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis.
    BMC infectious diseases, 2021, Sep-21, Volume: 21, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lipoproteins, LDL; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2021
Road to elimination of HCV: Clinical challenges in HCV management.
    Liver international : official journal of the International Association for the Study of the Liver, 2022, Volume: 42, Issue:9

    Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Homosexuality, Male; Humans; Male; Sex Workers; Sexual and Gender Minorities; Sofosbuvir

2022
Safety and efficacy of sofosbuvir-based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta-analysis.
    Journal of clinical pharmacy and therapeutics, 2022, Volume: 47, Issue:8

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome

2022
Defer no more: advances in the treatment and prevention of chronic hepatitis C virus infection in children.
    Current opinion in infectious diseases, 2022, 10-01, Volume: 35, Issue:5

    Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Infant, Newborn; Pregnancy; Sofosbuvir

2022
Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5.
    Hepatology international, 2022, Volume: 16, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Quinoxalines; Renal Insufficiency, Chronic; Sofosbuvir; Sustained Virologic Response

2022
Treatment of hepatitis C in children and adolescents: how far have we reached?
    World journal of pediatrics : WJP, 2023, Volume: 19, Issue:2

    Topics: Adolescent; Antiviral Agents; Child; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Treatment Outcome

2023
Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis.
    Medicine, 2022, Oct-21, Volume: 101, Issue:42

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Ribavirin; Sofosbuvir; Treatment Outcome

2022
Daclatasvir as a hepatitis C infection treatment option: an up-to-date evaluation.
    Expert opinion on pharmacotherapy, 2023, Volume: 24, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome

2023
The impact of sofosbuvir/velpatasvir/voxilaprevir treatment on serum hyperglycemia in hepatitis C virus infections: a systematic review and meta-analysis.
    Annals of medicine, 2023, Volume: 55, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Hyperglycemia; Randomized Controlled Trials as Topic; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2023
Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study.
    Therapeutic innovation & regulatory science, 2023, Volume: 57, Issue:5

    Topics: Anilides; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmacovigilance; Recurrence; Ribavirin; Ritonavir; Sofosbuvir; Sustained Virologic Response

2023
Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis.
    Viruses, 2023, 06-30, Volume: 15, Issue:7

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Neoplasms; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2023
Direct-Acting Antiviral Therapy for Treatment of Acute and Recent Hepatitis C Virus Infection: A Narrative Review.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 08-14, Volume: 77, Issue:Suppl 3

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir

2023
Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma.
    Alimentary pharmacology & therapeutics, 2020, Volume: 51, Issue:1

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2020
Overview of hepatitis C infection, molecular biology, and new treatment.
    Journal of infection and public health, 2020, Volume: 13, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins

2020
Direct-Acting Antiretroviral Therapy in Renal Transplant Recipients With Human Immunodeficiency Virus-Hepatitis C Virus Coinfection: Report of Our Experience and Literature Review.
    Transplantation proceedings, 2020, Volume: 52, Issue:2

    Topics: Adult; Antiviral Agents; Coinfection; Female; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2020
Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics.
    Journal of viral hepatitis, 2020, Volume: 27, Issue:8

    Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Child; Child, Preschool; Cyclopropanes; Disease Eradication; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Pediatrics; Proline; Pyrrolidines; Quality of Life; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; World Health Organization

2020
Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta-analysis.
    Scientific reports, 2020, 08-31, Volume: 10, Issue:1

    Topics: Antiviral Agents; Hepatitis C; Humans; Kidney Failure, Chronic; Sofosbuvir

2020
Hepatitis B virus reactivation after successful treatment of hepatitis C virus with sofosbuvir and ribavirin: A case report and literature review.
    Medicine, 2020, Oct-09, Volume: 99, Issue:41

    Topics: Antiviral Agents; Female; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Middle Aged; Recurrence; Ribavirin; Sofosbuvir

2020
An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease.
    PloS one, 2021, Volume: 16, Issue:2

    Topics: Antiviral Agents; Hepatitis C; Hepatitis C, Chronic; Humans; Renal Insufficiency, Chronic; Sofosbuvir; Treatment Outcome

2021
Hepatitis C-Associated Osteosclerosis: Improvement After Treatment with Sofosbuvir, Daclatasvir, and Ibandronate: Case Report and Literature Review.
    Calcified tissue international, 2021, Volume: 109, Issue:1

    Topics: Carbamates; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ibandronic Acid; Imidazoles; Male; Middle Aged; Osteosclerosis; Pyrrolidines; Sofosbuvir; Valine

2021
Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2022, 11-23, Volume: 37, Issue:12

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Renal Dialysis; Renal Insufficiency, Chronic; Sofosbuvir; United States

2022
Breakthroughs and challenges in the management of pediatric viral hepatitis.
    World journal of gastroenterology, 2021, May-28, Volume: 27, Issue:20

    Topics: Adult; Antiviral Agents; Child; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir

2021
Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis.
    Virology journal, 2021, 07-27, Volume: 18, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Drug Users; Fluorenes; Hepatitis C; Humans; Sofosbuvir; Sustained Virologic Response

2021
Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection.
    Pharmacotherapy, 2017, Volume: 37, Issue:6

    Topics: Antiviral Agents; Carbamates; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Treatment Outcome; Valine

2017
Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C.
    Expert opinion on drug metabolism & toxicology, 2017, Volume: 13, Issue:9

    Topics: Aminoisobutyric Acids; Animals; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Tablets; Treatment Outcome

2017
Cardiac Harms of Sofosbuvir: Systematic Review and Meta-Analysis.
    Drug safety, 2018, Volume: 41, Issue:1

    Topics: Antiviral Agents; Arrhythmias, Cardiac; Hepatitis C; Humans; Randomized Controlled Trials as Topic; Sofosbuvir

2018
Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C.
    The Annals of pharmacotherapy, 2018, Volume: 52, Issue:4

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides

2018
Interferon-free direct-acting antiviral therapy for acute hepatitis C virus infection in HIV-infected individuals: A literature review.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2018, Volume: 50, Issue:2

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Load

2018
Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C.
    Drugs, 2018, Volume: 78, Issue:2

    Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Combinations; Drug Therapy, Combination; Fluorenes; Genotype; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2018
Potential nephrotoxicity of sofosbuvir-based treatment in patients infected with hepatitis C virus: a review on incidence, type and risk factors.
    Expert review of clinical pharmacology, 2018, Volume: 11, Issue:5

    Topics: Acute Kidney Injury; Antiviral Agents; Drug Monitoring; Hepatitis C; Humans; Incidence; Kidney Diseases; Kidney Function Tests; Risk Factors; Sofosbuvir; Time Factors

2018
Sofosbuvir, velpatasvir and voxilaprevir combination therapy for treating patients with hepatitis C virus infection.
    Drugs of today (Barcelona, Spain : 1998), 2018, Volume: 54, Issue:4

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Outcome

2018
Sofosbuvir/velpatasvir/voxilaprevir: a highly effective option for retreatment of hepatitis C in difficult-to-treat patients.
    Antiviral therapy, 2019, Volume: 24, Issue:1

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides

2019
Was It Worth Introducing Health Economic Evaluation of Innovative Drugs in the French Regulatory Setting? The Case of New Hepatitis C Drugs.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2019, Volume: 22, Issue:2

    Topics: Antiviral Agents; Carbamates; Cost-Benefit Analysis; Economics, Medical; France; Hepatitis C; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Therapies, Investigational; Valine

2019
Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysis.
    Virology journal, 2019, 03-14, Volume: 16, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Prospective Studies; Renal Insufficiency, Chronic; Ribavirin; Sofosbuvir; Sustained Virologic Response

2019
A systematic review with meta-analysis: Is ribavirin necessary in sofosbuvir-based direct-acting antiviral therapies for patients with HCV recurrence after liver transplantation?
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2019, Volume: 83

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response

2019
Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure.
    Clinical and molecular hepatology, 2019, Volume: 25, Issue:4

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Proline; Quinoxalines; Randomized Controlled Trials as Topic; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure

2019
A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir.
    Current medicinal chemistry, 2013, Volume: 20, Issue:30

    Topics: Administration, Oral; DNA-Directed RNA Polymerases; Enzyme Inhibitors; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins

2013
Emerging treatments for hepatitis C.
    Expert opinion on emerging drugs, 2013, Volume: 18, Issue:4

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Discovery; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate

2013
New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C.
    Gut, 2014, Volume: 63, Issue:2

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Prodrugs; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2014
Sofosbuvir for the treatment of hepatitis C virus.
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:1

    Topics: Antiviral Agents; DNA-Directed RNA Polymerases; Hepacivirus; Hepatitis C; Sofosbuvir; Uridine Monophosphate; Virus Physiological Phenomena

2014
Treatment of hepatitis C virus genotype 3-infection.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sofosbuvir; Standard of Care; Time Factors; Treatment Outcome; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Viral Proteins

2014
Management of HCV patients with cirrhosis with direct acting antivirals.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1

    Topics: Algorithms; Aminoisobutyric Acids; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Leucine; Liver Cirrhosis; Oligopeptides; Proline; Quinolines; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Time Factors; Uridine Monophosphate

2014
Treating HCV in HIV 2013: on the cusp of change.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Leucine; Oligopeptides; Proline; Pyrrolidines; Quinolines; Sofosbuvir; Thiazoles; Treatment Outcome; Uridine Monophosphate; Valine

2014
Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1

    Topics: Aminoisobutyric Acids; Antiviral Agents; Clinical Trials as Topic; Drug Approval; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Leucine; Oligopeptides; Proline; Quinolines; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Time Factors; Uridine Monophosphate

2014
HCV direct-acting antiviral agents: the best interferon-free combinations.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials as Topic; Disease Eradication; Drug Discovery; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Leucine; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Pyrrolidines; Quinolines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Virus Replication

2014
Hepatitis C treatment: an incipient therapeutic revolution.
    Trends in molecular medicine, 2014, Volume: 20, Issue:6

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Molecular Targeted Therapy; Oligopeptides; Proline; Protease Inhibitors; Sofosbuvir; Uridine Monophosphate

2014
Interferon-free strategies with a nucleoside/nucleotide analogue.
    Seminars in liver disease, 2014, Volume: 34, Issue:1

    Topics: Animals; Antiviral Agents; Benzimidazoles; Drug Design; Drug Resistance, Viral; Fluorenes; Hepacivirus; Hepatitis C; Humans; Interferons; Molecular Targeted Therapy; Nucleosides; Nucleotides; Protease Inhibitors; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins

2014
Hepatitis C.
    Disease-a-month : DM, 2014, Volume: 60, Issue:5

    Topics: Adult; Age Distribution; Anti-HIV Agents; Communicable Disease Control; Disease Management; Female; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Needs Assessment; Prisoners; Prisons; Ribavirin; Risk Assessment; Sex Distribution; Simeprevir; Sofosbuvir; Sulfonamides; Telemedicine; Treatment Outcome; United States; Uridine Monophosphate; Young Adult

2014
Daclatasvir for the treatment of hepatitis C virus infection.
    Expert review of gastroenterology & hepatology, 2014, Volume: 8, Issue:7

    Topics: Administration, Oral; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Valine

2014
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
    Expert review of anti-infective therapy, 2014, Volume: 12, Issue:7

    Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials as Topic; Cyclopropanes; Disease Eradication; Drug Combinations; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine

2014
Sofosbuvir (Sovaldi) for the treatment of hepatitis C.
    Expert review of clinical pharmacology, 2014, Volume: 7, Issue:5

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins

2014
Antiviral treatment of hepatitis C.
    BMJ (Clinical research ed.), 2014, Jul-07, Volume: 348

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Viral Nonstructural Proteins

2014
Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus.
    The Journal of pharmacy and pharmacology, 2014, Volume: 66, Issue:12

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins

2014
Recent advances and future directions in the management of hepatitis C infections.
    Pharmacology & therapeutics, 2015, Volume: 145

    Topics: Animals; Antiviral Agents; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Failure; Uridine Monophosphate

2015
Recent advances in the treatment of hepatitis C.
    Discovery medicine, 2014, Volume: 18, Issue:99

    Topics: Animals; Antiviral Agents; Carrier Proteins; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Intracellular Signaling Peptides and Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins

2014
Hepatitis C management in post-transplant patients.
    Minerva gastroenterologica e dietologica, 2015, Volume: 61, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fluorenes; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Pyrrolidines; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Valine; Viral Load

2015
Sofosbuvir as backbone of interferon free treatments.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Dec-15, Volume: 46 Suppl 5

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis D, Chronic; Humans; Interferons; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2014
Efficacy of sofosbuvir-based therapies in HIV/HCV infected patients and persons who inject drugs.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Dec-15, Volume: 46 Suppl 5

    Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Sofosbuvir; Substance Abuse, Intravenous; Uridine Monophosphate

2014
How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35 Suppl 1

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine

2015
Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.
    Clinical therapeutics, 2015, Feb-01, Volume: 37, Issue:2

    Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Genotype; Headache; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Nausea; Polyethylene Glycols; Protease Inhibitors; Ribavirin; Simeprevir; Sofosbuvir

2015
Changing the face of hepatitis C management - the design and development of sofosbuvir.
    Drug design, development and therapy, 2015, Volume: 9

    Topics: Antiviral Agents; Drug Combinations; Drug Design; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir

2015
Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C.
    Expert opinion on drug safety, 2015, Volume: 14, Issue:8

    Topics: Antiviral Agents; Benzimidazoles; Drug Approval; Drug Combinations; Drug Interactions; Fluorenes; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate

2015
Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infection.
    International journal of clinical pharmacy, 2015, Volume: 37, Issue:5

    Topics: Antiviral Agents; Hepatitis C; Humans; Sofosbuvir; Viral Load

2015
Advances in hepatitis C therapies.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:13

    Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Transplantation; Liver Transplantation; Pyrrolidines; Simeprevir; Sofosbuvir; Valine

2015
Development of sofosbuvir for the treatment of hepatitis C virus infection.
    Annals of the New York Academy of Sciences, 2015, Volume: 1358

    Topics: Antiviral Agents; Drug Discovery; Hepacivirus; Hepatitis C; Humans; Sofosbuvir

2015
Daclatasvir (Daklinza) for HCV genotype 3 infection.
    The Medical letter on drugs and therapeutics, 2015, Oct-12, Volume: 57, Issue:1479

    Topics: Animals; Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Valine

2015
Mechanisms of Virologic Failure with Direct-Acting Antivirals in Hepatitis C and Strategies for Retreatment.
    Clinics in liver disease, 2015, Volume: 19, Issue:4

    Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Nucleic Acid Synthesis Inhibitors; Protease Inhibitors; Recurrence; Retreatment; RNA, Viral; Sofosbuvir; Treatment Failure; Viral Nonstructural Proteins

2015
Regimens for Patients Coinfected with Human Immunodeficiency Virus.
    Clinics in liver disease, 2015, Volume: 19, Issue:4

    Topics: Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferons; Nucleic Acid Synthesis Inhibitors; Polyethylene Glycols; Protease Inhibitors; Ribavirin; RNA, Viral; Sofosbuvir; Viral Nonstructural Proteins

2015
Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.
    The Annals of pharmacotherapy, 2016, Volume: 50, Issue:1

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Headache; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Nausea; Pyrrolidines; Sofosbuvir; Valine; Viral Nonstructural Proteins

2016
The hepatitis C revolution part 2: difficult-to-treat groups and experimental approaches.
    Current opinion in infectious diseases, 2015, Volume: 28, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Design; Drug Resistance, Viral; Fluorenes; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Sofosbuvir; Uridine Monophosphate

2015
Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection.
    Expert review of gastroenterology & hepatology, 2015, Volume: 9, Issue:12

    Topics: Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Resistance, Viral; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Ribavirin; Sofosbuvir

2015
Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.
    Expert opinion on investigational drugs, 2016, Volume: 25, Issue:5

    Topics: Amides; Antiviral Agents; Benzazepines; Benzofurans; Carbamates; Cyclopropanes; Drugs, Investigational; Hepatitis C; Humans; Imidazoles; Indoles; Isoquinolines; Quinoxalines; Sofosbuvir; Sulfonamides

2016
[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 1].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2016, Volume: 67, Issue:3

    Topics: Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Practice Guidelines as Topic; Quinoxalines; Republic of Korea; Sofosbuvir; Sulfonamides

2016
[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 2 and 3].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2016, Volume: 67, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Practice Guidelines as Topic; Republic of Korea; Ribavirin; Sofosbuvir

2016
Sexually-transmitted seronegative HCV infection in an HIV-positive post-liver transplant recipient. Case report and review of the literature.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2016, Volume: 79

    Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C; Hepatitis C Antibodies; HIV Infections; Humans; Liver Transplantation; Male; Middle Aged; RNA, Viral; Sexually Transmitted Diseases, Viral; Sofosbuvir; Transaminases; Transplant Recipients; Treatment Outcome

2016
Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options.
    World journal of gastroenterology, 2016, Jun-14, Volume: 22, Issue:22

    Topics: Administration, Oral; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Odds Ratio; Prospective Studies; Pyrrolidines; Randomized Controlled Trials as Topic; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Valine

2016
Safety and efficacy of sofosbuvir plus ledipasvir with and without ribavirin for chronic HCV genotype-1 infection: a systematic review and meta-analysis.
    Antiviral therapy, 2017, Volume: 22, Issue:5

    Topics: Animals; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Publication Bias; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load

2017
Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.
    The Annals of pharmacotherapy, 2017, Volume: 51, Issue:1

    Topics: Adult; Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Administration Schedule; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Sofosbuvir; Treatment Outcome

2017
Efficacy and safety of sofosbuvir-based interferon-free therapies for hepatitis C in liver transplant recipients.
    Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:4

    Topics: Antiviral Agents; Databases, Bibliographic; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Transplantation; Patient Compliance; Recurrence; Sofosbuvir; Treatment Outcome

2017
Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2016, Oct-24, Volume: 49, Issue:11

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine

2016
Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C.
    Expert opinion on drug metabolism & toxicology, 2017, Volume: 13, Issue:1

    Topics: Animals; Antiviral Agents; Benzimidazoles; Dose-Response Relationship, Drug; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate

2017
Liver transplantation from HCV RNA-positive donors in the era of interferon-free HCV therapeutics: a re-examination of the situation.
    Minerva gastroenterologica e dietologica, 2017, Volume: 63, Issue:1

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Neoplasms; Liver Transplantation; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Tissue Donors; Viral Load

2017
Hepatitis C virus genotype 4: Genotype 1's little brother.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Simeprevir; Sofosbuvir; Sustained Virologic Response

2017
Sofosbuvir in combination with daclatasvir in liver transplant recipients with HCV infection: A systematic review and meta-analysis.
    Clinics and research in hepatology and gastroenterology, 2017, Volume: 41, Issue:3

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepatitis C; Humans; Imidazoles; Liver Transplantation; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2017
Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.
    Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:8

    Topics: Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Interferons; Isoquinolines; Oligopeptides; Proline; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Time Factors; Valine; Viral Load

2017
Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection.
    Expert opinion on drug metabolism & toxicology, 2017, Volume: 13, Issue:4

    Topics: Administration, Oral; Antiviral Agents; Carbamates; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir

2017
HCV management in resource-constrained countries.
    Hepatology international, 2017, Volume: 11, Issue:3

    Topics: Aminoisobutyric Acids; Antiviral Agents; Australia; Benzimidazoles; Carbamates; Continuity of Patient Care; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Drugs, Generic; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Risk Factors; Sofosbuvir; Sulfonamides; Valine

2017
Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature.
    BMC infectious diseases, 2017, 03-01, Volume: 17, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; HIV Infections; Humans; Middle Aged; Sofosbuvir

2017
The HCV NS5B nucleoside and non-nucleoside inhibitors.
    Clinics in liver disease, 2011, Volume: 15, Issue:3

    Topics: Antiviral Agents; Clinical Trials as Topic; Deoxycytidine; Guanosine Monophosphate; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins

2011
Interferon free hepatitis C treatment regimens: the beginning of another era.
    Current gastroenterology reports, 2012, Volume: 14, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Protease Inhibitors; Ribavirin; Sofosbuvir; Uridine Monophosphate

2012
Update on combinations of DAAs with and without pegylated-interferon and ribavirin: triple and quadruple therapy more than doubles SVR.
    Clinics in liver disease, 2013, Volume: 17, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Peptides, Cyclic; Phosphinic Acids; Polyethylene Glycols; Protease Inhibitors; Quinolines; Ribavirin; Sofosbuvir; Uridine Monophosphate

2013
Nucleoside/nucleotide analogue polymerase inhibitors in development.
    Clinics in liver disease, 2013, Volume: 17, Issue:1

    Topics: Cytidine; Deoxycytidine; Drugs, Investigational; Enzyme Inhibitors; Hepacivirus; Hepatitis C; Humans; Protein Conformation; RNA-Dependent RNA Polymerase; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins

2013

Trials

71 trial(s) available for sofosbuvir and Hepatitis C

ArticleYear
Nonadherence to Ledipasvir/Sofosbuvir Did Not Predict Sustained Virologic Response in a Randomized Controlled Trial of Human Immunodeficiency Virus/Hepatitis C Virus Coinfected Persons Who Use Drugs.
    The Journal of infectious diseases, 2022, 03-02, Volume: 225, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Coinfection; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Pharmaceutical Preparations; Sofosbuvir; Substance-Related Disorders; Sustained Virologic Response; Treatment Outcome

2022
A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial.
    The lancet. Gastroenterology & hepatology, 2022, Volume: 7, Issue:4

    Topics: Adolescent; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; RNA; Sofosbuvir; Treatment Outcome; United States

2022
Predictors of 007 triphosphate concentrations in dried blood spots in persons with hepatitis C and active drug or alcohol use.
    The Journal of antimicrobial chemotherapy, 2022, 04-27, Volume: 77, Issue:5

    Topics: Dried Blood Spot Testing; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Polyphosphates; Sofosbuvir

2022
Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial.
    Journal of medicine and life, 2022, Volume: 15, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; COVID-19 Drug Treatment; Drug Therapy, Combination; Egypt; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2022
Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial.
    Journal of viral hepatitis, 2022, Volume: 29, Issue:9

    Topics: Amides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Nausea; Quinoxalines; Sofosbuvir; Sulfonamides

2022
Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial.
    The lancet. Gastroenterology & hepatology, 2022, Volume: 7, Issue:12

    Topics: Antiviral Agents; Drug Users; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; Substance Abuse, Intravenous

2022
Second-Phase Hepatitis C Plasma Viral Kinetics Directly Reflects Reduced Intrahepatic Burden of Hepatitis C Virus.
    The Journal of infectious diseases, 2023, 08-11, Volume: 228, Issue:3

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kinetics; Lactams, Macrocyclic; RNA, Viral; Sofosbuvir; Viremia

2023
The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis.
    Journal of viral hepatitis, 2023, Volume: 30, Issue:5

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Sofosbuvir; Treatment Outcome

2023
A randomized-controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C.
    Journal of hepatology, 2023, Volume: 79, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Retreatment; Ribavirin; Sofosbuvir; Treatment Outcome

2023
Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial).
    PloS one, 2023, Volume: 18, Issue:5

    Topics: Adolescent; Adult; Antiviral Agents; Equivalence Trials as Topic; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Sofosbuvir; Treatment Outcome

2023
Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study.
    The Korean journal of internal medicine, 2023, Volume: 38, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Republic of Korea; Sofosbuvir; Treatment Outcome

2023
Sustained virological response to antiviral drugs in treatment of different genotypes of HCV cirrhotic patients.
    Pakistan journal of pharmaceutical sciences, 2023, Volume: 36, Issue:3(Special)

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Sustained Virologic Response

2023
Community-Based Point-of-Diagnosis Hepatitis C Treatment for Marginalized Populations: A Nonrandomized Controlled Trial.
    JAMA network open, 2023, 10-02, Volume: 6, Issue:10

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; RNA; Sofosbuvir; Treatment Outcome

2023
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
    PloS one, 2020, Volume: 15, Issue:1

    Topics: Adenine; Adult; Aged; Alanine; Benzimidazoles; Coinfection; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Male; Middle Aged; RNA, Viral; Sofosbuvir; Tenofovir

2020
Viral clearance ameliorates hematological and inflammatory markers among diabetic patients infected with hepatitis C genotype 4.
    Clinical and experimental medicine, 2020, Volume: 20, Issue:2

    Topics: Adult; Antiviral Agents; Biomarkers; Carbamates; Diabetes Mellitus, Type 2; Female; Genotype; Glycated Hemoglobin; Hepacivirus; Hepatitis C; Humans; Imidazoles; Inflammation; Insulin Resistance; Interleukin-1beta; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2020
The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam.
    Trials, 2020, May-18, Volume: 21, Issue:1

    Topics: Administration, Oral; Antiviral Agents; Bayes Theorem; Carbamates; Drug Monitoring; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Vietnam

2020
Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
    The lancet. Gastroenterology & hepatology, 2020, Volume: 5, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Opiate Substitution Treatment; Outcome Assessment, Health Care; Pharmacists; Pyrrolidines; Scotland; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Valine

2020
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.
    The lancet. Gastroenterology & hepatology, 2020, Volume: 5, Issue:10

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; New Zealand; Non-Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Ribavirin; Safety; Sofosbuvir; Treatment Outcome; United States; Uridine Monophosphate; Viral Load

2020
Comparing direct acting antivirals for hepatitis C using observational data - Why and how?
    Pharmacology research & perspectives, 2020, Volume: 8, Issue:5

    Topics: Antiviral Agents; Bayes Theorem; Benzimidazoles; Carbamates; Comparative Effectiveness Research; Drug Combinations; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Propensity Score; Sofosbuvir; Treatment Failure

2020
Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study.
    The Lancet. Microbe, 2020, Volume: 1, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Infant; Pregnancy; Pregnant Women; Sofosbuvir; Treatment Outcome

2020
Novel combined single dose anti-hepatitis C therapy: a pilot study.
    Scientific reports, 2021, 02-25, Volume: 11, Issue:1

    Topics: Adult; Antiviral Agents; Catechin; Female; Genotype; Hepatitis C; Humans; Male; Middle Aged; Pilot Projects; Ribavirin; Sofosbuvir

2021
Eliminating hepatitis C in a rural Appalachian county: protocol for the Kentucky Viral Hepatitis Treatment Study (KeY Treat), a phase IV, single-arm, open-label trial of sofosbuvir/velpatasvir for the treatment of hepatitis C.
    BMJ open, 2021, 07-05, Volume: 11, Issue:7

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Kentucky; Pregnancy; Sofosbuvir; Treatment Outcome

2021
Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017, 04-15, Volume: 64, Issue:8

    Topics: Adult; Antiviral Agents; Hepatitis C; HIV Infections; HIV-1; Humans; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome

2017
Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017, Jul-01, Volume: 65, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Female; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Sofosbuvir; United States

2017
Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial.
    The lancet. Gastroenterology & hepatology, 2017, Volume: 2, Issue:5

    Topics: Acute Disease; Adult; Anti-HIV Agents; Antiviral Agents; Benzimidazoles; Coinfection; Drug Administration Schedule; Fluorenes; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Pilot Projects; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load

2017
Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon- Alfa in Treatment of a Cohort of Egyptian Patients with Hepatitis C Virus Infection.
    Infectious disorders drug targets, 2017, Volume: 17, Issue:2

    Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sofosbuvir

2017
Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:12

    Topics: Antiviral Agents; Carbamates; Case-Control Studies; Cohort Studies; Coinfection; Drug Combinations; Female; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Sofosbuvir

2017
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.
    PloS one, 2017, Volume: 12, Issue:5

    Topics: Administration, Oral; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Kinetics; Male; Middle Aged; Oligopeptides; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins

2017
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
    The New England journal of medicine, 2017, 06-01, Volume: 376, Issue:22

    Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Protease Inhibitors; Quinoxalines; Sofosbuvir; Sulfonamides; Viral Nonstructural Proteins

2017
Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III).
    Journal of viral hepatitis, 2018, Volume: 25, Issue:2

    Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine

2018
Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV.
    Gastroenterology, 2018, Volume: 154, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; DNA, Viral; Female; Fluorenes; Hepacivirus; Hepatitis B; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Male; Middle Aged; Prospective Studies; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Taiwan; Time Factors; Treatment Outcome; Uridine Monophosphate; Viral Load

2018
IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Immunologic Factors; Interferon Type I; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult

2018
Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4.
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatic Encephalopathy; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine

2018
Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus.
    Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:5

    Topics: Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Liver; Male; Mass Spectrometry; Middle Aged; Ribavirin; Sofosbuvir

2018
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
    Annals of internal medicine, 2018, 04-17, Volume: 168, Issue:8

    Topics: Adolescent; Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Feasibility Studies; Female; Genotype; Graft Rejection; Graft Survival; Hepatitis C; Humans; Imidazoles; Kidney; Kidney Transplantation; Male; Middle Aged; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Tissue Donors; Treatment Outcome

2018
Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents.
    Journal of internal medicine, 2018, Volume: 283, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fluorenes; Hepatitis C; Humans; Iceland; Incidence; Liver Cirrhosis; Liver Neoplasms; Mass Screening; Needle-Exchange Programs; Population Surveillance; Ribavirin; Sofosbuvir; Substance Abuse, Intravenous; Uridine Monophosphate

2018
Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment.
    Clinical pharmacokinetics, 2018, Volume: 57, Issue:11

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Drug Combinations; Drug Therapy, Combination; Female; Hepatic Insufficiency; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Uridine; Young Adult

2018
Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 06-01, Volume: 66, Issue:12

    Topics: Alkynes; Antiviral Agents; Benzimidazoles; Benzoxazines; Black or African American; Cohort Studies; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Therapy, Combination; Female; Fluorenes; Genome-Wide Association Study; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Polymorphism, Single Nucleotide; Recurrence; Sofosbuvir

2018
Impact of Interferon Lambda 4 Genotype on Interferon-Stimulated Gene Expression During Direct-Acting Antiviral Therapy for Hepatitis C.
    Hepatology (Baltimore, Md.), 2018, Volume: 68, Issue:3

    Topics: Antiviral Agents; Gene Expression Profiling; Gene Expression Regulation; Genotype; Hepatitis C; Humans; Interleukins; Liver; Liver Cirrhosis; Ribavirin; Sofosbuvir; Sustained Virologic Response

2018
Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.
    The Journal of antimicrobial chemotherapy, 2018, 08-01, Volume: 73, Issue:8

    Topics: Adenine; Adult; Antiviral Agents; Benzimidazoles; Coinfection; Drug Interactions; Fluorenes; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Organophosphates; Ribavirin; Sofosbuvir; Tenofovir; Uridine Monophosphate

2018
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
    Gastroenterology, 2018, Volume: 155, Issue:4

    Topics: Antiviral Agents; Carbamates; Drug Combinations; Drug Resistance, Bacterial; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Spain; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load

2018
Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis.
    Archives of virology, 2018, Volume: 163, Issue:10

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Leukocytes, Mononuclear; Liver Cirrhosis; Male; Middle Aged; Recurrence; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Young Adult

2018
Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
    Journal of gastroenterology, 2019, Volume: 54, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Japan; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2019
Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden.
    Infectious diseases (London, England), 2019, Volume: 51, Issue:2

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Russia; Sofosbuvir; Sweden; Young Adult

2019
Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection.
    Journal of hepatology, 2019, Volume: 70, Issue:5

    Topics: Adult; Aged; Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure

2019
Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection.
    Journal of medical virology, 2019, Volume: 91, Issue:7

    Topics: Adult; Antiviral Agents; Asian People; China; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Young Adult

2019
Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients.
    The New England journal of medicine, 2019, 04-25, Volume: 380, Issue:17

    Topics: Adult; Age Factors; Aged; Antiviral Agents; Carbamates; Female; Graft Rejection; Graft Survival; Heart Transplantation; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Heterocyclic Compounds, 4 or More Rings; Humans; Lung Transplantation; Male; Middle Aged; Pilot Projects; RNA, Viral; Sofosbuvir; Tissue Donors

2019
Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes.
    PloS one, 2019, Volume: 14, Issue:5

    Topics: Aged; Brazil; Carbamates; Drug Resistance, Viral; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Mutation; Pyrrolidines; RNA, Viral; Sequence Analysis, RNA; Sofosbuvir; Valine; Viral Nonstructural Proteins

2019
Randomized feasibility trial of directly observed versus unobserved hepatitis C treatment with ledipasvir-sofosbuvir among people who inject drugs.
    PloS one, 2019, Volume: 14, Issue:6

    Topics: Adult; Benzimidazoles; Female; Fluorenes; Hepatitis C; Humans; Male; Middle Aged; Prevalence; San Francisco; Sofosbuvir; Substance Abuse, Intravenous; Uridine Monophosphate

2019
Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 07-18, Volume: 69, Issue:3

    Topics: Acute Disease; Administration, Oral; Adult; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Administration Schedule; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Ribavirin; Sexual and Gender Minorities; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Load

2019
An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study.
    The International journal on drug policy, 2019, Volume: 72

    Topics: Adult; Antiviral Agents; Carbamates; Drug Combinations; Female; Hepatitis C; Hepatitis C Antibodies; Humans; Ill-Housed Persons; Imidazoles; Iran; Male; Middle Aged; Prevalence; Pyrrolidines; Sofosbuvir; Substance Abuse, Intravenous; Valine

2019
Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse.
    Liver international : official journal of the International Association for the Study of the Liver, 2019, Volume: 39, Issue:12

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Recurrence; Ribavirin; Salvage Therapy; Sofosbuvir; Sulfonamides; Sustained Virologic Response

2019
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.
    JAMA, 2013, Aug-28, Volume: 310, Issue:8

    Topics: Antiviral Agents; Body Weight; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Interleukins; Male; Middle Aged; Prognosis; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load

2013
All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear).
    Journal of viral hepatitis, 2013, Volume: 20, Issue:10

    Topics: Administration, Oral; Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load; Young Adult

2013
Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.
    Gastroenterology, 2014, Volume: 146, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Enzyme Inhibitors; Fatigue; Female; Fluorenes; Furans; Genotype; Headache; Hepacivirus; Hepatitis C; Humans; Incidence; Male; Middle Aged; Nausea; Sofosbuvir; Thiophenes; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins

2014
Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938.
    Antiviral therapy, 2014, Volume: 19, Issue:2

    Topics: Adult; Antiviral Agents; Cyclic P-Oxides; Double-Blind Method; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Nucleosides; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load; Young Adult

2014
Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
    Gastroenterology, 2015, Volume: 148, Issue:1

    Topics: Aged; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; New Zealand; Pilot Projects; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; United States; Uridine Monophosphate; Viral Load; Waiting Lists

2015
Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
    Gastroenterology, 2015, Volume: 148, Issue:1

    Topics: Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; New Zealand; Pilot Projects; Prospective Studies; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Spain; Time Factors; Treatment Outcome; United States; Uridine Monophosphate; Viral Load

2015
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
    Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Time Factors; Uridine Monophosphate; Valine; Young Adult

2015
Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2015, Volume: 13, Issue:11

    Topics: Antiviral Agents; Belgium; Carbamates; Cholestasis; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; France; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2015
Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant.
    Clinical transplantation, 2015, Volume: 29, Issue:12

    Topics: Allografts; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Prognosis; Prospective Studies; Recurrence; Simeprevir; Sofosbuvir

2015
Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong.
    Alimentary pharmacology & therapeutics, 2016, Volume: 43, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hong Kong; Humans; Male; Middle Aged; Ribavirin; RNA; Sofosbuvir; Treatment Outcome

2016
Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study.
    Annals of the rheumatic diseases, 2016, Volume: 75, Issue:10

    Topics: Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Vasculitis

2016
Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial.
    Annals of internal medicine, 2015, Dec-15, Volume: 163, Issue:12

    Topics: Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Furans; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Quinolines; RNA, Viral; Sofosbuvir; Thiophenes; Treatment Outcome; Viral Load

2015
Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial.
    Journal of hepatology, 2016, Volume: 65, Issue:1

    Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Patient Reported Outcome Measures; Quality of Life; Ribavirin; Sofosbuvir

2016
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.
    Gastroenterology, 2016, Volume: 151, Issue:3

    Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; New Zealand; Proline; Protease Inhibitors; Quinoxalines; Serine Proteases; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins; Young Adult

2016
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.
    Gastroenterology, 2016, Volume: 151, Issue:3

    Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Nonstructural Proteins

2016
Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2016, Volume: 22, Issue:10

    Topics: Aged; Antiviral Agents; Belgium; Carbamates; Compassionate Use Trials; Female; France; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Protease Inhibitors; Pyrrolidines; Recurrence; Reoperation; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2016
No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, 11-01, Volume: 63, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Male; Middle Aged; Sofosbuvir; Virus Activation

2016
Clinical experience with dolutegravir/abacavir/lamivudine in HIV-HCV co-infected patients treated with a sofosbuvir-based regimen-safety and efficacy.
    HIV clinical trials, 2016, Volume: 17, Issue:6

    Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Coinfection; Dideoxynucleosides; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Sofosbuvir; Treatment Outcome; Viral Load

2016
Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study.
    The Lancet. Infectious diseases, 2017, Volume: 17, Issue:2

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Germany; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Prospective Studies; RNA, Viral; Sofosbuvir

2017

Other Studies

492 other study(ies) available for sofosbuvir and Hepatitis C

ArticleYear
Synthesis and Anti-HCV Activities of 4'-Fluoro-2'-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4'-Fluoro-2'- C-methyluridine 5'-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection.
    Journal of medicinal chemistry, 2019, 05-09, Volume: 62, Issue:9

    Topics: Alanine; Animals; Antiviral Agents; Cell Line, Tumor; Dogs; Hepacivirus; Hepatitis C; Humans; Nucleic Acid Synthesis Inhibitors; Phosphoramides; Prodrugs; Replicon; Uracil Nucleotides; Uridine; Viral Nonstructural Proteins

2019
Synthesis of 3',4'-difluoro-3'-deoxyribonucleosides and its evaluation of the biological activities: discovery of a novel type of anti-HCV agent 3',4'-difluorocordycepin.
    Bioorganic & medicinal chemistry, 2014, Nov-01, Volume: 22, Issue:21

    Topics: Antiviral Agents; Cell Line; Deoxyadenosines; Deoxyribonucleosides; Halogenation; Hepacivirus; Hepatitis C; Humans; Structure-Activity Relationship

2014
Synthesis and biological evaluation of a novel β-D-2'-deoxy-2'-α-fluoro-2'-β-C-(fluoromethyl)uridine phosphoramidate prodrug for the treatment of hepatitis C virus infection.
    European journal of medicinal chemistry, 2018, Jan-01, Volume: 143

    Topics: Administration, Oral; Animals; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Hepacivirus; Hepatitis C; Humans; Liver; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Organophosphorus Compounds; Prodrugs; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Uridine; Virus Replication

2018
Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease.
    The American journal of gastroenterology, 2021, 09-01, Volume: 116, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Female; Fluorenes; Hepatitis C; Humans; Kidney Failure, Chronic; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2021
Sofosbuvir/Velpatasvir Prophylaxis for 12 Weeks in Hepatitis C Virus (HCV)-Negative Recipients Receiving Kidney Transplantation from HCV-Positive Donors.
    Annals of transplantation, 2021, Sep-07, Volume: 26

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Kidney Transplantation; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Treatment Outcome; Young Adult

2021
Outcomes using direct-acting antiviral hepatitis-C treatment in older versus younger Veterans.
    Journal of the American Geriatrics Society, 2021, Volume: 69, Issue:12

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Registries; Sofosbuvir; Sustained Virologic Response; United States; Veterans

2021
Circulating macrophage inflammatory protein-1β/IL-12p40 ratio predicts sofosbuvir-based treatment outcome in HCV- genotype 4 patients.
    Human antibodies, 2021, Volume: 29, Issue:4

    Topics: Chemokine CCL4; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interleukin-12 Subunit p40; Sofosbuvir; Treatment Outcome

2021
Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis.
    European journal of gastroenterology & hepatology, 2021, 12-01, Volume: 33, Issue:1S Suppl 1

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; End Stage Liver Disease; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Retrospective Studies; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2021
Seroprevalence, Genotyping, and Monitoring of Hepatitis C Viral Loads in Patients on Antivirals in Burkina Faso.
    Intervirology, 2022, Volume: 65, Issue:3

    Topics: Antiviral Agents; Burkina Faso; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Seroepidemiologic Studies; Sofosbuvir; Treatment Outcome; Viral Load

2022
Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders.
    Virology journal, 2021, 10-07, Volume: 18, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Iran; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2021
Real-life experience of treating HCV co-infection among HIV-infected population in Egypt: single-center experience.
    Expert review of anti-infective therapy, 2022, Volume: 20, Issue:5

    Topics: Antiviral Agents; Coinfection; Egypt; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Retrospective Studies; Sofosbuvir; Treatment Outcome

2022
The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients.
    Microbial pathogenesis, 2022, Volume: 162

    Topics: Antiviral Agents; Drug Therapy, Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Immunity, Innate; Nerve Tissue Proteins; Ribavirin; Sofosbuvir; Treatment Outcome

2022
Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance.
    Antiviral research, 2022, Volume: 197

    Topics: Antiviral Agents; Drug Resistance, Viral; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Humans; Replicon; Sofosbuvir

2022
Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 08-31, Volume: 75, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; Coinfection; DNA, Viral; Fluorenes; Follow-Up Studies; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Taiwan

2022
[A case of HCV genotype 3b with compensated stage cirrhosis who have two times treatment-experienced with the use of glecaprevir/pibrentasvir combined with sofosbuvir and ribavirin for 16 weeks].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2021, Dec-20, Volume: 29, Issue:12

    Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome

2021
Hepatitis C Virus Treatment Response to Direct-acting Antivirals Among Adolescents With HIV/HCV Coinfection: Real-world Data From Ukraine.
    The Pediatric infectious disease journal, 2022, 05-01, Volume: 41, Issue:5

    Topics: Adolescent; Antiviral Agents; Child; Cohort Studies; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Sofosbuvir; Treatment Outcome; Ukraine

2022
Monitoring of iron, lipid and liver profiles in Egyptian hepatitis C virus patients on sofosbuvir therapy.
    Journal of infection and public health, 2022, Volume: 15, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Iron; Lipids; Sofosbuvir

2022
Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection.
    Hepatology (Baltimore, Md.), 2022, Volume: 76, Issue:2

    Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Child; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome

2022
Drug delivery of sofosbuvir drug capsulated with the β-cyclodextrin basket loaded on chitosan nanoparticle surface for anti-hepatitis C virus (HCV).
    International journal of biological macromolecules, 2022, May-15, Volume: 207

    Topics: Animals; Antiviral Agents; beta-Cyclodextrins; Chitosan; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Mice; Nanoparticles; Pharmaceutical Preparations; Sofosbuvir; Treatment Outcome

2022
Sofosbuvir-based direct-acting antivirals for patients with decompensated hepatitis C virus-related cirrhosis.
    Journal of the Chinese Medical Association : JCMA, 2022, 05-01, Volume: 85, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome

2022
Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19.
    Scientific reports, 2022, 04-06, Volume: 12, Issue:1

    Topics: Antiviral Agents; Carbamates; Case-Control Studies; COVID-19 Drug Treatment; Disease Progression; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; RNA-Dependent RNA Polymerase; SARS-CoV-2; Sofosbuvir; Treatment Outcome

2022
Case study of hepatitis C virus control in Egypt: impact of access program.
    Antiviral therapy, 2022, Volume: 27, Issue:2

    Topics: Egypt; Hepacivirus; Hepatitis C; Humans; Prevalence; Sofosbuvir

2022
Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2022, Volume: 121, Issue:11

    Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzopyrans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Lipids; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sugars; Sulfonamides; Treatment Outcome

2022
Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study.
    The Korean journal of internal medicine, 2022, Volume: 37, Issue:6

    Topics: Antiviral Agents; Cohort Studies; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Republic of Korea; RNA; Sofosbuvir; Treatment Outcome

2022
Hepatitis C viral clearance with coadministration of crushed sofosbuvir/velpatasvir and high-dose pantoprazole after liver transplantation.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2022, 11-22, Volume: 79, Issue:Suppl 4

    Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Transplantation; Pancreatitis; Pantoprazole; Sofosbuvir

2022
Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study.
    BMJ open, 2022, 06-08, Volume: 12, Issue:6

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Iran; Liver Cirrhosis; Sofosbuvir; Treatment Outcome

2022
[Efficacy and tolerance of direct-acting antiviral drugs for the treatment of hepatitis C in Joseph Raseta Befelatanana Teaching Hospital in Antananarivo, Madagascar].
    Medecine tropicale et sante internationale, 2021, 09-30, Volume: 1, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hospitals, Teaching; Humans; Madagascar; Retrospective Studies; Ribavirin; Sofosbuvir

2021
Comparative Effectiveness of Direct-Acting Antivirals for Posttraumatic Stress Disorder in Veterans Affairs Patients With Hepatitis C Virus Infection.
    American journal of epidemiology, 2022, 08-22, Volume: 191, Issue:9

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Stress Disorders, Post-Traumatic; Sustained Virologic Response; Treatment Outcome; Veterans

2022
In-depth investigation of the Silymarin effect on the pharmacokinetic parameters of sofosbuvir, GS-331007 and ledipasvir in rat plasma using LC-MS.
    Biomedical chromatography : BMC, 2022, Volume: 36, Issue:9

    Topics: Animals; Antiviral Agents; Benzimidazoles; Chromatography, Liquid; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; Male; Rats; Silymarin; Sofosbuvir; Tandem Mass Spectrometry

2022
Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry.
    Journal of gastroenterology and hepatology, 2022, Volume: 37, Issue:8

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Registries; Sofosbuvir; Sulfonamides; Treatment Outcome

2022
Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China.
    BioMed research international, 2022, Volume: 2022

    Topics: Adult; Antiviral Agents; Carbamates; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Kidney; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Viremia

2022
RNA-Dependent RNA Polymerase of the Second Human Pegivirus Exhibits a High-Fidelity Feature.
    Microbiology spectrum, 2022, 10-26, Volume: 10, Issue:5

    Topics: Antiviral Agents; Coinfection; Flaviviridae Infections; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Nucleosides; Pegivirus; Phylogeny; RNA Viruses; RNA-Dependent RNA Polymerase; RNA, Viral; Sofosbuvir

2022
Severe impairment of patient-reported outcomes in patients with chronic hepatitis C virus infection seen in real-world practices across the world: Data from the global liver registry.
    Journal of viral hepatitis, 2022, Volume: 29, Issue:11

    Topics: Antiviral Agents; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatigue; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Patient Reported Outcome Measures; Quality of Life; Registries; Sofosbuvir

2022
Dual versus triple therapy in treatment of hepatitis C virus (HCV).
    Irish journal of medical science, 2023, Volume: 192, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome

2023
Real-world Safety and Effectiveness of 24-week Sofosbuvir and Ribavirin Treatment in Patients Infected with Rare Chronic Hepatitis C Virus Genotypes 3, 4, 5, or 6 in Japan.
    Internal medicine (Tokyo, Japan), 2023, May-15, Volume: 62, Issue:10

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Japan; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome

2023
High sustained virologic response rate after 8 weeks of direct-acting antivirals in cancer patients with chronic hepatitis C virus.
    European journal of gastroenterology & hepatology, 2022, 10-01, Volume: 34, Issue:10

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Neoplasms; Male; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2022
Results of interferon-free treatment for HCV-infected patients with decompensated cirrhosis from a Brazilian real-life cohort.
    Medicine, 2022, Sep-02, Volume: 101, Issue:35

    Topics: Aged; Antiviral Agents; Brazil; Female; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2022
Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents.
    Asian Pacific journal of cancer prevention : APJCP, 2022, Sep-01, Volume: 23, Issue:9

    Topics: Aged; alpha-Fetoproteins; Antiviral Agents; Carbamates; Cross-Sectional Studies; Drug Therapy, Combination; Egypt; Fibrosis; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Leukocytes, Mononuclear; Pyrrolidines; Ribavirin; RNA; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2022
Long-Term Follow-Up of Thalassemia Major Patients with Hepatitis C Virus Treated with Sofosbuvir and Daclatasvir: A Cohort Study.
    Archives of medical research, 2022, Volume: 53, Issue:7

    Topics: Antiviral Agents; beta-Thalassemia; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Iron Overload; Male; Pyrrolidines; Sofosbuvir; Treatment Outcome

2022
Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells.
    Scientific reports, 2022, 11-02, Volume: 12, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; COVID-19 Drug Treatment; Hepacivirus; Hepatitis C; Humans; Lung; Nucleosides; SARS-CoV-2; Sofosbuvir

2022
Direct-acting antiviral agent use and gastrointestinal safety in patients with chronic hepatitis C: a pharmacovigilance study based on FDA Adverse Event Reporting System.
    International journal of clinical pharmacy, 2023, Volume: 45, Issue:1

    Topics: Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmacovigilance; Sofosbuvir

2023
Serial changes in renal indices in chronic HCV patients with and without HIV co-infection receiving sofosbuvir and tenofovir-based therapies.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2023, 04-03, Volume: 117, Issue:4

    Topics: Antiviral Agents; Coinfection; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Prospective Studies; Sofosbuvir; Tenofovir

2023
Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health Disorders.
    Viruses, 2022, 11-11, Volume: 14, Issue:11

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Mental Disorders; Sofosbuvir

2022
Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir.
    Internal medicine (Tokyo, Japan), 2023, Sep-01, Volume: 62, Issue:17

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Neoplasm Recurrence, Local; Ribavirin; Sofosbuvir

2023
Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients.
    BMC gastroenterology, 2022, Dec-03, Volume: 22, Issue:1

    Topics: Antiviral Agents; Circulating MicroRNA; Egypt; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; MicroRNAs; Ribavirin; Sofosbuvir

2022
Treatment-experienced patient with Roux-en-Y gastric bypass successfully treated with sofosbuvir/velpatasvir/voxilaprevir: A case report.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2023, 03-07, Volume: 80, Issue:6

    Topics: Antiviral Agents; Gastric Bypass; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir

2023
Real World Efficacy and Safety of Sofosbuvir + Velpatasvir + Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy.
    Journal of gastrointestinal and liver diseases : JGLD, 2022, 12-17, Volume: 31, Issue:4

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Romania; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2022
Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study.
    eLife, 2023, Jan-09, Volume: 12

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interleukins; Pilot Projects; Ribavirin; Sofosbuvir; Treatment Outcome

2023
Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs.
    PloS one, 2023, Volume: 18, Issue:1

    Topics: Drug Costs; Health Expenditures; Hepatitis C; Humans; Medication Adherence; Retrospective Studies; Sofosbuvir

2023
Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 06-08, Volume: 76, Issue:11

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2023
Sustained virological response in an HCV-infected patient on an enzyme-inducing anti-epileptic agent despite undetectable trough plasma levels of velpatasvir.
    Journal of hepatology, 2023, Volume: 78, Issue:5

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2023
Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis.
    Journal of gastroenterology, 2023, Volume: 58, Issue:4

    Topics: Antiviral Agents; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Humans; Hypertension, Portal; Liver Cirrhosis; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2023
Antiviral Treatment Failures After Transplantation of Organs From Donors With Hepatitis C Infection: A Report of 4 Cases.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2023, Volume: 82, Issue:3

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Sustained Virologic Response; Tissue Donors; Treatment Failure

2023
Hepatitis C micro-elimination through the retrieval strategy of patients lost to follow-up.
    BMC gastroenterology, 2023, Feb-13, Volume: 23, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lost to Follow-Up; Sofosbuvir

2023
A simplified point-of-service model for hepatitis C in people who inject drugs in South Africa.
    Harm reduction journal, 2023, 03-04, Volume: 20, Issue:1

    Topics: Drug Users; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Seroepidemiologic Studies; Sofosbuvir; South Africa; Substance Abuse, Intravenous

2023
Next-generation sequencing analysis of hepatitis C virus resistance-associated substitutions in direct-acting antiviral failure in South Korea.
    Clinical and molecular hepatology, 2023, Volume: 29, Issue:2

    Topics: Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Ribavirin; Sofosbuvir; Viral Nonstructural Proteins

2023
Visual symptoms with Sofosbuvir in hepatitis C treatment - a case report from Pakistan.
    JPMA. The Journal of the Pakistan Medical Association, 2023, Volume: 73, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pakistan; Sofosbuvir; Treatment Outcome

2023
Budget impact analysis of two treatment approaches for hepatitis C in Malaysia through the use of voluntary and compulsory licensing options.
    Frontiers in public health, 2023, Volume: 11

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Malaysia; Sofosbuvir

2023
Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system.
    Hepatology (Baltimore, Md.), 2023, 08-01, Volume: 78, Issue:2

    Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Viral Nonstructural Proteins

2023
Human pegivirus viremia in HCV/HIV co-infected patients: Direct acting antivirals exert anti-pegivirus effects.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2023, Volume: 162

    Topics: Antiviral Agents; Coinfection; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferons; Male; Pegivirus; Polyethylene Glycols; RNA, Viral; Sofosbuvir; Viremia

2023
Newly diagnosed hepatitis C infection after pancreas transplantation with multiple treatment failures.
    BMJ case reports, 2023, May-03, Volume: 16, Issue:5

    Topics: Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pancreas Transplantation; Pyrrolidines; Quinoxalines; Sofosbuvir; Treatment Failure

2023
Impact of oral antiviral therapy against HCV on gut microbiota. A prospective study.
    The new microbiologica, 2023, Volume: 46, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Gastrointestinal Microbiome; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Macrocyclic Compounds; Male; Prospective Studies; Sofosbuvir

2023
Efficacy and safety of pan-genotypic sofosbuvir and velpatasvir in patients with hepatitis C and HIV coinfection on dolutegravir-based antiretroviral therapy.
    Journal of viral hepatitis, 2023, Volume: 30, Issue:9

    Topics: Adult; Antiviral Agents; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Sofosbuvir; Treatment Outcome; Young Adult

2023
Sustained virologic response in DAA-treated HCV patients on anti-epileptic drugs.
    Journal of hepatology, 2023, Volume: 79, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; Genotype; Hepacivirus; Hepatitis C; Humans; Quinoxalines; Sofosbuvir; Sustained Virologic Response

2023
The pre-conception maternal exposure to Sofosbuvir affects the mitochondrial biogenesis in prenatal fetal tissues: Experimental study on rats.
    Molecular medicine (Cambridge, Mass.), 2023, 06-06, Volume: 29, Issue:1

    Topics: Animals; DNA, Mitochondrial; Female; Fetus; Genotype; Hepatitis C; Humans; Male; Maternal Exposure; Organelle Biogenesis; Placenta; Pregnancy; Rats; Sofosbuvir

2023
Treatment effectiveness and side effects of patients with hepatitis C in the prisons of Southern Taiwan: a real-life retrospective analysis.
    BMJ open, 2023, 06-07, Volume: 13, Issue:6

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Prisons; Retrospective Studies; Sofosbuvir; Taiwan; Treatment Outcome

2023
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2023, Volume: 43, Issue:9

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interleukins; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome

2023
Pre-existing, treatment-specific resistance-associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct-acting antivirals.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2023, Volume: 131, Issue:8

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response

2023
Fitness-Dependent, Mild Mutagenic Activity of Sofosbuvir for Hepatitis C Virus.
    Antimicrobial agents and chemotherapy, 2023, 07-18, Volume: 67, Issue:7

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Mutagens; Ribavirin; Sofosbuvir; Treatment Outcome

2023
Spectroscopic study to verify the anti-hepatitis C virus (HCV) treatment through a delivery system of the sofosbuvir drug on chitosan and pycnogenol nanoparticles surface.
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2023, Dec-05, Volume: 302

    Topics: Animals; Antiviral Agents; Chitosan; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Mice; Pharmaceutical Preparations; Ribavirin; Sofosbuvir; Spectrum Analysis

2023
Sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection.
    The Korean journal of internal medicine, 2023, Volume: 38, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Sofosbuvir; Treatment Outcome

2023
Prediction of response to sofosbuvir-based therapy using serum interleukin-12 and single nucleotide polymorphism of the interleukin 28B gene as predictive factors in HCV positive genotype-4 patients.
    Medicine, 2023, Jul-14, Volume: 102, Issue:28

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukin-12; Interleukins; Polymorphism, Single Nucleotide; Ribavirin; Sofosbuvir; Treatment Outcome

2023
An insight into the hepatoprotective role of Velpatasvir and Sofosbuvir per se and in combination against carbon tetrachloride-induced hepatic fibrosis in rats.
    Environmental science and pollution research international, 2023, Volume: 30, Issue:42

    Topics: Animals; Antioxidants; Antiviral Agents; Carbon Tetrachloride; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Interleukin-6; Liver Cirrhosis; NF-kappa B; Rats; Sofosbuvir

2023
Dismal prognosis for cirrhotic patients with hepatitis C after initial failure of direct acting anti-virals, but salvage therapy may be life-saving.
    Infectious diseases (London, England), 2023, Volume: 55, Issue:11

    Topics: Adult; Antiviral Agents; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Salvage Therapy; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2023
Efficacy and Safety of Directly Acting Antivirals in Patients with Hepatitis C Infection on Hemodialysis.
    The Journal of the Association of Physicians of India, 2023, Volume: 71, Issue:8

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; India; Prospective Studies; Renal Dialysis; Sofosbuvir; Treatment Outcome

2023
Sofosbuvir plus glecaprevir/pibrentasvir as salvage therapy after liver transplantation in NS5A inhibitor-experienced patients. A case series.
    Gaceta medica de Mexico, 2023, Volume: 159, Issue:4

    Topics: Antiviral Agents; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Transplantation; Retrospective Studies; Salvage Therapy; Sofosbuvir

2023
Construction and characterization of a new hepatitis C virus genotype 6a subgenomic replicon that is prone to render the sofosbuvir resistance.
    Journal of medical virology, 2023, Volume: 95, Issue:9

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Subgenomic RNA

2023
The Intergeneration Long-Lasting Consequences of Pre-Conceptional Exposure to Sofosbuvir on the Ovarian Tissues of F1 Offspring: Experimental Study on Rats.
    International journal of molecular sciences, 2023, Sep-05, Volume: 24, Issue:18

    Topics: Animals; Cell Communication; Female; Fertilization; Hepatitis C; Humans; Male; Pregnancy; Rats; Reproduction; Sofosbuvir

2023
Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017-2021.
    Harm reduction journal, 2023, 10-01, Volume: 20, Issue:1

    Topics: Analgesics, Opioid; Antiviral Agents; Fentanyl; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Hydrocodone; Oxycodone; Sofosbuvir

2023
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis.
    Viruses, 2023, 09-29, Volume: 15, Issue:10

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome

2023
Direct-Acting Antiviral Drug Modulates the Mitochondrial Biogenesis in Different Tissues of Young Female Rats.
    International journal of molecular sciences, 2023, Oct-31, Volume: 24, Issue:21

    Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Organelle Biogenesis; Rats; Rats, Wistar; Sofosbuvir; Treatment Outcome

2023
Usefulness Of Sofosbuvir And Daclatasvir Combination In The Treatment Of HCV Infection In Childhood Cancer Patients: Experience From A Tertiary Care Hospital.
    JPMA. The Journal of the Pakistan Medical Association, 2023, Volume: 73, Issue:11

    Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Neoplasms; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Tertiary Care Centers; Treatment Outcome

2023
Effectiveness of generic sofosbuvir in the treatment of chronic hepatitis C virus infection in Saudi patients.
    Saudi medical journal, 2023, Volume: 44, Issue:12

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Drugs, Generic; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Saudi Arabia; Sofosbuvir; Treatment Outcome

2023
Trends in Renal Function Among Heart Transplant Recipients of Donor-Derived Hepatitis C Virus.
    ASAIO journal (American Society for Artificial Internal Organs : 1992), 2020, Volume: 66, Issue:5

    Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Heart Transplantation; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Kidney Diseases; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Tissue Donors; Transplant Recipients; Uridine Monophosphate

2020
Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India.
    PloS one, 2019, Volume: 14, Issue:8

    Topics: Adult; Antiviral Agents; Carbamates; Cohort Studies; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; India; Markov Chains; Quality-Adjusted Life Years; Sofosbuvir; Universal Health Insurance

2019
Treatment of hepatitis C in two paediatric patients using sofosbuvir during haematopoietic stem cell transplantation.
    Antiviral therapy, 2019, Volume: 24, Issue:8

    Topics: Antiviral Agents; Child; Child, Preschool; Dasatinib; Female; Hematopoietic Stem Cell Transplantation; Hepatitis C; Humans; Ribavirin; RNA, Viral; Sofosbuvir; Viral Load

2019
Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh.
    The International journal on drug policy, 2019, Volume: 74

    Topics: Adult; Aged; Antiviral Agents; Bangladesh; Carbamates; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; Prospective Studies; Pyrrolidines; RNA, Viral; Sofosbuvir; Substance Abuse, Intravenous; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult

2019
Prevalence of Hepatitis C Virus Genotypes in Pakistan: Current Scenario and Review of Literature.
    Viral immunology, 2019, Volume: 32, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Genotyping Techniques; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Pakistan; Prevalence; RNA, Viral; Sofosbuvir; Sustained Virologic Response

2019
Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015-March 2018.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 08-22, Volume: 71, Issue:5

    Topics: Adolescent; Adult; Antiviral Agents; Georgia; Georgia (Republic); Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Sustained Virologic Response

2020
Efficacy, Safety, and Predictors of Direct-acting antivirals in Hepatitis C Virus Patients with Heterogeneous Liver Diseases.
    The new microbiologica, 2019, Volume: 42, Issue:4

    Topics: 2-Naphthylamine; Antiviral Agents; Biomarkers, Pharmacological; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Retrospective Studies; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil

2019
Access to Direct-Acting Antiviral Treatment for Hepatitis C Virus Among Veterans With Serious Mental Illness.
    Psychiatric services (Washington, D.C.), 2020, 02-01, Volume: 71, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Female; Health Services Accessibility; Hepatitis C; Humans; Logistic Models; Male; Mental Disorders; Middle Aged; Sofosbuvir; Treatment Outcome; United States; United States Department of Veterans Affairs; Veterans

2020
Successful sofosbuvir lead-in monotherapy for the treatment of hepatitis C virus (HCV) infection in a pregnant woman living with HIV.
    BMJ case reports, 2019, Oct-23, Volume: 12, Issue:10

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carbamates; Female; Hepatitis C; Herpes Genitalis; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Sofosbuvir

2019
CCR5 receptor antagonism inhibits hepatitis C virus (HCV) replication in vitro.
    PloS one, 2019, Volume: 14, Issue:10

    Topics: CCR5 Receptor Antagonists; Cell Line; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Imidazoles; Maraviroc; Raltegravir Potassium; Receptors, CCR5; Sofosbuvir; Sulfoxides; Virus Replication

2019
Successful evolution of morphea after hepatitis C virus eradication with direct-acting antiviral agent treatment.
    Revista espanola de enfermedades digestivas, 2019, Volume: 111, Issue:12

    Topics: Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Scleroderma, Localized; Sofosbuvir; Thigh; Uridine Monophosphate

2019
Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis.
    Journal of viral hepatitis, 2020, Volume: 27, Issue:4

    Topics: Adult; Antiviral Agents; Carbamates; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Scotland; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2020
NS5A-P32 Deletion in Hepatitis C Genotype 1b Infection is the Most Refractory Treatment-Mediated Amino Acid Change Exhibiting Resistance to all NS5A Inhibitors.
    Seminars in liver disease, 2020, Volume: 40, Issue:2

    Topics: Aminoisobutyric Acids; Animals; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Mice; Sofosbuvir

2020
Hepatitis C virus eradication with directly acting antivirals improves health-related quality of life and psychological symptoms.
    World journal of gastroenterology, 2019, Dec-28, Volume: 25, Issue:48

    Topics: Aged; Antiviral Agents; Anxiety; Benzimidazoles; Depression; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Psychological Tests; Quality of Life; Self Report; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2019
[Progress of antiviral therapy for hepatitis C virus-related decompensated cirrhosis].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2019, Dec-20, Volume: 27, Issue:12

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Failure; Ribavirin; Sofosbuvir; Treatment Outcome

2019
The paediatric population: the forgotten element to eliminating hepatitis C virus.
    The lancet. Gastroenterology & hepatology, 2020, Volume: 5, Issue:4

    Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Chronic Disease; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Infectious Disease Transmission, Vertical; Liver Diseases; Male; Prevalence; Risk Factors; Sofosbuvir; Uridine Monophosphate; Young Adult

2020
Hepatitis C virus therapy in children: No one should be left behind.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:2

    Topics: Benzimidazoles; Child; Child, Preschool; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir

2020
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir; Treatment Outcome

2020
The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment.
    Journal of gastroenterology and hepatology, 2020, Volume: 35, Issue:9

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Male; Pyrrolidines; Renal Dialysis; Renal Insufficiency; Safety; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2020
Hepatitis C Virus-associated Lymphoplasmacytic Lymphoma With Waldenström Macroglobulinemia: Response to Direct-acting Antiviral Therapy.
    Clinical lymphoma, myeloma & leukemia, 2020, Volume: 20, Issue:4

    Topics: Benzimidazoles; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sofosbuvir; Waldenstrom Macroglobulinemia

2020
A financial incentive program to improve appointment attendance at a safety-net hospital-based primary care hepatitis C treatment program.
    PloS one, 2020, Volume: 15, Issue:2

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Female; Fluorenes; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Odds Ratio; Primary Health Care; Program Evaluation; Reward; Safety-net Providers; Sofosbuvir; Sustained Virologic Response; Young Adult

2020
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV.
    PloS one, 2020, Volume: 15, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; United States; Uridine Monophosphate; Viral Load

2020
Living Donor Liver Transplantation From Hepatitis C-Infected Donor to Hepatitis C-Infected Recipient.
    Hepatology (Baltimore, Md.), 2020, Volume: 72, Issue:3

    Topics: Adult; Antiviral Agents; Carbamates; Child; Fatty Liver; Female; Hepacivirus; Hepatectomy; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Function Tests; Liver Neoplasms; Liver Transplantation; Living Donors; Monitoring, Physiologic; Sofosbuvir; Transplant Recipients; Treatment Outcome; Viral Load

2020
Contrasting Role of Dose Increase in Modulating Sofosbuvir-Induced Hepatocyte Toxicity.
    Drug research, 2020, Volume: 70, Issue:4

    Topics: Animals; Antiviral Agents; Cells, Cultured; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Hepatitis C; Hepatocytes; Humans; Male; Oxidative Stress; Primary Cell Culture; Rats; Sofosbuvir

2020
Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population.
    Medicine, 2020, Volume: 99, Issue:11

    Topics: Antiviral Agents; Benzimidazoles; Black or African American; Coinfection; Female; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; New Jersey; Retrospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2020
Universal Disease Screening and Treatment - The Egyptian Example.
    The New England journal of medicine, 2020, Mar-19, Volume: 382, Issue:12

    Topics: Adolescent; Adult; Antiviral Agents; Egypt; Hepatitis C; Humans; Mass Screening; Sofosbuvir

2020
Therapeutic Drug Monitoring-Guided Crushed Sofosbuvir-Velpatasvir Treatment: A Case Study.
    Therapeutic drug monitoring, 2020, Volume: 42, Issue:2

    Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Drug Monitoring; Female; Half-Life; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Neoplasms; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Tablets

2020
Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2020, Volume: 26, Issue:9

    Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Outcome

2020
Micellar high performance liquid chromatographic method for separation and validation of two anti-hepatitis C- virus drugs in pure form, human plasma and human urine.
    Annales pharmaceutiques francaises, 2020, Volume: 78, Issue:3

    Topics: Antiviral Agents; Chromatography, High Pressure Liquid; Cost-Benefit Analysis; Hepatitis C; Humans; Limit of Detection; Reproducibility of Results; Ribavirin; Sofosbuvir; Solubility

2020
Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.
    European journal of hospital pharmacy : science and practice, 2020, Volume: 27, Issue:e1

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Prospective Studies; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome

2020
Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan.
    Journal of viral hepatitis, 2020, Volume: 27, Issue:9

    Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Taiwan

2020
High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia.
    Journal of viral hepatitis, 2020, Volume: 27, Issue:9

    Topics: Antiviral Agents; Cambodia; Carbamates; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pilot Projects; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2020
Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort.
    Journal of viral hepatitis, 2020, Volume: 27, Issue:10

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Prospective Studies; Pyrrolidines; Sofosbuvir; Valine

2020
English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed.
    Alimentary pharmacology & therapeutics, 2020, Volume: 52, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; England; Female; Fluorenes; Hepatitis C; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Registries; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uridine Monophosphate; Valine; Young Adult

2020
Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:8

    Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2020
Direct-acting antivirals ability to clear intestinal HCV-RNA in liver transplant patients.
    Transplant infectious disease : an official journal of the Transplantation Society, 2020, Volume: 22, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir

2020
HCV eradication in chronic kidney disease: ready for prime time?
    The lancet. Gastroenterology & hepatology, 2020, Volume: 5, Issue:10

    Topics: Benzimidazoles; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Renal Insufficiency, Chronic; Ribavirin; Sofosbuvir

2020
Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus.
    European journal of gastroenterology & hepatology, 2021, 06-01, Volume: 33, Issue:6

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response

2021
Epclusa Approved For Children With Hepatitis C.
    The American journal of nursing, 2020, Volume: 120, Issue:7

    Topics: Antiviral Agents; Carbamates; Child; Drug Approval; Drug Combinations; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir

2020
Modeling based response guided therapy in subjects with recent hepatitis C infection.
    Antiviral research, 2020, Volume: 180

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Duration of Therapy; Female; Hepatitis C; Humans; Male; Middle Aged; Models, Theoretical; Predictive Value of Tests; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Young Adult

2020
High sustained viral response among HCV genotype 3 patients with advanced liver fibrosis: real-world data of HCV elimination program in Georgia.
    BMC research notes, 2020, Jul-11, Volume: 13, Issue:1

    Topics: Adolescent; Adult; Antiviral Agents; Female; Genotype; Georgia (Republic); Health Services; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Young Adult

2020
Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection.
    Clinical journal of gastroenterology, 2020, Volume: 13, Issue:6

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir; Treatment Outcome

2020
Ukrainian health authorities adopt hepatitis C project.
    Lancet (London, England), 2020, 07-25, Volume: 396, Issue:10246

    Topics: Antiviral Agents; Carbamates; Delivery of Health Care; Drug Therapy, Combination; Drugs, Generic; Health Plan Implementation; Hepacivirus; Hepatitis C; Humans; Imidazoles; Physicians; Pyrrolidines; Sofosbuvir; Ukraine; Valine

2020
Diversity of the hepatitis C virus NS5B gene during HIV co-infection.
    PloS one, 2020, Volume: 15, Issue:8

    Topics: 2-Naphthylamine; Adult; AIDS-Related Opportunistic Infections; Amino Acid Sequence; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Coinfection; Drug Resistance, Viral; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; HIV; Humans; Phylogeny; RNA-Dependent RNA Polymerase; RNA, Viral; Sofosbuvir; Sulfonamides; Uracil; Viral Nonstructural Proteins

2020
Acute Renal Failure in a Patient on Ledipasvir-Sofosbuvir Therapy for Hepatitis C.
    American journal of therapeutics, 2020, 07-31, Volume: 28, Issue:6

    Topics: Acute Kidney Injury; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Treatment Outcome

2020
Acute hepatitis C infection with secondary liver injury successfully treated with sofosbuvir/velpatasvir combination.
    British journal of hospital medicine (London, England : 2005), 2020, Aug-02, Volume: 81, Issue:8

    Topics: Acute Disease; Adult; Antiviral Agents; Carbamates; Drug Combinations; Genotype; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Sofosbuvir

2020
Transfer of daclatasvir and sofosbuvir's main metabolite, GS-331007, across the human placenta ex vivo.
    American journal of obstetrics and gynecology, 2020, Volume: 223, Issue:6

    Topics: Antiviral Agents; Carbamates; Female; Hepatitis C; Humans; Imidazoles; Maternal-Fetal Exchange; Placenta; Pregnancy; Pregnancy Complications, Infectious; Pyrrolidines; Sofosbuvir; Uridine; Valine

2020
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 11-02, Volume: 73, Issue:9

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome

2021
Hepatitis C virus-associated decompensated liver cirrhosis with refractory hepatic encephalopathy successfully treated by balloon-occluded retrograde transvenous obliteration after sofosbuvir/velpatasvir.
    Clinical journal of gastroenterology, 2020, Volume: 13, Issue:6

    Topics: Balloon Occlusion; Carbamates; Female; Hepacivirus; Hepatic Encephalopathy; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Middle Aged; Sofosbuvir; Treatment Outcome

2020
Efficacy and Safety of Ledispavir/Sofosbuvir with or without Ribavirin in patients with Decompensated Liver Cirrhosis and Hepatitis C Infection: a Cohort Study.
    Journal of gastrointestinal and liver diseases : JGLD, 2020, Sep-09, Volume: 29, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Romania; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load

2020
Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors.
    Hepatology (Baltimore, Md.), 2021, Volume: 73, Issue:6

    Topics: Antiviral Agents; Carbamates; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Kidney; Kidney Transplantation; Linear Models; Liver; Liver Transplantation; Male; Middle Aged; Proof of Concept Study; Prospective Studies; Sofosbuvir; Sustained Virologic Response; Tissue Donors; Transplant Recipients; Viral Load; Viremia

2021
Treatment outcomes and costs of a simplified antiviral treatment strategy for hepatitis C among monoinfected and HIV and/or hepatitis B virus-co-infected patients in Myanmar.
    Journal of viral hepatitis, 2021, Volume: 28, Issue:1

    Topics: Antiviral Agents; Coinfection; Hepacivirus; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Myanmar; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2021
Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.
    Scientific reports, 2020, 10-06, Volume: 10, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; Coronavirus RNA-Dependent RNA Polymerase; COVID-19; Drug Discovery; Drug Repositioning; Exonucleases; Hepacivirus; Hepatitis C; Humans; Pandemics; Pneumonia, Viral; Prodrugs; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Sofosbuvir; Viral Nonstructural Proteins; Virus Replication

2020
Safety and efficacy of Sofosbuvir and Velpatasvir in children with active hepatitis C virus infection undergoing haploidentical transplantation.
    Transplant infectious disease : an official journal of the Transplantation Society, 2021, Volume: 23, Issue:2

    Topics: Antiviral Agents; Carbamates; Child; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir; Transplantation, Haploidentical; Treatment Outcome

2021
Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study.
    Journal of acquired immune deficiency syndromes (1999), 2021, 02-01, Volume: 86, Issue:2

    Topics: Anilides; Antiviral Agents; Benzimidazoles; Coinfection; Cyclopropanes; Female; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine

2021
The Effects of Supplement Therapy on HCV-Related HCC: a Case Report of a Patient Who Had Undergone TACE for Six Times.
    Journal of gastrointestinal cancer, 2021, Volume: 52, Issue:2

    Topics: Aged; Antibiotics, Antineoplastic; Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Doxorubicin; Female; Hepatitis C; Humans; Liver Neoplasms; Myanmar; Sofosbuvir; Treatment Outcome

2021
Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2021, 09-27, Volume: 36, Issue:10

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Renal Insufficiency; Sofosbuvir; Treatment Outcome; Valine; Young Adult

2021
Interferon lambda 4 gene polymorphisms as a predicting tool of response to hepatitis C virus genotype 4 patients treated with Sofosbuvir and Ribavirin.
    Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2020, Volume: 86

    Topics: Alleles; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Interleukins; Pharmacogenetics; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Ribavirin; Sofosbuvir

2020
A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir.
    The Journal of general virology, 2021, Volume: 102, Issue:1

    Topics: Antiviral Agents; Brazil; Carbamates; Cell Line, Tumor; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Mutation; Pyrrolidines; Recurrence; Sofosbuvir; Valine; Viral Nonstructural Proteins; Virus Replication

2021
Direct-acting antiviral treatment failure in genotype 2 hepatitis C chronic infection.
    Journal of viral hepatitis, 2021, Volume: 28, Issue:2

    Topics: Antiviral Agents; Carbamates; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Treatment Failure; Valine

2021
Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection.
    Canadian journal of gastroenterology & hepatology, 2020, Volume: 2020

    Topics: Antiviral Agents; Child; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmaceutical Preparations; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2020
Real-world efficacy and safety of direct-acting antiviral drugs in patients with chronic hepatitis C and inherited blood disorders.
    European journal of gastroenterology & hepatology, 2021, 12-01, Volume: 33, Issue:1S Suppl 1

    Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2021
Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients.
    European journal of gastroenterology & hepatology, 2020, Volume: 32, Issue:8

    Topics: Antiviral Agents; Carbamates; Child; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Neoplasms; Male; Morbidity; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2020
A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2.
    Antiviral research, 2021, Volume: 185

    Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Chromosomes, Artificial, Bacterial; COVID-19; COVID-19 Drug Treatment; HEK293 Cells; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Replicon; RNA-Binding Proteins; SARS-CoV-2; Sofosbuvir; Vero Cells; Virus Replication

2021
Sofosbuvir-based Treatment for HCV: A Safe Option in Patients Undergoing Hemodialysis.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2020, Volume: 30, Issue:11

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Renal Dialysis; Ribavirin; Sofosbuvir; Treatment Outcome

2020
Combination treatment with sofosbuvir and ribavirin for patients diagnosed with hepatitis C genotype 2: A real-world, single-center study.
    Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2021, Volume: 22, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome

2021
Outcome of hepatitis C-related liver transplantation in direct-acting antiviral era.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2020, Volume: 39, Issue:6

    Topics: Adult; Antiviral Agents; Female; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Severity of Illness Index; Sofosbuvir; Survival Rate; Young Adult

2020
Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study.
    Clinical and molecular hepatology, 2021, Volume: 27, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Mongolia; Sofosbuvir; Treatment Outcome

2021
Improving access to the treatment of hepatitis C in low- and middle-income countries: evaluation of a patient assistance programme.
    International journal of clinical pharmacy, 2021, Volume: 43, Issue:4

    Topics: Antiviral Agents; Developing Countries; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir

2021
Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre- or post-liver transplant.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2021, Volume: 21, Issue:5

    Topics: Antiviral Agents; Child; Coinfection; End Stage Liver Disease; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Liver Transplantation; Prospective Studies; Retrospective Studies; Severity of Illness Index; Sofosbuvir; Treatment Outcome

2021
Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C).
    Gut, 2021, Volume: 70, Issue:12

    Topics: Antiviral Agents; Carbamates; Drug Combinations; Hemodialysis Units, Hospital; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Mass Screening; Pilot Projects; Renal Dialysis; Seroepidemiologic Studies; Sofosbuvir; Sustained Virologic Response; Taiwan; Uremia; Viremia

2021
Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis.
    Clinical and molecular hepatology, 2021, Volume: 27, Issue:1

    Topics: Aged; Antiviral Agents; Drug Interactions; Female; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Renal Dialysis; Sofosbuvir

2021
Occurrence and recurrence of hepatocellular carcinoma in patients with HCV genotype 1b related cirrhosis treated with Ledipasvir + Sofosbuvir ± Ribavirin.
    Journal of gastrointestinal and liver diseases : JGLD, 2020, 12-13, Volume: 29, Issue:4

    Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Fluorenes; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Neoplasm Recurrence, Local; Retrospective Studies; Ribavirin; Sofosbuvir

2020
Concomitant use of direct-acting antivirals (DAA) and central nervous system drugs in patients with hepatitis C virus infection.
    Adicciones, 2022, Nov-29, Volume: 34, Issue:4

    Topics: Antiviral Agents; Central Nervous System Agents; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir

2022
Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation.
    Clinical and translational medicine, 2021, Volume: 11, Issue:1

    Topics: Antiviral Agents; Female; Hepatitis C; Humans; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Middle Aged; Sofosbuvir; Treatment Outcome

2021
Long-Lasting Imprint in the Soluble Inflammatory Milieu Despite Early Treatment of Acute Symptomatic Hepatitis C.
    The Journal of infectious diseases, 2022, 08-26, Volume: 226, Issue:3

    Topics: Antigens, Neoplasm; Antiviral Agents; Cell Adhesion Molecules; Cohort Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir

2022
Improvement in Liver Stiffness in Pediatric Patients with Hepatitis C Virus after Treatment with Direct Acting Antivirals.
    The Journal of pediatrics, 2021, Volume: 233

    Topics: Adolescent; Antiviral Agents; Aspartate Aminotransferases; Benzimidazoles; Child; Elasticity Imaging Techniques; Female; Fluorenes; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Prospective Studies; Sofosbuvir

2021
Comment on the paper "Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results".
    PloS one, 2021, Volume: 16, Issue:2

    Topics: Cost-Benefit Analysis; Genotype; Germany; Hepacivirus; Hepatitis C; Humans; Sofosbuvir

2021
Improvement of Skeletal Muscle Mass after Ledipasvir and Sofosbuvir Treatment for Hepatitis C Virus in Decompensated Liver Cirrhosis.
    Internal medicine (Tokyo, Japan), 2021, Volume: 60, Issue:5

    Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Muscle, Skeletal; Quality of Life; Sofosbuvir; Treatment Outcome

2021
The impact of public coverage of newer hepatitis C medications on utilization, adherence, and costs in British Columbia.
    PloS one, 2021, Volume: 16, Issue:3

    Topics: Adult; Antiviral Agents; Benzimidazoles; British Columbia; Female; Fluorenes; Health Care Costs; Hepatitis C; Humans; Male; Medication Adherence; Middle Aged; Sofosbuvir

2021
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan.
    Liver international : official journal of the International Association for the Study of the Liver, 2021, Volume: 41, Issue:6

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Neoplasms; Middle Aged; Registries; Sofosbuvir; Sustained Virologic Response; Taiwan; Treatment Failure; Treatment Outcome

2021
Expression profiling of miRNA-196a biomarker in naïve hepatitis C virus-infected and Sofosbuvir plus Daclatasvir-treated patients.
    Archives of microbiology, 2021, Volume: 203, Issue:5

    Topics: Adult; Antiviral Agents; Biomarkers; Blood Chemical Analysis; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Host Microbial Interactions; Humans; Imidazoles; Male; MicroRNAs; Middle Aged; Pyrrolidines; Real-Time Polymerase Chain Reaction; RNA, Viral; ROC Curve; Sofosbuvir; Valine; Viral Load

2021
Sofosbuvir in HCV patients with chronic kidney disease: No time for caution.
    Liver international : official journal of the International Association for the Study of the Liver, 2021, Volume: 41, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Renal Insufficiency, Chronic; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2021
Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system.
    The lancet. Gastroenterology & hepatology, 2021, Volume: 6, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cambodia; Carbamates; Drug Therapy, Combination; Female; Follow-Up Studies; Health Services Accessibility; Hepatitis C; Humans; Imidazoles; Male; Mass Screening; Middle Aged; Pilot Projects; Program Evaluation; Public Health; Pyrrolidines; Rural Health Services; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult

2021
Ledipasvir/Sofosbuvir Eradicates Hepatitis C in an Immunodeficient STAT3-GOF Patient.
    Journal of clinical immunology, 2021, Volume: 41, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Child; Female; Fluorenes; Gain of Function Mutation; Genotype; Hepatitis C; Humans; Sofosbuvir; STAT3 Transcription Factor

2021
Signatures of immune dysfunction in HIV and HCV infection share features with chronic inflammation in aging and persist after viral reduction or elimination.
    Proceedings of the National Academy of Sciences of the United States of America, 2021, 04-06, Volume: 118, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Aging; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cells, Cultured; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Lymphocytes; Male; Middle Aged; Myeloid Cells; Sofosbuvir; Viral Load

2021
Feasible TLC-Spectro-Densitometry Technique for Simultaneous Determination of Two Hepatitis C Antiviral Drugs, Sofosbuvir and Simeprevir: Application to Combined Pharmaceutical Dosage Forms and Human Plasma.
    Journal of chromatographic science, 2021, May-20, Volume: 59, Issue:6

    Topics: Antiviral Agents; Capsules; Chromatography, Thin Layer; Densitometry; Hepatitis C; Humans; Limit of Detection; Simeprevir; Sofosbuvir

2021
Affordable treatment and political commitment are crucial to eliminate hepatitis C globally.
    The lancet. Gastroenterology & hepatology, 2021, Volume: 6, Issue:6

    Topics: Benzimidazoles; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Sofosbuvir; Valine

2021
Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase.
    European journal of gastroenterology & hepatology, 2021, 12-01, Volume: 33, Issue:1S Suppl 1

    Topics: Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; World Health Organization

2021
Treatment of viral hepatitis C genotypes 1 and 2 by sofosbuvir and ledipasvir with or without ribavirin combination: A possible alternative to pangenotypic treatment in a low-income country?
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021, Volume: 107

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Developing Countries; Drug Interactions; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Treatment Outcome; Young Adult

2021
Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2021, Volume: 32, Issue:2

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome; Turkey

2021
Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis.
    Journal of gastroenterology and hepatology, 2021, Volume: 36, Issue:10

    Topics: Antiviral Agents; Cohort Studies; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2021
Reactivation of hepatitis C virus with severe hepatitis flare during steroid administration for interstitial pneumonia.
    Clinical journal of gastroenterology, 2021, Volume: 14, Issue:4

    Topics: Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; Humans; Lung Diseases, Interstitial; Sofosbuvir; Symptom Flare Up

2021
Hepatitis B Surface Antigen Decline during Sofosbuvir and Ribavirin Therapy in Hepatitis B Inactive Carriers Who Were Co-infected with Hepatitis C.
    Internal medicine (Tokyo, Japan), 2021, Nov-15, Volume: 60, Issue:22

    Topics: Antiviral Agents; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; Humans; Retrospective Studies; Ribavirin; Sofosbuvir

2021
Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy.
    Journal of viral hepatitis, 2021, Volume: 28, Issue:9

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Neoplasms; Retreatment; Sofosbuvir; Sustained Virologic Response

2021
Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir.
    Journal of hepatology, 2021, Volume: 75, Issue:4

    Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Resistance; Female; Hepatitis C; Humans; Longitudinal Studies; Male; Middle Aged; Pyrrolidines; Quinoxalines; RNA-Dependent RNA Polymerase; Sofosbuvir; Sulfonamides; United States; Viral Nonstructural Proteins

2021
Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection.
    Journal of hepatology, 2021, Volume: 75, Issue:4

    Topics: Adult; Antiviral Agents; Australia; Canada; Carbamates; Drug Combinations; Female; Germany; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Netherlands; New Zealand; Sofosbuvir; Switzerland; Time Factors; Treatment Outcome; United Kingdom

2021
Sofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China.
    Scientific reports, 2021, 05-28, Volume: 11, Issue:1

    Topics: Adult; Antiviral Agents; China; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Male; Ribavirin; Rural Population; Sofosbuvir; Sustained Virologic Response

2021
Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan.
    BMC gastroenterology, 2021, Jun-12, Volume: 21, Issue:1

    Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Sofosbuvir; Sustained Virologic Response; Taiwan; Treatment Outcome

2021
Beta-thalassemia major alters sofosbuvir/ledipasvir exposure in Hepatitis C virus infected adolescent patients.
    Clinics and research in hepatology and gastroenterology, 2021, Volume: 45, Issue:5

    Topics: Adolescent; Adult; Antiviral Agents; Benzimidazoles; beta-Thalassemia; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmaceutical Preparations; Prospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2021
Outcomes of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2021, Volume: 21, Issue:11

    Topics: Antiviral Agents; Carbamates; Drug Combinations; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Kidney Transplantation; Sofosbuvir

2021
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis.
    Clinical and molecular hepatology, 2021, Volume: 27, Issue:4

    Topics: Antiviral Agents; Carbamates; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome

2021
Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India.
    PloS one, 2021, Volume: 16, Issue:7

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Cost of Illness; Disability Evaluation; Drugs, Generic; Female; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; India; International Normalized Ratio; Liver Cirrhosis; Male; Middle Aged; Quality of Life; Sofosbuvir; Young Adult

2021
The Moral Necessity to Increase Access to HCV+ Transplants With Early Treatment for HCV-naive Patients.
    Transplantation, 2022, 02-01, Volume: 106, Issue:2

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Morals; Sofosbuvir; Transplants

2022
Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
    Nephrology (Carlton, Vic.), 2018, Volume: 23, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; India; Kidney Diseases; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Viral Load

2018
Recurrent Mixed Cryoglobulinemia Despite Sustained Virologic Response to Treatment: A Case Report.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 70, Issue:2

    Topics: Antiviral Agents; Cryoglobulinemia; Hepatitis C; Humans; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response

2017
Experience with direct acting anti-viral agents for treating hepatitis C virus infection in renal transplant recipients.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2017, Volume: 36, Issue:2

    Topics: Acute Disease; Adult; Antiviral Agents; Biomarkers; Carbamates; Creatinine; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; India; Kidney Function Tests; Kidney Transplantation; Male; Middle Aged; Nephritis, Interstitial; Pyrrolidines; Retrospective Studies; RNA, Viral; Sofosbuvir; Time Factors; Valine

2017
Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017, Jun-01, Volume: 64, Issue:11

    Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine

2017
Sofosbuvir-based regimens against an "easy" villain: HCV genotype 2.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:8

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome

2017
Ventricular Tachycardia as a Complication of Ledipasvir and Sofosbuvir Treatment for HCV Infection.
    Internal medicine (Tokyo, Japan), 2017, Volume: 56, Issue:7

    Topics: Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C; Humans; Risk Factors; Sofosbuvir; Tachycardia, Ventricular

2017
Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing?
    Clinics and research in hepatology and gastroenterology, 2017, Volume: 41, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Fluorenes; Hepatitis C; Humans; Sofosbuvir; Tenofovir; Treatment Outcome

2017
Reactivation of Hepatitis B Virus Following Treatment of Hepatitis C Virus Infection in Coinfected Patients.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017, 05-15, Volume: 64, Issue:10

    Topics: Benzimidazoles; Coinfection; Fluorenes; Hepacivirus; Hepatitis B virus; Hepatitis C; HIV Infections; Humans; Sofosbuvir

2017
Interferon-free therapy with sofosbuvir plus ribavirin for successful treatment of genotype 2 hepatitis C virus with lichen planus: a case report.
    Clinical journal of gastroenterology, 2017, Volume: 10, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Lichen Planus; Lip; Lip Diseases; Male; Middle Aged; Ribavirin; Sofosbuvir

2017
Mixed Essential Cryoglobulinemia.
    Mayo Clinic proceedings, 2017, Volume: 92, Issue:5

    Topics: Antiviral Agents; Carbamates; Cryoglobulinemia; Exanthema; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Immunologic Factors; Male; Middle Aged; Rituximab; Sofosbuvir

2017
Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:11

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Function Tests; Male; Middle Aged; Myanmar; Odds Ratio; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Viral Load; Young Adult

2017
High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Registries; Retrospective Studies; Simeprevir; Sofosbuvir; Treatment Outcome; Young Adult

2017
Hepatitis B virus reactivation after effective sofosbuvir and ribavirin treatment in a patient with occult hepatitis B virus infection.
    The new microbiologica, 2017, Volume: 40, Issue:3

    Topics: Aged; Anti-Inflammatory Agents; Antiviral Agents; Cryoglobulinemia; DNA, Viral; Female; Guanine; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Immunologic Factors; Prednisolone; Recurrence; Ribavirin; Rituximab; Sofosbuvir; Viral Load

2017
Exploring the Case for Eminent Domain of Hepatitis C Virus Treatment Patents.
    Journal of health care for the poor and underserved, 2017, Volume: 28, Issue:2

    Topics: Antiviral Agents; Benzimidazoles; Budgets; Drug Combinations; Drug Costs; Drug Industry; Fluorenes; Hepatitis C; Humans; Patents as Topic; Public Health; Sofosbuvir; United States; Uridine Monophosphate

2017
Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study.
    Advances in medical sciences, 2017, Volume: 62, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Ribavirin; Safety; Sofosbuvir; Treatment Outcome

2017
Nucleotide Substrate Specificity of Anti-Hepatitis C Virus Nucleoside Analogs for Human Mitochondrial RNA Polymerase.
    Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:8

    Topics: Amides; Antiviral Agents; Catalytic Domain; DNA-Directed RNA Polymerases; Hepacivirus; Hepatitis C; Humans; Mitochondria; Nucleosides; Phosphoric Acids; Sofosbuvir; Structure-Activity Relationship; Substrate Specificity

2017
Belgian experience with direct acting antivirals in people who inject drugs.
    Drug and alcohol dependence, 2017, 08-01, Volume: 177

    Topics: Adult; Aged; Antiviral Agents; Belgium; Carbamates; Cohort Studies; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Simeprevir; Sofosbuvir; Substance Abuse, Intravenous; Valine

2017
Kidney transplant recipients with hepatitis C virus experienced 100% sustained virologic response at 12 weeks when treated with sofosbuvir-ledipasvir.
    Hepatology (Baltimore, Md.), 2017, Volume: 66, Issue:4

    Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C; Humans; Kidney Transplantation; Postoperative Complications; Randomized Controlled Trials as Topic; Sofosbuvir; Sustained Virologic Response; Time Factors; Uridine Monophosphate

2017
Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C.
    American family physician, 2017, May-15, Volume: 95, Issue:10

    Topics: Antiviral Agents; Carbamates; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir

2017
A not so easy genotype-striking regional differences in SOF/RBV treatment responses in HCV GT2.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:8

    Topics: Antiviral Agents; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir

2017
Chemical Analysis of Counterfeit Hepatitis C Drug Found in Japan.
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2017, 10-01, Volume: 137, Issue:10

    Topics: Antiviral Agents; Benzimidazoles; Chromatography, Liquid; Counterfeit Drugs; Drugs, Chinese Herbal; Ephedrine; Fluorenes; Gas Chromatography-Mass Spectrometry; Glycyrrhizic Acid; Hepatitis C; Japan; Magnetic Resonance Spectroscopy; Mass Spectrometry; Sofosbuvir; Tablets; Uridine Monophosphate; Vitamins

2017
Two Antiviral Drugs Approved For Adolescents With HCV.
    The American journal of nursing, 2017, Volume: 117, Issue:8

    Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Fluorenes; Hepacivirus; Hepatitis C; Humans; Infant, Newborn; Sofosbuvir; Uridine Monophosphate

2017
Daclatasvir-Sofosbuvir for treatment of hepatitis C virus in patients with inherited bleeding disorders.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2017, Volume: 36, Issue:4

    Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genetic Diseases, Inborn; Hemorrhage; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sofosbuvir; Treatment Outcome; Valine

2017
A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:1

    Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2018
Treatment of Patients With Hepatitis C Virus Infection With Ledipasvir-Sofosbuvir in the Liver Transplant Setting.
    Transplantation, 2017, Volume: 101, Issue:11

    Topics: Administration, Oral; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Ribavirin; Saudi Arabia; Sofosbuvir; Sustained Virologic Response; Tablets; Time Factors; Treatment Outcome; Uridine Monophosphate; Viral Load

2017
Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes.
    The International journal on drug policy, 2017, Volume: 47

    Topics: Adult; Antiviral Agents; Coinfection; Female; Genotype; Health Services; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Polyethylene Glycols; Program Development; Program Evaluation; Recombinant Proteins; Ribavirin; Risk Factors; Sex Factors; Sofosbuvir; Substance Abuse, Intravenous; Sustained Virologic Response; Treatment Outcome; Ukraine; Young Adult

2017
Effectiveness and Safety of Sofosbuvir in Treatment-NäiveChildren with Hepatitis C Infection.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2017, Volume: 27, Issue:7

    Topics: Antiviral Agents; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome

2017
Clearance of Hepatitis C Virus Prior to Lung Transplantation: A Case Report.
    Transplantation proceedings, 2017, Volume: 49, Issue:7

    Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepacivirus; Hepatitis C; Humans; Lung Transplantation; Male; Middle Aged; Preoperative Care; Sofosbuvir; Uridine Monophosphate

2017
Sofosbuvir-Based Regimens in HIV/HCV Coinfected Patients After Liver Transplantation: Results From the ANRS CO23 CUPILT Study.
    Transplantation, 2018, Volume: 102, Issue:1

    Topics: Antiviral Agents; Coinfection; Female; Hepatitis C; HIV Infections; Humans; Liver; Liver Transplantation; Male; Middle Aged; Sofosbuvir

2018
Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice.
    Archives of virology, 2018, Volume: 163, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir

2018
Let's Make a Deal: Shortening the Solid Organ Transplant Waiting Time in Exchange for Transmitting and Treating Hepatitis C Infection in the Era of Safe and Effective Directly Acting Antivirals.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 01-06, Volume: 66, Issue:2

    Topics: Antiviral Agents; Heart Transplantation; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Sofosbuvir; Waiting Lists

2018
Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation.
    Hepatology (Baltimore, Md.), 2018, Volume: 67, Issue:2

    Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Risk Assessment; Sofosbuvir; Sulfonamides; Sustained Virologic Response; United States; United States Food and Drug Administration; Viral Nonstructural Proteins

2018
Administration of crushed ledipasvir-sofosbuvir tablets via gastrostomy button in a patient coinfected with HIV and hepatitis C virus.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2017, 11-01, Volume: 74, Issue:21

    Topics: Anti-HIV Agents; Benzimidazoles; Female; Fluorenes; Gastrostomy; Hepatitis C; HIV Infections; Humans; Sofosbuvir; Tablets; Treatment Outcome; Uridine Monophosphate; Viral Load; Young Adult

2017
New Oral HCV Drug.
    The American journal of nursing, 2017, Volume: 117, Issue:11

    Topics: Administration, Oral; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Contraindications, Drug; Cyclopropanes; Drug Approval; Drug Combinations; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides

2017
Hepatitis C Treatment with Sofosbuvir and Ledipasvir Accompanied by Immediate Improvement in Hemoglobin A1c.
    Digestion, 2017, Volume: 96, Issue:4

    Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Glycated Hemoglobin; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Pilot Projects; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate

2017
Treatment of Acute Hepatitis C With Ledipasvir and Sofosbuvir in Patients With Hematological Malignancies Allows Early Re-start of Chemotherapy.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2018, Volume: 16, Issue:6

    Topics: Adult; Antineoplastic Agents; Antiviral Agents; Benzimidazoles; Drug Therapy; Female; Fluorenes; Hematologic Neoplasms; Hepatitis C; Humans; Male; Middle Aged; Sofosbuvir

2018
The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype.
    Transplant infectious disease : an official journal of the Transplantation Society, 2018, Volume: 20, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Calcineurin Inhibitors; Carbamates; Cell Line; Cyclosporine; Everolimus; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Liver Transplantation; Pyrrolidines; Sirolimus; Sofosbuvir; Valine; Virus Replication

2018
Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient.
    Transplant infectious disease : an official journal of the Transplantation Society, 2018, Volume: 20, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Tissue Donors; Transplant Recipients; Viral Load

2018
A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2018, Volume: 16, Issue:1

    Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Phenotype; Pyrrolidines; Recurrence; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Viral Load

2018
Sofosbuvir, pegylated interferon, and ribavirin for retreatment of hepatitis C virus genotype 1b following sofosbuvir and ledipasvir failure.
    Hepatology (Baltimore, Md.), 2018, Volume: 67, Issue:5

    Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; Sofosbuvir

2018
Real-world Outcomes of Hepatitis C Treatment during the Interferon-free Era at an Urban Safety-net Hospital.
    Journal of health care for the poor and underserved, 2017, Volume: 28, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Hospitals, Urban; Humans; Interferons; Male; Middle Aged; Retrospective Studies; RNA, Viral; Safety-net Providers; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult

2017
Sexual Dysfunction in a Patient Taking Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C: A Case Report.
    Journal of pharmacy practice, 2019, Volume: 32, Issue:2

    Topics: Adult; Antiviral Agents; Benzimidazoles; Drug-Related Side Effects and Adverse Reactions; Fluorenes; Hepatitis C; Humans; Male; Sexual Dysfunction, Physiological; Sofosbuvir; Uridine Monophosphate

2019
Sorafenib tosylate, Ribavirn and Sofosbuvir combination therapy for HCV virus infected patients with decompensated liver cancer.
    Pakistan journal of pharmaceutical sciences, 2017, Volume: 30, Issue:6(Suppleme

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Ribavirin; Sofosbuvir; Sorafenib; Sustained Virologic Response; Treatment Outcome

2017
Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.
    Clinical transplantation, 2018, Volume: 32, Issue:2

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Imidazoles; Italy; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prognosis; Prospective Studies; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Valine

2018
Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis.
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:4

    Topics: Acute Disease; Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Pyrrolidines; Renal Dialysis; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult

2018
A preliminary analysis of hepatitis C virus in pancreatic islet cells.
    Virology journal, 2017, 12-20, Volume: 14, Issue:1

    Topics: Antiviral Agents; Cells, Cultured; Cytokines; HEK293 Cells; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Interferon-alpha; Islets of Langerhans; MicroRNAs; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Sofosbuvir; Viral Nonstructural Proteins; Virion; Virus Internalization; Virus Replication

2017
UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2018, Jan-15, Volume: 1073

    Topics: Antiviral Agents; Carbamates; Chromatography, High Pressure Liquid; Coinfection; Hepatitis C; HIV Infections; Humans; Imidazoles; Limit of Detection; Linear Models; Pyrrolidines; Reproducibility of Results; Sofosbuvir; Tandem Mass Spectrometry; Valine

2018
Comparison between core-shell and totally porous particle stationary phases for fast and green LC determination of five hepatitis-C antiviral drugs.
    Journal of separation science, 2018, Volume: 41, Issue:8

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Chromatography, High Pressure Liquid; Fluorenes; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Imidazoles; Molecular Conformation; Particle Size; Porosity; Pyrrolidines; Simeprevir; Sofosbuvir; Surface Properties; Valine

2018
Sustained improvement of psoriasis associated with HCV after virologic response to sofosbuvir/ribavirin.
    Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2017, Volume: 18, Issue:4

    Topics: Adolescent; Antiviral Agents; Hepatitis C; Humans; Male; Psoriasis; Ribavirin; Sofosbuvir

2017
Interferon-free treatments in patients with hepatitis C genotype 3 infection in a tertiary hospital.
    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2018, Volume: 31, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Combinations; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Tertiary Care Centers; Uridine Monophosphate

2018
Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series.
    Melanoma research, 2018, Volume: 28, Issue:2

    Topics: Aged; Antibodies, Monoclonal, Humanized; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Fluorenes; Hepatitis B; Hepatitis C; Humans; Interferons; Lung Neoplasms; Male; Melanoma; Middle Aged; Nivolumab; Programmed Cell Death 1 Receptor; Skin Neoplasms; Sofosbuvir

2018
Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors.
    Hepatology (Baltimore, Md.), 2019, Volume: 69, Issue:5

    Topics: Amino Acid Substitution; Antiviral Agents; Carbamates; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Valine; Viral Nonstructural Proteins

2019
Nonstructural protein 5A/P32 deletion after failure of ledipasvir/sofosbuvir in hepatitis C virus genotype 1b infection.
    Hepatology (Baltimore, Md.), 2018, Volume: 68, Issue:1

    Topics: Aged; Antiviral Agents; Benzimidazoles; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Sequence Deletion; Sofosbuvir; Treatment Failure; Viral Nonstructural Proteins

2018
A case of a patient infected with a hepatitis C virus genotype 3a multidrug resistant variant in Pakistan.
    Infectious diseases of poverty, 2018, Feb-11, Volume: 7, Issue:1

    Topics: Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Pakistan; Phylogeny; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load

2018
Preliminary experience with sofosbuvir-based treatment regimens for patients dependent on hemodialysis.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2018, Volume: 37, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Fluorenes; Hepatitis C; Humans; Kidney Failure, Chronic; Renal Dialysis; Sofosbuvir

2018
Editorial: sofosbuvir plus daclatasvir for the treatment of hepatitis C-can one size fit all?
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:6

    Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine

2018
Editorial: are additional tests needed to predict sustained virologic response in hepatitis C treated with interferon-free direct-acting antiviral combinations?
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:6

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Kinetics; Sofosbuvir; Sustained Virologic Response; Treatment Failure

2018
The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data.
    European journal of gastroenterology & hepatology, 2018, Volume: 30, Issue:7

    Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate; Virus Activation

2018
High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection.
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:9

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Resistance, Viral; Drug Substitution; Drug Therapy, Combination; Female; Genotype; Germany; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Viral Nonstructural Proteins; Young Adult

2018
Drug executives should take a Hippocratic oath.
    Nature, 2018, 03-29, Volume: 555, Issue:7698

    Topics: Consumer Behavior; Drug Industry; Hepatitis C; Hippocratic Oath; Humans; Patents as Topic; Patient Satisfaction; Sofosbuvir; Trust; Workforce

2018
Impact of Sofosbuvir-Based Regimens for the Treatment of Hepatitis C After Liver Transplant on Renal Function: Results of a Canadian National Retrospective Study.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2019, Volume: 17, Issue:1

    Topics: Aged; Antiviral Agents; Canada; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis C; Humans; Kidney; Kidney Diseases; Liver Transplantation; Male; Middle Aged; Recovery of Function; Recurrence; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome

2019
Direct-acting antivirals response in an acute nosocomial genotype 1b HCV outbreak.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2018, Volume: 50, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Cross Infection; Disease Outbreaks; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors

2018
A case report of sofosbuvir and daclatasvirto treat a patient with acute hepatitis C virus genotype 2 monoinfection.
    Medicine, 2018, Volume: 97, Issue:15

    Topics: Acute Disease; Adult; Carbamates; China; Drug Therapy, Combination; Early Diagnosis; Early Medical Intervention; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Pyrrolidines; Sofosbuvir; Tattooing; Valine

2018
Hepatitis C Virus Eradication in Kidney Transplant Recipients: A Single-Center Experience in Portugal.
    Transplantation proceedings, 2018, Volume: 50, Issue:3

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Immunosuppression Therapy; Kidney Transplantation; Male; Middle Aged; Portugal; Postoperative Complications; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response

2018
Daclatasvir and Sofosbuvir With or Without Ribavirin in Liver Transplant Recipients: A Single-Center Real-World Study.
    Transplantation proceedings, 2018, Volume: 50, Issue:3

    Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2018
Economic evaluation of Zepatier for the management of HCV in the Italian scenario.
    The European journal of health economics : HEPAC : health economics in prevention and care, 2018, Volume: 19, Issue:9

    Topics: Antiviral Agents; Benzofurans; Cost of Illness; Cost-Benefit Analysis; Drug Combinations; Hepacivirus; Hepatitis C; Humans; Imidazoles; Interferons; Italy; Markov Chains; Quality-Adjusted Life Years; Quinoxalines; Ribavirin; Sofosbuvir

2018
Take a Bow, Pharma, for the Hepatitis C Drugs.
    Managed care (Langhorne, Pa.), 2018, Volume: 27, Issue:4

    Topics: Antiviral Agents; Benzimidazoles; Drug Industry; Fluorenes; Hepatitis C; Humans; Sofosbuvir; United States; Uridine Monophosphate

2018
Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact.
    European journal of gastroenterology & hepatology, 2018, Volume: 30, Issue:8

    Topics: Aged; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Egypt; Female; Hepatitis C; Humans; Imidazoles; Incidence; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Pyrrolidines; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine

2018
Case report: Identification of recombinant HCV genotype 1b-2b by viral sequencing in two patients with treatment failure, who responded to re-treatment with sofosbuvir and daclatasvir.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2018, Volume: 24, Issue:11

    Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotyping Techniques; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retreatment; RNA, Viral; Sequence Analysis, RNA; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Valine; Viral Nonstructural Proteins

2018
Direct-Acting Antiviral Therapy for Hepatitis C Infection in a Large Immigrant Community.
    Journal of immigrant and minority health, 2019, Volume: 21, Issue:3

    Topics: Africa, Eastern; Age Factors; Aged; Antiviral Agents; Benzimidazoles; Emigrants and Immigrants; Ethnicity; Female; Fluorenes; Genotype; Hepatitis C; Humans; Male; Middle Aged; Middle East; Retrospective Studies; Severity of Illness Index; Sex Factors; Socioeconomic Factors; Sofosbuvir; Sustained Virologic Response; Treatment Failure; United States; Uridine Monophosphate

2019
Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.
    Journal of gastroenterology and hepatology, 2018, Volume: 33, Issue:12

    Topics: Adult; Antiviral Agents; Carbamates; Computer Simulation; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Drugs, Generic; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; India; Male; Models, Economic; Quality of Life; Quality-Adjusted Life Years; Sofosbuvir; Time Factors; Treatment Outcome

2018
Simultaneous quantitation of two direct acting hepatitis C antivirals (sofosbuvir and daclatasvir) by an HPLC-UV method designated for their pharmacokinetic study in rabbits.
    Journal of pharmaceutical and biomedical analysis, 2018, Sep-05, Volume: 158

    Topics: Animals; Antiviral Agents; Biological Availability; Carbamates; Chromatography, High Pressure Liquid; Drug Combinations; Hepacivirus; Hepatitis C; Imidazoles; Lactones; Limit of Detection; Liquid-Liquid Extraction; Male; Models, Animal; Pyrrolidines; Rabbits; Reproducibility of Results; Sensitivity and Specificity; Sofosbuvir; Spectrophotometry, Ultraviolet; Sulfones; Ultrasonic Waves; Valine

2018
Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.
    PloS one, 2018, Volume: 13, Issue:6

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Germany; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Ribavirin; Ritonavir; Sofosbuvir; Treatment Outcome

2018
Editorial: genotype 3 HCV-who still needs ribavirin in a pan-genotypic era?
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:11

    Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir

2018
Editorial: genotype 3 HCV-who still needs ribavirin in a pan-genotypic era? Authors' reply.
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:11

    Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir

2018
GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo.
    Acta pharmacologica Sinica, 2018, Volume: 39, Issue:11

    Topics: Animals; Antiviral Agents; Carbamates; Cell Line, Tumor; Dogs; Drug Combinations; Drug Stability; Drug Synergism; Hepacivirus; Hepatitis C; Humans; Imidazoles; Macrocyclic Compounds; Male; Microsomes, Liver; Mutation; Pyrrolidines; Rats, Sprague-Dawley; Serine Proteases; Serine Proteinase Inhibitors; Sofosbuvir; Valine; Viral Nonstructural Proteins

2018
Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study.
    Medicine, 2018, Volume: 97, Issue:27

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2018
The "real-world" efficacy and safety of DAAs for the treatment of HCV patients throughout Japan.
    Journal of gastroenterology, 2018, Volume: 53, Issue:10

    Topics: Benzimidazoles; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Japan; Red Cross; Sofosbuvir

2018
Ledipasvir/Sofosbuvir Effectively Treats Hepatitis C Virus Infections in an Underserved Population.
    Digestive diseases and sciences, 2018, Volume: 63, Issue:12

    Topics: Antiviral Agents; Benzimidazoles; Drug Monitoring; Female; Fluorenes; Genes, Viral; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Patient Compliance; Prevalence; Sofosbuvir; Uridine Monophosphate; Vulnerable Populations

2018
Successful Treatment With Ledipasvir/Sofosbuvir in an Infant With Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency With HCV Allowed Gene Therapy with Strimvelis.
    Hepatology (Baltimore, Md.), 2018, Volume: 68, Issue:6

    Topics: Adenosine Deaminase; Agammaglobulinemia; Antiviral Agents; Benzimidazoles; Fluorenes; Genetic Therapy; Hepatitis C; Humans; Infant; Male; Severe Combined Immunodeficiency; Sofosbuvir; Uridine Monophosphate

2018
Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:11

    Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Germany; Hepacivirus; Hepatitis C; Humans; Male; Registries; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Load

2018
Remission of chronic inflammatory demyelinating polyneuropathy after hepatitis C virus eradication with sofosbuvir and ledipasvir therapy.
    Muscle & nerve, 2018, Volume: 58, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepacivirus; Hepatitis C; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Male; Middle Aged; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Recurrence; Sofosbuvir

2018
Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation.
    Transplant infectious disease : an official journal of the Transplantation Society, 2018, Volume: 20, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Interactions; Female; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Male; Middle Aged; Organ Transplantation; Retrospective Studies; Simeprevir; Sofosbuvir; Sustained Virologic Response; Young Adult

2018
Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia Major.
    Indian journal of pediatrics, 2019, Volume: 86, Issue:2

    Topics: Adolescent; Antiviral Agents; Benzimidazoles; beta-Thalassemia; Carbamates; Child; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load

2019
Potential Overestimation of Racial Disparities in Response to the 8-Week Ledipasvir/Sofosbuvir Regimen for Hepatitis C Virus Genotype 1 Infection.
    Gastroenterology, 2018, Volume: 155, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Health Status Disparities; Hepacivirus; Hepatitis C; Humans; Sofosbuvir

2018
Lack of Patient Compliance in Real-World Practice Negatively Affects Sustained Viral Response Rates to Direct Acting Agent Therapy for Hepatitis C.
    Digestive diseases and sciences, 2018, Volume: 63, Issue:12

    Topics: Antiviral Agents; Benzimidazoles; Drug Monitoring; Female; Fluorenes; Genes, Viral; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Patient Compliance; Patient Dropouts; Patient Education as Topic; Patient Medication Knowledge; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; United States; Uridine Monophosphate

2018
Study on fluorescence properties of HCV antiviral (velpatasvir) and its fluorimetric determination in presence of sofosbuvir; application to stability study and human plasma.
    Luminescence : the journal of biological and chemical luminescence, 2018, Volume: 33, Issue:7

    Topics: Antiviral Agents; Carbamates; Drug Stability; Fluorescence; Fluorometry; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Limit of Detection; Sofosbuvir

2018
Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.
    Annals of hepatology, 2018, Aug-24, Volume: 17, Issue:5

    Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; United States; Uridine Monophosphate; Viral Load

2018
Effectiveness of 8 weeks of ledipasvir/sofosbuvir for hepatitis C in HCV-HIV-coinfected patients.
    Antiviral therapy, 2019, Volume: 24, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Uridine Monophosphate

2019
Does Ribavirin Still Have a Role in Sofosbuvir and Velpatasvir Therapy for Patients With HCV Genotype 3 Infection and Cirrhosis?
    Gastroenterology, 2018, Volume: 155, Issue:4

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome

2018
Regulation of human placental drug transporters in HCV infection and their influence on direct acting antiviral medications.
    Placenta, 2018, Volume: 69

    Topics: Antiviral Agents; ATP-Binding Cassette Transporters; Biological Transport; Female; Guanine; Hepatitis C; Humans; Placenta; Pregnancy; Sofosbuvir; Solute Carrier Proteins; Tenofovir; Trophoblasts

2018
No clinical impact of HCV RNA determination at the end of treatment in patients receiving directly acting antivirals.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:12

    Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C; Humans; RNA; Sofosbuvir

2018
Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection.
    Hepatology international, 2018, Volume: 12, Issue:6

    Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Sofosbuvir; Sustained Virologic Response; Time Factors; Tomography, X-Ray Computed; Ultrasonography

2018
Eradication of HCV in Renal Transplant Recipients and Its Effects on Quality of Life.
    BioMed research international, 2018, Volume: 2018

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Italy; Kidney Transplantation; Male; Middle Aged; Quality of Life; Ribavirin; Sofosbuvir; Treatment Outcome

2018
Eight-Week Hepatitis C Treatment with New Direct Acting Antivirals Has a Better Safety Profile While Being Effective in the Treatment-Naïve Geriatric Population Without Liver Cirrhosis and Hepatitis C Virus-RNA < 6 Million IU/mL.
    Digestive diseases and sciences, 2018, Volume: 63, Issue:12

    Topics: Age Factors; Aged; Antiviral Agents; Benzimidazoles; California; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Viral Load

2018
Evidence of HCV recovery after therapy of hepatitis C virus infection by direct acting antivirals.
    Clinics and research in hepatology and gastroenterology, 2019, Volume: 43, Issue:2

    Topics: Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Kidney; Living Donors; Male; Middle Aged; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load

2019
Hand-foot syndrome due to hepatitis C therapy.
    Revista da Associacao Medica Brasileira (1992), 2018, Volume: 64, Issue:5

    Topics: Antiviral Agents; Hand-Foot Syndrome; Hepatitis C; Humans; Interferons; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir

2018
Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients.
    BMC infectious diseases, 2018, Oct-16, Volume: 18, Issue:1

    Topics: Aged; Cardiotoxicity; Chronic Disease; Drug Therapy, Combination; Echocardiography; Female; Heart Function Tests; Hepatitis C; Humans; Longitudinal Studies; Male; Middle Aged; Sofosbuvir; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left

2018
Using telehealth to improve access to hepatitis C treatment in the direct-acting antiviral therapy era.
    Journal of telemedicine and telecare, 2020, Volume: 26, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Australia; Benzimidazoles; Carbamates; Delivery of Health Care; Female; Fluorenes; Health Services Accessibility; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sofosbuvir; Telemedicine; Treatment Outcome; Valine

2020
Predictive value of IL-28B rs12979860 variants for peg-IFN, sofosbuvir plus ribavirin treatment of HCV infection in Pakistani population.
    Personalized medicine, 2018, Volume: 15, Issue:6

    Topics: Adult; Antiviral Agents; Biomarkers, Pharmacological; Cross-Sectional Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Pakistan; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2018
Gilead injects own generics into shrinking HCV drug market.
    Nature biotechnology, 2018, 11-09, Volume: 36, Issue:11

    Topics: Antiviral Agents; Benzimidazoles; Biotechnology; Drug Costs; Drug Industry; Drugs, Generic; Fluorenes; Hepatitis C; Humans; Sofosbuvir; United States; Uridine Monophosphate

2018
Reply to: "Sofosbuvir/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: Response to EASL recommendations on treatment of Hepatitis C 2018": EASL Recommendations on Treatment of Hepatitis C 2018: Precision on the tr
    Journal of hepatology, 2019, Volume: 70, Issue:3

    Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Sofosbuvir

2019
Sofosbuvir/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018.
    Journal of hepatology, 2019, Volume: 70, Issue:3

    Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Sofosbuvir

2019
Successful direct-acting antiviral treatment of three patients with genotype 2/1 recombinant hepatitis C virus.
    Clinical journal of gastroenterology, 2019, Volume: 12, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; RNA; Sofosbuvir; Sulfonamides; Valine

2019
[Treatment of Hepatitis C: State of the Art 2018].
    Deutsche medizinische Wochenschrift (1946), 2018, Volume: 143, Issue:24

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response

2018
Effective drugs on the road to HCV elimination and a therapeutic gap to close.
    The lancet. Gastroenterology & hepatology, 2019, Volume: 4, Issue:2

    Topics: Asia; Carbamates; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir

2019
Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia - a case report.
    BMC infectious diseases, 2018, Dec-19, Volume: 18, Issue:1

    Topics: Acute Disease; Antiviral Agents; Benzimidazoles; Early Medical Intervention; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Severity of Illness Index; Sofosbuvir; Time Factors; Uridine Monophosphate

2018
Sofosbuvir and Daclatsvir in Treatment of Hepatitis C Virus-related Membranoproliferative Glomerulonephritis With Cryoglobulinemia in a Patient With Hepatitis C Genotype 4.
    Iranian journal of kidney diseases, 2018, Volume: 12, Issue:6

    Topics: Antiviral Agents; Carbamates; Cryoglobulinemia; Drug Therapy, Combination; Female; Glomerulonephritis, Membranoproliferative; Hepacivirus; Hepatitis C; Humans; Imidazoles; Middle Aged; Pyrrolidines; Sofosbuvir; Treatment Outcome; Valine

2018
Long-awaited treatment for hepatitis C virus decompensated cirrhosis.
    Journal of gastroenterology, 2019, Volume: 54, Issue:3

    Topics: Carbamates; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Japan; Liver Cirrhosis; Ribavirin; Sofosbuvir

2019
Hepatitis C Virus: No Longer a Barrier to Oncology Care.
    The American journal of gastroenterology, 2019, Volume: 114, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Neoplasms; Prospective Studies; Sofosbuvir; Sustained Virologic Response

2019
Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice.
    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2019, Volume: 32, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2019
Brazil's Fight against Hepatitis C - Universalism, Local Production, and Patents.
    The New England journal of medicine, 2019, Feb-14, Volume: 380, Issue:7

    Topics: Antiviral Agents; Brazil; Disease Eradication; Drug Costs; Drug Industry; Drugs, Generic; Government Agencies; Hepatitis C; Humans; Legislation, Drug; Patents as Topic; Public Health Practice; Sofosbuvir

2019
Virological Response to Sofosbuvir-Based Treatment in Renal Transplant Recipients With Hepatitis C in Pakistan.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2019, Volume: 17, Issue:Suppl 1

    Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Kidney Transplantation; Male; Middle Aged; Pakistan; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Viral Load

2019
Impact of Sofosbuvir-Based Therapy on Liver Transplant Candidates with Hepatitis C Virus Infection.
    Pharmacotherapy, 2019, Volume: 39, Issue:4

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepatitis C; Humans; Liver Cirrhosis; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Proportional Hazards Models; Sofosbuvir; Transplant Recipients; Waiting Lists; Young Adult

2019
Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection.
    Clinical and molecular hepatology, 2019, Volume: 25, Issue:1

    Topics: Aged; Anemia, Hemolytic; Carnitine; Drug Therapy, Combination; Female; Hepatitis C; Humans; Male; Middle Aged; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Treatment Outcome

2019
Impact of direct-acting antivirals for hepatitis C virus therapy on tacrolimus dosing in liver transplant recipients.
    Transplant infectious disease : an official journal of the Transplantation Society, 2019, Volume: 21, Issue:3

    Topics: Aged; Antiviral Agents; Disease Management; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Tacrolimus

2019
Effectiveness and safety of sofosbuvir-based direct-acting antiviral combinations in HCV-2 and HCV-3 kidney transplant recipients.
    Kidney international, 2019, Volume: 95, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Kidney Transplantation; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Transplant Recipients; Treatment Outcome

2019
Hepatitis C Virus Genotype 8 Infection-Successful Treatment With Sofosbuvir/Velpatasvir.
    The Journal of infectious diseases, 2019, 07-19, Volume: 220, Issue:4

    Topics: Adult; Antiviral Agents; Carbamates; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir; Treatment Outcome

2019
Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients.
    BMC infectious diseases, 2019, May-03, Volume: 19, Issue:1

    Topics: Adult; Aged; Aminoisobutyric Acids; Anti-Retroviral Agents; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Cyclopropanes; Drug Interactions; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Outcome; Viral Load

2019
Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4.
    Cells, 2019, 05-05, Volume: 8, Issue:5

    Topics: Adolescent; Benzimidazoles; Child; Drug Resistance, Viral; Female; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Phylogeny; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins

2019
Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015.
    Zeitschrift fur Gastroenterologie, 2019, Volume: 57, Issue:5

    Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Prospective Studies; Registries; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2019
SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.
    PloS one, 2019, Volume: 14, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carbamates; Drug Interactions; Female; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Safety; Sofosbuvir; Treatment Outcome; Young Adult

2019
Sofosbuvir induced leucocytoclasic vasculitis: a case report.
    BMC dermatology, 2019, 05-17, Volume: 19, Issue:1

    Topics: Antiviral Agents; Drug Eruptions; Hepatitis C; Humans; Male; Middle Aged; Skin; Sofosbuvir; Vasculitis, Leukocytoclastic, Cutaneous

2019
High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting.
    Virology journal, 2019, 06-03, Volume: 16, Issue:1

    Topics: Adult; Antiviral Agents; Asian People; China; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response

2019
Effectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C.
    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2019, Volume: 32, Issue:4

    Topics: Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Recurrence; Regression Analysis; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Failure

2019
Drug-Drug Interactions in Children and Adolescents Receiving Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Virus Infection.
    Clinical drug investigation, 2019, Volume: 39, Issue:9

    Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Drug Interactions; Female; Fluorenes; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Risk Assessment; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2019
Ledipasvir and Sofosbuvir for Acute Hepatitis C Virus Monoinfection Associated with a High Risk of Acute Liver Failure.
    Internal medicine (Tokyo, Japan), 2019, Oct-15, Volume: 58, Issue:20

    Topics: Acute Disease; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; Humans; Liver Failure, Acute; Male; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate

2019
Follow-up Results of
    Anticancer research, 2019, Volume: 39, Issue:7

    Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome

2019
Successful treatment with sofosbuvir and daclatasvir plus ribavirin in acute hepatitis C-infected patient with hepatic decompensation.
    Journal of the Chinese Medical Association : JCMA, 2019, Volume: 82, Issue:7

    Topics: Acute Disease; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Liver Failure; Male; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Valine

2019
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
    Journal of hepatology, 2019, Volume: 71, Issue:5

    Topics: Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Lactams, Macrocyclic; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Retreatment; Ribavirin; Ritonavir; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Valine; Viral Nonstructural Proteins

2019
Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients.
    Transplant infectious disease : an official journal of the Transplantation Society, 2019, Volume: 21, Issue:5

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C; Humans; Kidney; Kidney Transplantation; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Tissue Donors; Transplant Recipients; Viral Load; Viremia

2019
Hepatotoxicity and virological breakthrough of HCV following treatment with sofosbuvir, daclatasvir, and ribavirin in patients previously treated for tuberculosis.
    Journal of medical virology, 2019, Volume: 91, Issue:12

    Topics: Aged; Antitubercular Agents; Antiviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Pyrrolidines; Ribavirin; Sofosbuvir; Tuberculosis; Valine

2019
Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection.
    Medicine, 2019, Volume: 98, Issue:30

    Topics: Adult; Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Hemophilia A; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Imidazoles; Interferons; Isoquinolines; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine

2019
Low-density lipoprotein receptor-deficient hepatocytes differentiated from induced pluripotent stem cells allow familial hypercholesterolemia modeling, CRISPR/Cas-mediated genetic correction, and productive hepatitis C virus infection.
    Stem cell research & therapy, 2019, 07-29, Volume: 10, Issue:1

    Topics: Antiviral Agents; Apolipoprotein A-II; Cell Differentiation; Cholesterol; CRISPR-Cas Systems; Gene Editing; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Hyperlipoproteinemia Type II; Induced Pluripotent Stem Cells; Phenotype; Plasmids; Promoter Regions, Genetic; Proprotein Convertase 9; Receptors, LDL; Sofosbuvir; Sterol Regulatory Element Binding Protein 2

2019
Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort.
    European journal of clinical pharmacology, 2019, Volume: 75, Issue:11

    Topics: Aged; Anemia; Antiviral Agents; Carbamates; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Imidazoles; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Tacrolimus; Valine

2019
Recurrent hepatitis C treatment with direct acting antivirals - a real life study at a Brazilian liver transplant center.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2019, Volume: 52, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load

2019
Targeted drugs to tackle hepatitis C.
    Nature, 2013, May-02, Volume: 497, Issue:7447

    Topics: Age Factors; Carrier State; Clinical Trials, Phase III as Topic; Drug Approval; Hepacivirus; Hepatitis C; Humans; Male; Mass Screening; Middle Aged; Molecular Targeted Therapy; Risk Assessment; Sofosbuvir; Uridine Monophosphate

2013
Trials wrap on interferon-free hepatitis C regimen.
    Managed care (Langhorne, Pa.), 2013, Volume: 22, Issue:4

    Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Hepatitis C; Humans; Interferons; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2013
All-oral HCV therapies near approval.
    Nature reviews. Drug discovery, 2013, Volume: 12, Issue:6

    Topics: Administration, Oral; Animals; Drug Approval; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate; Viral Hepatitis Vaccines

2013
Pharmaceuticals. Advocates protest the cost of a hepatitis C cure.
    Science (New York, N.Y.), 2013, Dec-13, Volume: 342, Issue:6164

    Topics: Antiviral Agents; Consumer Advocacy; Cost of Illness; Drug Approval; Drugs, Generic; Hepacivirus; Hepatitis C; Humans; Prevalence; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate

2013
Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Volume: 58, Issue:7

    Topics: Aminoisobutyric Acids; Anti-HIV Agents; Antiviral Agents; Carbamates; Developing Countries; Drug Industry; Drug Therapy, Combination; Health Services Accessibility; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Leucine; Oligopeptides; Proline; Pyrrolidines; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate; Valine

2014
FDA approvals usher in the post-interferon era in HCV.
    Nature biotechnology, 2014, Volume: 32, Issue:1

    Topics: Drug Approval; Drug Industry; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Simeprevir; Sofosbuvir; Sulfonamides; United States; United States Food and Drug Administration; Uridine Monophosphate

2014
Screening urged for hepatitis C but drug costs are prohibitive.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2014, Mar-18, Volume: 186, Issue:5

    Topics: Antiviral Agents; Canada; Drug Costs; Hepatitis C; Humans; Mass Screening; Sofosbuvir; Uridine Monophosphate

2014
Hepatitis C treatment & management.
    Journal of medicine and life, 2014, Mar-15, Volume: 7, Issue:1

    Topics: Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Recurrence; Ribavirin; Sofosbuvir; Time Factors; Uridine Monophosphate

2014
Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens.
    Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:6

    Topics: Adult; Antiviral Agents; Chronic Disease; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2014
Hepatitis C could be virtually eliminated by 2030, experts believe.
    BMJ (Clinical research ed.), 2014, Apr-10, Volume: 348

    Topics: Antiviral Agents; Disease Eradication; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate

2014
Hepatitis C drugs not reaching poor.
    Nature, 2014, Apr-17, Volume: 508, Issue:7496

    Topics: Anti-HIV Agents; Antiviral Agents; Developing Countries; Drug Costs; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate

2014
Hepatitis C: Treatment triumphs.
    Nature, 2014, Jun-05, Volume: 510, Issue:7503

    Topics: Administration, Oral; Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Interferon Type I; Ribavirin; Sofosbuvir; Uridine Monophosphate

2014
Sovaldi makes blockbuster history, ignites drug pricing unrest.
    Nature biotechnology, 2014, Volume: 32, Issue:6

    Topics: Drug Industry; Health Care Costs; Hepatitis C; Income; Sofosbuvir; United States; Uridine Monophosphate

2014
WHO issues guidelines on HCV amid drug cost controversy.
    JAMA, 2014, Jun-11, Volume: 311, Issue:22

    Topics: Antiviral Agents; Drug Costs; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Practice Guidelines as Topic; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; World Health Organization

2014
Elimination on the agenda for hepatitis C.
    The Lancet. Infectious diseases, 2014, Volume: 14, Issue:6

    Topics: Antiviral Agents; Disease Eradication; Global Health; Hepatitis C; Humans; Injections; Interferons; Ribavirin; Sofosbuvir; Substance Abuse, Intravenous; Uridine Monophosphate

2014
Sofosbuvir for the treatment of hepatitis C virus infection.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2015, Feb-17, Volume: 187, Issue:3

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate

2015
Medicine. Hepatitis C can be cured globally, but at what cost?
    Science (New York, N.Y.), 2014, Jul-11, Volume: 345, Issue:6193

    Topics: Antiviral Agents; Developing Countries; Drug Costs; Drugs, Generic; Global Health; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate

2014
Payers consider waiting out budget-busting hepatitis C drug.
    Managed care (Langhorne, Pa.), 2014, Volume: 23, Issue:5

    Topics: Antiviral Agents; Hepatitis C; Humans; Managed Care Programs; Medicaid; Politics; Product Surveillance, Postmarketing; Sofosbuvir; United States; Uridine Monophosphate

2014
Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication?
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:1

    Topics: Administration, Oral; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2015
Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin.
    Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Female; Genome, Viral; Genotyping Techniques; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Phylogeny; Recombination, Genetic; Ribavirin; Sequence Analysis, RNA; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins

2015
US health insurers say Gilead hepatitis C drug too costly.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Jul-15, Volume: 59, Issue:2

    Topics: Antiviral Agents; Health Care Costs; Hepatitis C; Humans; Insurance Carriers; Sofosbuvir; United States; Uridine Monophosphate

2014
Successful treatment with sofosbuvir of fibrosing cholestatic hepatitis C after liver transplantation in an HIV-HCV-coinfected patient.
    Antiviral therapy, 2015, Volume: 20, Issue:3

    Topics: Adult; Antiviral Agents; Coinfection; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Liver Transplantation; Male; Sofosbuvir; Treatment Outcome

2015
Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir.
    Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:1

    Topics: Amino Acid Substitution; Clinical Trials, Phase III as Topic; Computational Biology; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Sequence Analysis, RNA; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate; Viral Nonstructural Proteins

2015
Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation.
    Transplant international : official journal of the European Society for Organ Transplantation, 2015, Volume: 28, Issue:2

    Topics: Aged; Antiviral Agents; Drug Combinations; Hepatitis C; Humans; Interferon-alpha; Kidney Transplantation; Liver Transplantation; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Sofosbuvir; Uridine Monophosphate

2015
Sofosbuvir and ribavirin use in wait-listed patients with hepatitis C should be selective.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:1

    Topics: Administration, Oral; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Waiting Lists

2015
The solid-gold wonder drug. A long, difficult and costly research effort gives doctors a new cure for hepatitis C.
    Scientific American, 2014, Volume: 311, Issue:3

    Topics: Drug Combinations; Drug Costs; Hepatitis C; Humans; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate

2014
Guideline: New HCV drugs should go to sickest patients.
    JAMA, 2014, Sep-17, Volume: 312, Issue:11

    Topics: Antiviral Agents; Drug Costs; Hepatitis C; Humans; Patient Selection; Practice Guidelines as Topic; Societies, Medical; Sofosbuvir; United States; Uridine Monophosphate

2014
A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients.
    BMC infectious diseases, 2014, Volume: 14 Suppl 6

    Topics: Antiviral Agents; Healthcare Disparities; Hepatitis C; Humans; Sofosbuvir; Substance Abuse, Intravenous; Uridine Monophosphate

2014
Mutant Ninja viruses.
    Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:2

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Male; Ribavirin; Sofosbuvir; Uridine Monophosphate

2015
Editorial: patients' preferences and health utility assessment in those with HCV treated with sofosbuvir - stating the obvious?
    Alimentary pharmacology & therapeutics, 2014, Volume: 40, Issue:9

    Topics: Antiviral Agents; Hepatitis C; Humans; Patient Acceptance of Health Care; Patient Preference; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2014
Sovaldi dilemma likely to get worse.
    Managed care (Langhorne, Pa.), 2014, Volume: 23, Issue:9

    Topics: Antiviral Agents; Benzimidazoles; Drug Combinations; Fluorenes; Hepatitis C; Humans; Prescription Fees; Sofosbuvir; United States; Uridine Monophosphate

2014
The uses and abuses of cost-effectiveness analysis.
    Modern healthcare, 2014, Aug-11, Volume: 44, Issue:32

    Topics: Cost Savings; Cost-Benefit Analysis; Drug Costs; Hepatitis C; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Sofosbuvir; Uridine Monophosphate

2014
New nucleotide polymerase inhibitors to rapidly permit hematopoietic stem cell donation from a positive HCV-RNA donor.
    Blood, 2014, Oct-16, Volume: 124, Issue:16

    Topics: Adult; Female; Hematopoietic Stem Cell Transplantation; Hepacivirus; Hepatitis C; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; RNA, Viral; Siblings; Sofosbuvir; Tissue Donors; Uridine Monophosphate

2014
Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2015, Volume: 21, Issue:2

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate

2015
Treatment of HCV prior to liver transplantation to prevent HCV recurrence - wise or wasteful?
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:1

    Topics: Administration, Oral; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Recurrence; Ribavirin; Sofosbuvir; Uridine Monophosphate

2015
Sofosbuvir treatment in the pre and post liver transplantation phase: the sooner, the better.
    Gastroenterology, 2015, Volume: 148, Issue:1

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Ribavirin; Sofosbuvir; Uridine Monophosphate

2015
Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
    Global public health, 2015, Volume: 10, Issue:3

    Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Trees; Disease Progression; Drug Therapy, Combination; Egypt; Enzyme-Linked Immunosorbent Assay; Hepatitis C; Humans; Incidence; Interferons; Markov Chains; Mass Screening; Models, Economic; Polymerase Chain Reaction; Prevalence; Quality of Life; Ribavirin; Sofosbuvir; Uridine Monophosphate

2015
Perspective: incision revision.
    Nature, 2014, Dec-04, Volume: 516, Issue:7529

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Sofosbuvir; Uridine Monophosphate

2014
What is the role of sofosbuvir in treating hepatitis C infection?
    JAAPA : official journal of the American Academy of Physician Assistants, 2015, Volume: 28, Issue:2

    Topics: Antiviral Agents; Contraindications; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Ribavirin; Sofosbuvir

2015
Haemophilia-related outcome after liver transplantation and treatment with sofosbuvir/ribavirin in a HCV-HIV coinfected man with liver failure and hepatocellular carcinoma.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2015, Volume: 21, Issue:2

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, Hepatocellular; Coinfection; Hemophilia A; Hepatitis C; HIV Infections; Humans; Liver Failure; Liver Transplantation; Male; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2015
Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant.
    Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:6

    Topics: Aged; Antiviral Agents; Female; Genotype; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Immunosuppression Therapy; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate

2015
A novel method for the measurement of hepatitis C virus infectious titres using the IncuCyte ZOOM and its application to antiviral screening.
    Journal of virological methods, 2015, Jun-15, Volume: 218

    Topics: Antiviral Agents; Carbamates; Cell Line, Tumor; Fluorescent Antibody Technique; Genome, Viral; Hepacivirus; Hepatitis C; Humans; Imidazoles; Microbial Sensitivity Tests; Pyrrolidines; RNA, Viral; Sofosbuvir; Valine; Viral Load; Virus Replication

2015
HIV-hepatitis C co-infection.
    The Lancet. Infectious diseases, 2015, Volume: 15, Issue:4

    Topics: Antiviral Agents; Carbamates; Coinfection; Hepatitis C; HIV Infections; Humans; Imidazoles; Pyrrolidines; Randomized Controlled Trials as Topic; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Valine

2015
[Joint opinion of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Daclatasvir-benefit assessment according to § 35a SGB V the G-BA].
    Zeitschrift fur Gastroenterologie, 2015, Volume: 53, Issue:2

    Topics: Anti-HIV Agents; Carbamates; Drug Combinations; Gastroenterology; Germany; Hepatitis C; Imidazoles; Internal Medicine; Pyrrolidines; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Valine

2015
Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2015, Volume: 21, Issue:6

    Topics: Aged; Allografts; Antiviral Agents; Drug Therapy, Combination; Female; Fibrosis; Genotype; Hepacivirus; Hepatitis C; Humans; Liver; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recurrence; Retrospective Studies; Simeprevir; Sofosbuvir

2015
Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment.
    Blood, 2015, Apr-09, Volume: 125, Issue:15

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Ribavirin; Sofosbuvir; Uridine Monophosphate

2015
King of the pills.
    Science (New York, N.Y.), 2015, May-08, Volume: 348, Issue:6235

    Topics: Anti-HIV Agents; Chemistry, Organic; Drug Discovery; Hepatitis C; History, 20th Century; History, 21st Century; Sofosbuvir; Uridine Monophosphate

2015
Dare to refuse the exorbitant price of Sovaldi!
    Prescrire international, 2014, Volume: 23, Issue:154

    Topics: Antiviral Agents; Drug Costs; Drug Industry; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate

2014
Photo-distributed lichenoid eruption secondary to direct anti-viral therapy for hepatitis C.
    Journal of cutaneous pathology, 2015, Volume: 42, Issue:10

    Topics: Antiviral Agents; Biopsy; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C; Humans; Incidence; Lichenoid Eruptions; Male; Middle Aged; Simeprevir; Sofosbuvir

2015
Campaigners challenge patent applications for hepatitis C drug in five countries.
    BMJ (Clinical research ed.), 2015, Jun-01, Volume: 350

    Topics: Antiviral Agents; Argentina; Brazil; China; Drug Costs; Drugs, Generic; Hepatitis C; Humans; Legislation, Drug; Patents as Topic; Russia; Sofosbuvir; Ukraine; Uridine Monophosphate

2015
Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:3

    Topics: Aged; Analysis of Variance; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Patient Safety; Reference Values; Retrospective Studies; Ribavirin; Risk Assessment; Severity of Illness Index; Simeprevir; Sofosbuvir; Treatment Outcome

2015
Antiviral treatment with sofosbuvir and simeprevir in a kidney transplant recipient with HCV-decompensated cirrhosis: viral eradication and removal from the liver transplant waiting list.
    Transplant international : official journal of the European Society for Organ Transplantation, 2015, Volume: 28, Issue:11

    Topics: Administration, Oral; Allografts; Antiviral Agents; Female; Genotype; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Kidney; Kidney Transplantation; Liver Cirrhosis; Liver Transplantation; Middle Aged; Renal Insufficiency; Simeprevir; Sofosbuvir; Transplant Recipients; Treatment Outcome; Waiting Lists

2015
Simeprevir-induced severe withdrawal syndrome in an HIV/HCV coinfected patient on long-term maintenance methadone therapy.
    European journal of clinical pharmacology, 2015, Volume: 71, Issue:8

    Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Interactions; Hepatitis C; Heroin Dependence; HIV Infections; Humans; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Ribavirin; Simeprevir; Sofosbuvir; Substance Withdrawal Syndrome

2015
A New Standard of Care? Standard Dose Sofosbuvir in an HCV-Infected Liver Transplant Recipient Undergoing Hemodialysis.
    Digestive diseases and sciences, 2016, Volume: 61, Issue:1

    Topics: Antiviral Agents; Biopsy; Drug Therapy, Combination; End Stage Liver Disease; Hepatitis C; Hepatorenal Syndrome; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Liver Transplantation; Male; Middle Aged; Recurrence; Renal Dialysis; Simeprevir; Sofosbuvir; Time Factors; Treatment Outcome

2016
Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease.
    Journal of hepatology, 2015, Volume: 63, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Kidney Failure, Chronic; Male; Middle Aged; Simeprevir; Sofosbuvir

2015
Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:4

    Topics: Antiviral Agents; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir

2015
China rejects patent on hepatitis C drug sofosbuvir.
    BMJ (Clinical research ed.), 2015, Jun-23, Volume: 350

    Topics: Antiviral Agents; China; Cost Control; Drug Costs; Hepatitis C; Humans; Product Surveillance, Postmarketing; Sofosbuvir; Uridine Monophosphate

2015
Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans.
    Alimentary pharmacology & therapeutics, 2015, Volume: 42, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir; Veterans

2015
Clinical decompensation after achieving SVR with sofosbuvir, daclatasvir and ribavirin in a patient with recurrent HCV post-liver transplant.
    Journal of gastrointestinal and liver diseases : JGLD, 2015, Volume: 24, Issue:2

    Topics: Antiviral Agents; Biomarkers; Carbamates; Drug Therapy, Combination; End Stage Liver Disease; Hepatitis B virus; Hepatitis C; Humans; Imidazoles; Liver Transplantation; Male; Pyrrolidines; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Valine; Viral Load; Virus Activation

2015
Prophylaxis of HCV reinfection and direct-acting antiviral agents during liver transplantation.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2015, Volume: 21, Issue:10

    Topics: Antiviral Agents; Female; Hepatitis C; Humans; Male; Postoperative Complications; Simeprevir; Sofosbuvir

2015
Lawsuit seeks access to data from hepatitis C drug trial.
    BMJ (Clinical research ed.), 2015, Jun-30, Volume: 350

    Topics: Access to Information; Antiviral Agents; Benzimidazoles; Clinical Trials as Topic; Drug Approval; Fluorenes; Hepatitis C; Humans; Product Surveillance, Postmarketing; Research Design; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate

2015
[Joint Statement of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Ledipasvir / sofosbuvir-benefit assessment according to § 35a SGB V the G-BA].
    Zeitschrift fur Gastroenterologie, 2015, Volume: 53, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Evidence-Based Medicine; Fluorenes; Gastroenterology; Germany; Hepatitis C; HIV Infections; Humans; Practice Guidelines as Topic; Risk Assessment; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2015
Severe Cholestatic Hepatitis C in Transplant Recipients: No Longer a Threat to Graft Survival.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2015, Volume: 13, Issue:11

    Topics: Antiviral Agents; Cholestasis; Female; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Sofosbuvir

2015
Reply: To PMID 25825070.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2015, Volume: 21, Issue:10

    Topics: Antiviral Agents; Female; Hepatitis C; Humans; Male; Postoperative Complications; Simeprevir; Sofosbuvir

2015
Sofosbuvir (Sovaldi) for hepatitis C virus.
    The Nurse practitioner, 2015, Sep-13, Volume: 40, Issue:9

    Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Approval; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate

2015
Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency.
    Infectious diseases (London, England), 2015, Volume: 47, Issue:12

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Failure, Chronic; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Viral Load

2015
Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.
    Journal of comparative effectiveness research, 2016, Volume: 5, Issue:2

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Standard of Care; Treatment Outcome; Valine

2016
Interferon-Free Sofosbuvir-Based Anti-HCV Therapy After Liver Transplantation.
    Annals of transplantation, 2015, Sep-22, Volume: 20

    Topics: Antiviral Agents; Female; Graft Survival; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2015
Validation and Application of a Liquid Chromatography-Tandem Mass Spectrometry Method To Determine the Concentrations of Sofosbuvir Anabolites in Cells.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:12

    Topics: Antiviral Agents; Chromatography, High Pressure Liquid; Erythrocytes; Half-Life; Hepatitis C; Hepatocytes; Humans; Monocytes; Nonlinear Dynamics; Phosphates; Phosphorylation; Quality Control; Reproducibility of Results; Sofosbuvir; Tandem Mass Spectrometry

2015
Acute liver failure during hepatitis C treatment with sofosbuvir and ledipasvir.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:12

    Topics: Acute-On-Chronic Liver Failure; Aged; Antiviral Agents; Benzimidazoles; End Stage Liver Disease; Fatal Outcome; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Sofosbuvir

2015
The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular disease.
    Antiviral therapy, 2016, Volume: 21, Issue:3

    Topics: Aged; Antiviral Agents; Benzimidazoles; Cardiovascular Diseases; Cross Infection; Disease Outbreaks; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Pilot Projects; Sofosbuvir; Uridine Monophosphate

2016
Sofosbuvir-Induced Erythrodermic Pityriasis Rubra Pilaris-Like Drug Eruption.
    Journal of drugs in dermatology : JDD, 2015, Volume: 14, Issue:10

    Topics: Antiviral Agents; Drug Eruptions; Hepatitis C; Humans; Male; Middle Aged; Pityriasis Rubra Pilaris; Sofosbuvir

2015
Harvoni (ledipasvir and sofosbuvir) for hepatitis C.
    The Nurse practitioner, 2015, Nov-15, Volume: 40, Issue:11

    Topics: Antiviral Agents; Benzimidazoles; Contraindications; Drug Interactions; Fluorenes; Hepatitis C; Humans; Nurse Practitioners; Patient Education as Topic; Practice Guidelines as Topic; Sofosbuvir; Uridine Monophosphate

2015
Course of hepatitis C virus (HCV) RNA and HCV core antigen testing are predictors for reaching sustained virologic response in liver transplant recipients undergoing sofosbuvir treatment in a real-life setting.
    Transplant infectious disease : an official journal of the Transplantation Society, 2016, Volume: 18, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Viral Core Proteins; Viral Load

2016
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.
    Gastroenterology, 2016, Volume: 150, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; North America; Prospective Studies; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load; Young Adult

2016
Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2016, Volume: 22, Issue:1

    Topics: Aged; Antiviral Agents; Female; Hepatitis C; Humans; Immunosuppression Therapy; Liver Transplantation; Longitudinal Studies; Male; Middle Aged; Postoperative Complications; Registries; Simeprevir; Sofosbuvir; Treatment Outcome

2016
Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2016, Volume: 16, Issue:5

    Topics: Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Glomerular Filtration Rate; Graft Survival; Hepacivirus; Hepatitis C; Humans; Kidney Failure, Chronic; Kidney Function Tests; Kidney Transplantation; Male; Middle Aged; Pilot Projects; Prognosis; Risk Factors; Safety; Sofosbuvir; Viral Load

2016
L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions.
    The Journal of infectious diseases, 2016, Apr-15, Volume: 213, Issue:8

    Topics: Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis C; High-Throughput Nucleotide Sequencing; Humans; Molecular Epidemiology; Sequence Analysis, RNA; Sofosbuvir

2016
Hepatitis C Direct Acting Antiviral Therapies in a New York City HIV/AIDS Special Needs Plan: Uptake and Barriers.
    AIDS patient care and STDs, 2015, Volume: 29, Issue:12

    Topics: Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Medicaid; Middle Aged; New York City; Sofosbuvir; Treatment Outcome; United States

2015
Liver failure in human immunodeficiency virus - Hepatitis C virus coinfection treated with sofosbuvir, ledipasvir and antiretroviral therapy.
    Journal of hepatology, 2016, Volume: 64, Issue:3

    Topics: Antiviral Agents; Coinfection; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Liver Failure; Sofosbuvir; Uridine Monophosphate

2016
Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
    Antiviral research, 2016, Volume: 126

    Topics: Adenosine; Antiviral Agents; Cell Line; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutation; Oligopeptides; Protease Inhibitors; Replicon; Ribavirin; RNA, Viral; Sofosbuvir; Viral Nonstructural Proteins; Virus Replication

2016
Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.
    AIDS (London, England), 2016, Jan-02, Volume: 30, Issue:1

    Topics: Adult; Antiviral Agents; Coinfection; Drug-Related Side Effects and Adverse Reactions; Follow-Up Studies; Hepatitis C; HIV Infections; Humans; Liver Transplantation; Male; Middle Aged; Prospective Studies; Recurrence; Sofosbuvir; Transplant Recipients; Treatment Outcome; Viral Load

2016
Treatment of hepatitis C in a pediatric patient using simeprevir and sofosbuvir immediately after an umbilical cord blood transplantation.
    Bone marrow transplantation, 2016, Volume: 51, Issue:5

    Topics: Antiviral Agents; Biopsy; Child, Preschool; Cord Blood Stem Cell Transplantation; Female; Fetal Blood; Genotype; Hepacivirus; Hepatitis C; Humans; Immunosuppression Therapy; Liver; Simeprevir; Sofosbuvir; Treatment Outcome

2016
Letter: self-pay behaviour patients with chronic hepatitis C who required direct acting anti-viral urgently in a real-world setting.
    Alimentary pharmacology & therapeutics, 2016, Volume: 43, Issue:6

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Male; Ribavirin; Sofosbuvir

2016
Sofosbuvir and Simeprevir for Treatment of Recurrent Hepatitis C Infection After Liver Transplant.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2017, Volume: 15, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load

2017
Letter: safety and efficacy of sofosbuvir plus daclatasvir with ribavirin for 12 weeks in Chinese treatment-experienced cirrhotic genotype 1b patients with HCV.
    Alimentary pharmacology & therapeutics, 2016, Volume: 43, Issue:7

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Male; Ribavirin; Sofosbuvir

2016
Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, 06-15, Volume: 62, Issue:12

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Male; Middle Aged; New York City; Risk Factors; Simeprevir; Sofosbuvir; Treatment Outcome; Viral Load

2016
Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.
    Transplantation, 2016, Volume: 100, Issue:5

    Topics: Aged; Antiviral Agents; Biopsy; Canada; Creatinine; Female; Fibrosis; Genotype; Glomerular Filtration Rate; Hepatitis C; Humans; Interferons; Kidney; Liver Transplantation; Male; Middle Aged; Prospective Studies; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir

2016
Development of highly aggressive mantle cell lymphoma after sofosbuvir treatment of hepatitis C.
    Blood cancer journal, 2016, Mar-11, Volume: 6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Disease Progression; Hepatitis C; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Sofosbuvir; Treatment Outcome

2016
Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus.
    World journal of gastroenterology, 2016, Mar-07, Volume: 22, Issue:9

    Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepacivirus; Hepatitis C; Humans; Kaplan-Meier Estimate; Liver Failure; Liver Transplantation; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Recurrence; Ribavirin; Risk Factors; Sofosbuvir; Time Factors; Treatment Outcome; Virus Activation

2016
Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation.
    Transplant infectious disease : an official journal of the Transplantation Society, 2016, Volume: 18, Issue:3

    Topics: Aged; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Benzimidazoles; Europe; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2016
Successful therapy with Ledipasvir/Sofosbuvir for hepatitis C reactivation in a hematopoietic stem cell transplant recipient.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:11

    Topics: Anemia, Aplastic; Benzimidazoles; Female; Fluorenes; Hematopoietic Stem Cell Transplantation; Hepacivirus; Hepatitis C; Humans; Middle Aged; Myelodysplastic Syndromes; Sofosbuvir; Transplant Recipients; Treatment Outcome; Uridine Monophosphate; Virus Activation

2016
Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.
    Clinical transplantation, 2016, Volume: 30, Issue:6

    Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Immunosuppression Therapy; Liver Transplantation; Male; Middle Aged; Prospective Studies; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Young Adult

2016
12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, 06-15, Volume: 62, Issue:12

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Valine; Viral Load; Young Adult

2016
Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens.
    Journal of hepatology, 2016, Volume: 65, Issue:3

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; RNA Viruses; Simeprevir; Sofosbuvir

2016
New Indications for Harvoni.
    The Medical letter on drugs and therapeutics, 2016, Jan-04, Volume: 58, Issue:1485

    Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Approval; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Liver Cirrhosis; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate

2016
Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients.
    Hepatology (Baltimore, Md.), 2016, Volume: 64, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Cohort Studies; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2016
Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir.
    Hepatology (Baltimore, Md.), 2016, Volume: 64, Issue:3

    Topics: Adult; Antiviral Agents; Carbamates; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Sofosbuvir

2016
Hepatotoxicity and potential drug interaction with ledipasvir/sofosbuvir in HIV/HCV infected patients.
    Journal of hepatology, 2016, Volume: 65, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; Chemical and Drug Induced Liver Injury; Drug Interactions; Drug Therapy, Combination; Fluorenes; Hepatitis C; HIV Infections; Humans; Sofosbuvir

2016
Biochemical Characterization of the Active Anti-Hepatitis C Virus Metabolites of 2,6-Diaminopurine Ribonucleoside Prodrug Compared to Sofosbuvir and BMS-986094.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:8

    Topics: Adenosine; Antiviral Agents; Cell Line; DNA-Directed RNA Polymerases; Guanosine Monophosphate; Hepacivirus; Hepatitis C; Humans; Prodrugs; Ribonucleosides; RNA; RNA, Mitochondrial; RNA, Viral; Sofosbuvir; Transcription, Genetic; Viral Nonstructural Proteins; Virus Replication

2016
Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.
    PLoS medicine, 2016, Volume: 13, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Health Expenditures; Hepatitis C; Humans; Prescription Fees; Sofosbuvir; Uridine Monophosphate

2016
Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study.
    Journal of hepatology, 2016, Volume: 65, Issue:4

    Topics: Antiviral Agents; Compassionate Use Trials; Drug Therapy, Combination; France; Hepacivirus; Hepatitis C; Humans; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2016
Payers Sued Over Coverage Of Expensive Hepatitis C Drugs.
    Managed care (Langhorne, Pa.), 2016, Volume: 25, Issue:4

    Topics: Drug Combinations; Drug Costs; Hepatitis C; Insurance, Health; Macrocyclic Compounds; Ritonavir; Sofosbuvir; Sulfonamides; United States; Uracil

2016
Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.
    Gastroenterology, 2016, Volume: 151, Issue:3

    Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; United States; United States Department of Veterans Affairs; Uracil; Uridine Monophosphate; Valine

2016
Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data.
    PloS one, 2016, Volume: 11, Issue:6

    Topics: Asian People; Benzimidazoles; China; Costs and Cost Analysis; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Markov Chains; Models, Economic; Sofosbuvir

2016
Drug Pricing Evolution in Hepatitis C.
    PloS one, 2016, Volume: 11, Issue:6

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Discovery; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Oligopeptides; Ribavirin; Ritonavir; Sofosbuvir; Switzerland; United States

2016
All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, 09-15, Volume: 63, Issue:6

    Topics: Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2016
Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2016, Volume: 19, Issue:4

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug Combinations; Female; Fluorenes; Health Services Accessibility; Hepacivirus; Hepatitis C; HIV Protease Inhibitors; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Markov Chains; Medicaid; Middle Aged; Proline; Ritonavir; Severity of Illness Index; Sofosbuvir; Sulfonamides; United States; Uracil; Uridine Monophosphate; Valine

2016
Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:1

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response

2017
Nursing Problems in Care of a Patient with Very Early HCV Infection Recurrence After Liver Transplantation: A Case Report.
    Annals of transplantation, 2016, Jun-30, Volume: 21

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferons; Liver Failure; Liver Transplantation; Oligopeptides; Postoperative Complications; Recurrence; Reoperation; Ribavirin; Sofosbuvir; Treatment Outcome; Young Adult

2016
Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV.
    Antiviral therapy, 2016, Volume: 21, Issue:7

    Topics: Aged; Antiviral Agents; Benzimidazoles; Coinfection; DNA, Viral; Drug Therapy, Combination; Female; Fluorenes; Hepatitis B; Hepatitis C; Humans; Male; Middle Aged; Pilot Projects; Sofosbuvir

2016
Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2016, Volume: 49

    Topics: Antiviral Agents; Carbamates; Coinfection; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Valine

2016
IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting.
    The Journal of antimicrobial chemotherapy, 2016, Volume: 71, Issue:11

    Topics: Adult; Antiviral Agents; Coinfection; Female; Hepatitis C; HIV Infections; Humans; Liver Transplantation; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Transplant Recipients; Treatment Outcome

2016
[Not Available].
    MMW Fortschritte der Medizin, 2016, Volume: 158, Issue:13

    Topics: AIDS-Related Opportunistic Infections; Benzimidazoles; Cross-Cultural Comparison; Cross-Sectional Studies; Developing Countries; Drug Costs; Europe; Fluorenes; Hepatitis B; Hepatitis C; HIV Infections; Humans; Medical Tourism; Sofosbuvir; United States; Uridine Monophosphate

2016
Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a Reinfection.
    PloS one, 2016, Volume: 11, Issue:7

    Topics: Antiviral Agents; Cell Line, Tumor; Cyclophilins; Cyclosporine; Endoplasmic Reticulum; Enzyme Inhibitors; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Kinetics; Sofosbuvir; Viral Nonstructural Proteins

2016
Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection.
    Pharmacotherapy, 2016, Volume: 36, Issue:9

    Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C; HIV Infections; Humans; Kidney; Middle Aged; Sofosbuvir; Tenofovir

2016
Reply to: "HCV RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin".
    Journal of hepatology, 2016, Volume: 65, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kinetics; Ribavirin; RNA; RNA, Viral; Sofosbuvir; Sustained Virologic Response

2016
HCV-RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin.
    Journal of hepatology, 2016, Volume: 65, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kinetics; Ribavirin; RNA; RNA, Viral; Sofosbuvir; Sustained Virologic Response

2016
Public participation in decision-making on the coverage of new antivirals for hepatitis C.
    Journal of health organization and management, 2016, Aug-15, Volume: 30, Issue:5

    Topics: Antiviral Agents; Brazil; Community Participation; Decision Making; England; Health Care Rationing; Hepatitis C; Humans; Insurance Coverage; Insurance, Health; Republic of Korea; Sofosbuvir; United States

2016
A pill too hard to swallow: how the NHS is limiting access to high priced drugs.
    BMJ (Clinical research ed.), 2016, Jul-27, Volume: 354

    Topics: Antiviral Agents; Cost Control; Costs and Cost Analysis; Drug Costs; Health Services Accessibility; Hepatitis C; Humans; Legislation, Drug; Sofosbuvir; State Medicine; United Kingdom

2016
Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post-liver transplant patients with hepatitis C genotype 1.
    Alimentary pharmacology & therapeutics, 2016, Volume: 44, Issue:7

    Topics: Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Simeprevir; Sofosbuvir; Treatment Outcome

2016
Sofosbuvir/velpatasvir (Epclusa) for hepatitis C.
    The Medical letter on drugs and therapeutics, 2016, Aug-15, Volume: 58, Issue:1501

    Topics: Antiviral Agents; Carbamates; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Protease Inhibitors; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins; Virus Replication

2016
Patents: problem or panacea?
    BMJ (Clinical research ed.), 2016, Aug-23, Volume: 354

    Topics: Drug Costs; Hepatitis C; Humans; Patents as Topic; Pharmaceutical Preparations; Sofosbuvir

2016
Curing HCV infection with 4 weeks-regimen of sofosbuvir and ledipasvir: To be remembered.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2016, Volume: 48, Issue:12

    Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Middle Aged; Sofosbuvir

2016
Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis.
    Alimentary pharmacology & therapeutics, 2016, Volume: 44, Issue:10

    Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States

2016
New Drug Treats All Genotypes of Chronic HCV.
    The American journal of nursing, 2016, Volume: 116, Issue:10

    Topics: Antiviral Agents; Carbamates; Drug Combinations; Drug Interactions; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir; United States; United States Food and Drug Administration

2016
New Hepatitis C Drugs Are Very Costly And Unavailable To Many State Prisoners.
    Health affairs (Project Hope), 2016, 10-01, Volume: 35, Issue:10

    Topics: Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C; Humans; Male; North Carolina; Prisoners; Prisons; Retrospective Studies; Sofosbuvir; State Government; United States; Uridine Monophosphate

2016
Compulsory licences for direct acting antiviral drugs for hepatitis C.
    BMJ (Clinical research ed.), 2016, Oct-05, Volume: 355

    Topics: Antiviral Agents; Hepatitis C; Humans; Italy; Legislation, Drug; Licensure; Sofosbuvir

2016
Questions hang over European patent for hepatitis C drug after ruling.
    BMJ (Clinical research ed.), 2016, Oct-10, Volume: 355

    Topics: Antiviral Agents; Europe; Hepatitis C; Humans; Patents as Topic; Sofosbuvir

2016
The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.
    Hepatology (Baltimore, Md.), 2017, Volume: 65, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Asian; Black People; Cohort Studies; Databases, Factual; Drug Therapy, Combination; Ethnicity; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Prognosis; Racial Groups; Ribavirin; Risk Assessment; Simeprevir; Sofosbuvir; Survival Rate; Treatment Outcome; United States; White People

2017
Remission of Follicular Lymphoma after Treatment for Hepatitis C Virus Infection.
    The New England journal of medicine, 2016, Oct-27, Volume: 375, Issue:17

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Lymphoma, Follicular; Male; Ribavirin; Sofosbuvir; Viral Load

2016
The 2016 Lasker-DeBakey Clinical Medical Research Award: Innovative hepatitis C virus (HCV) replicons leading to drug development for hepatitis C cure.
    Science China. Life sciences, 2016, Volume: 59, Issue:11

    Topics: Antiviral Agents; Awards and Prizes; Biomedical Research; Hepacivirus; Hepatitis C; Host-Pathogen Interactions; Humans; Replicon; Sofosbuvir; Virus Replication

2016
HCV-associated cryoglobulinemia vasculitis: are its days numbered?
    Annals of the rheumatic diseases, 2017, Volume: 76, Issue:3

    Topics: Cryoglobulinemia; Hepacivirus; Hepatitis C; Humans; Ribavirin; Sofosbuvir; Vasculitis

2017
First Case in Kazakhstan of Successful Therapy With 2 Consecutive Direct-Acting Antiviral Regimens in a Patient with Hepatitis C Virus-Induced Decompensated Liver Cirrhosis on a Liver Transplant Wait List.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2016, Volume: 14, Issue:Suppl 3

    Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C; Humans; Kazakhstan; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Male; Medication Adherence; Proline; Recurrence; Retreatment; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine; Waiting Lists

2016
Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents.
    Drug and alcohol dependence, 2016, Dec-01, Volume: 169

    Topics: Aged; Alcohol Drinking; Alcoholism; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Treatment Outcome

2016
Betting on hepatitis C: how financial speculation in drug development influences access to medicines.
    BMJ (Clinical research ed.), 2016, Jul-27, Volume: 354

    Topics: Antiviral Agents; Drug Discovery; Drug Industry; Hepatitis C; Humans; Sofosbuvir

2016
High cost of new drugs.
    BMJ (Clinical research ed.), 2016, Jul-27, Volume: 354

    Topics: Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Costs; Drug Industry; Fluorenes; Hepatitis C; Humans; Sofosbuvir; United Kingdom

2016
[Sofosbuvir and daclatasvir combination therapy in hemodialysis patient with liver transplantation].
    Nephrologie & therapeutique, 2016, Volume: 12, Issue:7

    Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Sofosbuvir; Treatment Outcome; Valine

2016
Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Postoperative Period; Preoperative Period; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response

2017
Psoriasis as a Manifestation of an Immune Reconstitution in Two Patients with Hepatitis C Treated with Ledipasvir/Sofosbuvir.
    Acta dermato-venereologica, 2017, 04-06, Volume: 97, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Combined Modality Therapy; Dermatologic Agents; Disease Progression; Fluorenes; Hepatitis C; Humans; Male; Psoriasis; Risk Factors; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Ultraviolet Therapy; Uridine Monophosphate

2017
Sofosbuvir and Daclatasvir Anti-Viral Therapy Fails to Clear HEV Viremia and Restore Reactive T Cells in a HEV/HCV Co-Infected Liver Transplant Recipient.
    Gastroenterology, 2017, Volume: 152, Issue:1

    Topics: Antiviral Agents; Coinfection; Hepatitis C; HIV Infections; Humans; Sofosbuvir; T-Lymphocytes; Viremia

2017
Wales approves new hepatitis C drug while England deliberates.
    BMJ (Clinical research ed.), 2016, Dec-01, Volume: 355

    Topics: Antiviral Agents; Carbamates; Drug Approval; Drug Combinations; England; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir; State Medicine; Wales

2016
The enigma of value: in search of affordable and accessible health care.
    The European journal of health economics : HEPAC : health economics in prevention and care, 2017, Volume: 18, Issue:6

    Topics: Budgets; Cost-Benefit Analysis; Costs and Cost Analysis; Economics, Pharmaceutical; Fees, Pharmaceutical; Health Expenditures; Health Services Accessibility; Hepatitis C; Humans; Sofosbuvir; State Medicine; Switzerland; United Kingdom

2017
Sofosbuvir and ribavirin in acute hepatitis C-infected patient with decompensated cirrhosis.
    Medicine, 2016, Volume: 95, Issue:49

    Topics: Administration, Oral; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome

2016
Hepatitis C Virus in Kidney Transplant Recipients: A Problem on the Path to Eradication.
    Transplantation proceedings, 2016, Volume: 48, Issue:9

    Topics: Adult; Antiviral Agents; Female; Graft Survival; Hepacivirus; Hepatitis C; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Incidence; Kidney; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Ribavirin; Sofosbuvir; Tacrolimus

2016
Hepatitis C Treatment With Direct-Acting Antivirals in Kidney Transplant: Preliminary Results From a Multicenter Study.
    Transplantation proceedings, 2016, Volume: 48, Issue:9

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunosuppression Therapy; Kidney Transplantation; Lactams, Macrocyclic; Macrocyclic Compounds; Postoperative Complications; Proline; Prospective Studies; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Spain; Sulfonamides; Treatment Outcome; Valine

2016
Sofosbuvir/ledipasvir and ribavirin tolerability and efficacy in pediatric liver transplant recipients.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2017, Volume: 23, Issue:4

    Topics: Adolescent; Antiviral Agents; Benzimidazoles; Biliary Atresia; Budd-Chiari Syndrome; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Infant; Liver; Liver Cirrhosis; Liver Transplantation; Male; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate

2017
Effect of minor populations of NS5A and NS5B resistance-associated variants on HCV genotype-3 response to daclatasvir plus sofosbuvir, with or without ribavirin.
    Antiviral therapy, 2017, Volume: 22, Issue:3

    Topics: Alleles; Amino Acid Substitution; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Polymorphism, Genetic; Pyrrolidines; Ribavirin; Sequence Analysis, DNA; Sofosbuvir; Treatment Failure; Treatment Outcome; Valine; Viral Load; Viral Nonstructural Proteins

2017
Successful treatment of donor-derived hepatitis C infection in a lung transplant recipient.
    Transplant infectious disease : an official journal of the Transplantation Society, 2017, Volume: 19, Issue:2

    Topics: Adult; Allografts; Antibodies, Monoclonal; Antiviral Agents; Basiliximab; Disease Transmission, Infectious; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B virus; Hepatitis C; HIV; Humans; Immunosuppression Therapy; Klebsiella pneumoniae; Liver Transplantation; Male; Middle Aged; Nausea; Polymerase Chain Reaction; Pulmonary Disease, Chronic Obstructive; Recombinant Fusion Proteins; RNA, Viral; Simeprevir; Sofosbuvir; Tissue and Organ Procurement; Transplant Recipients; Treatment Outcome

2017
Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.
    Transplant infectious disease : an official journal of the Transplantation Society, 2017, Volume: 19, Issue:2

    Topics: Acetaminophen; Adult; Allografts; Antiviral Agents; Benzimidazoles; Blood-Borne Pathogens; Chemical and Drug Induced Liver Injury; Disease Transmission, Infectious; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Kidney Failure, Chronic; Kidney Transplantation; Liver Transplantation; Male; Middle Aged; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sofosbuvir; Transplant Recipients; Viral Load

2017
Eight- or 12-Week Treatment of Hepatitis C with Ledipasvir/Sofosbuvir: Real-World Experience in a Large Integrated Health System.
    Drugs, 2017, Volume: 77, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; Delivery of Health Care, Integrated; Fluorenes; Hepatitis C; Humans; Sofosbuvir; Time Factors

2017
Prevalence of sofosbuvir resistance-associated variants in Brazilian and worldwide NS5B sequences of genotype-1 HCV.
    Antiviral therapy, 2017, Volume: 22, Issue:5

    Topics: Amino Acid Substitution; Antiviral Agents; Brazil; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Mutation; Prevalence; Public Health Surveillance; Sofosbuvir; Viral Nonstructural Proteins

2017
Treatment of de novo hepatitis C virus-related fibrosing cholestatic hepatitis after orthotopic heart transplantation by ledipasvir and sofosbuvir.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2017, Volume: 116, Issue:5

    Topics: Acute Kidney Injury; Antiviral Agents; Benzimidazoles; Fluorenes; Heart Failure; Heart Transplantation; Hepatic Encephalopathy; Hepatitis C; Humans; Liver Function Tests; Male; Middle Aged; Myocardial Infarction; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2017
Prevention of allograft HCV recurrence with peri-transplant human monoclonal antibody MBL-HCV1 combined with a single oral direct-acting antiviral: A proof-of-concept study.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:3

    Topics: Allografts; Antibodies, Monoclonal; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C; Hepatitis C Antibodies; Humans; Liver Transplantation; Male; Middle Aged; Oligopeptides; Proof of Concept Study; RNA, Viral; Secondary Prevention; Sofosbuvir; Sustained Virologic Response; Transplant Recipients; Treatment Outcome

2017
Costly Cures.
    State legislatures, 2017, Volume: 43, Issue:2

    Topics: Budgets; Hepatitis C; Hepatitis C, Chronic; Humans; Medicaid; Severity of Illness Index; Sofosbuvir; State Government; United States

2017
Sofosbuvir in the treatment of early HCV infection in HIV-infected men.
    HIV clinical trials, 2017, Volume: 18, Issue:2

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Interleukins; Male; Middle Aged; Mutation; Pilot Projects; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load

2017
Identification of Predictors for Treatment Failure in Hepatitis C Virus Patients Treated With Ledipasvir and Sofosbuvir.
    The Annals of pharmacotherapy, 2017, Volume: 51, Issue:7

    Topics: Aged; Antiviral Agents; Benzimidazoles; Case-Control Studies; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Odds Ratio; Retrospective Studies; Sofosbuvir; Treatment Failure; Treatment Outcome; Viral Load

2017
Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017, Jun-15, Volume: 64, Issue:12

    Topics: Administration, Oral; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Practice Patterns, Physicians'; Proline; Registries; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Valine; Veterans

2017
In vitro selection of resistance to sofosbuvir in HCV replicons of genotype-1 to -6.
    Antiviral therapy, 2017, Volume: 22, Issue:7

    Topics: Amino Acid Substitution; Antiviral Agents; Cell Line; Drug Resistance, Viral; Genome, Viral; Genotype; Hepacivirus; Hepatitis C; High-Throughput Nucleotide Sequencing; Humans; Models, Molecular; Mutation; Phenotype; Protein Conformation; Sofosbuvir; Structure-Activity Relationship; Viral Nonstructural Proteins; Virus Replication

2017
Effectiveness of Sofosbuvir and Ribavirin for Eradicating Hepatitis C Virus in Renal Transplant Recipients in Pakistan: Where Resources Are Scarce.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2017, Volume: 15, Issue:Suppl 1

    Topics: Adult; Antiviral Agents; Developing Countries; Drug Therapy, Combination; Female; Genotype; Health Resources; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Pakistan; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load; Young Adult

2017
Liver transplantation for fulminant genotype 2a/c hepatitis C virus marked by a rapid recurrence followed by cure.
    Transplant infectious disease : an official journal of the Transplantation Society, 2017, Volume: 19, Issue:3

    Topics: Acute Disease; Administration, Oral; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Failure, Acute; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Risk Factors; Sofosbuvir; Valine

2017
Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis.
    Gastroenterology, 2017, Volume: 152, Issue:8

    Topics: Aged; Antiviral Agents; B-Lymphocyte Subsets; Biomarkers; Carbamates; Case-Control Studies; Cryoglobulinemia; Cytokines; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis Viruses; Humans; Imidazoles; Immune Tolerance; Immunity, Cellular; Male; Middle Aged; Phenotype; Prospective Studies; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; T-Lymphocyte Subsets; Time Factors; Treatment Outcome; Valine; Vasculitis; Viral Load

2017
Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program.
    Expert review of gastroenterology & hepatology, 2017, Volume: 11, Issue:6

    Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Health Services Accessibility; Hepacivirus; Hepatitis C; Humans; Ireland; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Program Evaluation; Prospective Studies; Registries; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate

2017
[Biliary and kidney lithiasis during treatment with daclatasvir/sofosbuvir/ribavirin and atazanavir/ritonavir + abacavir/lamivudine in an HIV/HCV genotype 4-infected patient: a case report.]
    Recenti progressi in medicina, 2017, Volume: 108, Issue:2

    Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Biliary Tract Diseases; Carbamates; Coinfection; Dideoxynucleosides; Drug Combinations; Drug Interactions; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Kidney Calculi; Lamivudine; Lithiasis; Male; Pyrrolidines; Ribavirin; Ritonavir; Sofosbuvir; Valine

2017
Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis.
    Gastroenterology, 2017, Volume: 153, Issue:1

    Topics: Antiviral Agents; B-Lymphocytes; Carbamates; CD4-Positive T-Lymphocytes; Cryoglobulinemia; Cryoglobulins; Drug Therapy, Combination; Female; Hepatitis C; Humans; Imidazoles; Immunoglobulin M; Interleukins; Lymphocyte Count; Male; Middle Aged; Prospective Studies; Pyrrolidines; Receptors, Complement 3d; Receptors, CXCR5; Sofosbuvir; Sustained Virologic Response; T-Lymphocytes, Regulatory; Th17 Cells; Valine; Vasculitis

2017
Synthesis of diastereomerically pure nucleotide phosphoramidates.
    The Journal of organic chemistry, 2011, Oct-21, Volume: 76, Issue:20

    Topics: Amides; Amino Acids; Antiviral Agents; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; DNA-Directed RNA Polymerases; Electrons; Esters; Hepacivirus; Hepatitis C; Humans; Magnetic Resonance Spectroscopy; Nucleosides; Nucleotides; Phenols; Phosphoric Acids; Prodrugs; Sofosbuvir; Stereoisomerism; Structure-Activity Relationship; Uridine Monophosphate; Viral Proteins

2011
Synthesis of stable isotope labeled analogs of the anti-hepatitis C virus nucleotide prodrugs PSI-7977 and PSI-352938.
    Nucleosides, nucleotides & nucleic acids, 2011, Volume: 30, Issue:11

    Topics: Antiviral Agents; Cyclic P-Oxides; Halogenation; Hepacivirus; Hepatitis C; Humans; Isotope Labeling; Nucleosides; Prodrugs; Sofosbuvir; Uridine Monophosphate

2011
Trial watch: an all-oral and interferon-free future for HCV therapy?
    Nature reviews. Drug discovery, 2011, Dec-01, Volume: 10, Issue:12

    Topics: Administration, Oral; Clinical Trials, Phase III as Topic; Forecasting; Hepatitis C; Humans; Interferons; Nucleic Acid Synthesis Inhibitors; RNA-Dependent RNA Polymerase; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins

2011
Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes.
    The protein journal, 2013, Volume: 32, Issue:1

    Topics: Amino Acid Sequence; Antiviral Agents; Catalytic Domain; Enzyme Inhibitors; Genotype; Hepacivirus; Hepatitis C; Humans; Models, Molecular; Molecular Sequence Data; Sequence Alignment; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins

2013